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 1 Introduction 1 
1 Introduction 
Within the last 100 years the leading causes of death have changed dramatically. Until the 
middle of the twentieth century death was mainly due to infectious diseases. After the 
discovery of penicillin by Alexander Fleming in 1928 (reviewed in Bentley, 2005) and the 
following development of industrially produced antibiotics in addition to improved hygiene, 
the death toll from infectious diseases has declined drastically (reviewed in Gootz, 1990). 
Now cancer has become the second-ranking cause of death in the western world after 
cardiovascular diseases (Fig. 1.1). Thus, the development of a cure for cancer has become a 
major issue. 
Causes of death in Germany (2003)
cardiovascular diseases
43%
cancer 27%
accidents 8%
respiratory diseases 7%
endocrine and metabolic
diseases 5%
digestive diseases 3%
infectious diseases 3%
nervous system
diseases 2%
all other diseases 2%
Fig. 1.1:  The eight major causes of death in Germany. Source: Federal statistic office Germany. Distribution of 
death causes is similar in all western countries. 
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1.1 Cancer 
What exactly is cancer? “It is easy to forget that cancer is not a single disease, but many 
diseases” (Bergers and Benjamin, 2003), which is the reason why it is so hard to grasp or 
understand cancer and to develop a holistic treatment against it. During the past 25 years 
cancer researchers have enumerated an amazing range of phenotypes and have catalogued 
thousands of molecular alterations that are associated with cancer and malignant diseases 
(reviewed in Zhao et al., 2004). Generally, a cancer cell is a cell that undergoes uncontrolled 
proliferation meaning the cell has escaped normal growth regulating mechanisms. To achieve 
this, a cell has to undergo several discrete genetic changes, which comprise the alteration of 
oncogenes, gain of telomerase activity, tissue invasiveness and angiogenesis. A summary of 
the single stages of tumor progression can be seen in Figure 1.2. (Fuster and Esko, 2005). 
Oncogenes are a heterogeneous group of genes that encode proteins capable of inducing 
cellular transformation. In general, one can define proto-oncogenes or cellular oncogenes (c-
onc), which are found in normal cells, and viral oncogenes (v-onc), which tumor viruses 
might have acquired from the genome of an infected cell. Most oncogenes are derived from 
genes that encode growth-controlling proteins.  
An example of a retrovirus that carries an oncogene is the Rous sarcoma virus. Its oncogene 
v-src encodes a 60-kDa protein kinase that catalyzes the addition of phosphate to tyrosine 
residues on proteins. C-src, its cellular counterpart, belongs to the multigene family of 
membrane-associated non-receptor tyrosine kinases and its activity has been shown to be 
elevated in many human epithelial cancers. C-src is known to increase cellular proliferation. 
Additionally it seems to promote invasion and motility and thus might contribute to tumor 
progression. The exact function of c-src in cancer is still unclear. (reviewed in Frame, 2004; 
Frame, 2002; Yeatman, 2004). Other examples of oncogenes encode growth factor receptors 
like erbB, which interacts with the major mechanisms of cell death signaling and promotes 
cell survival (Danielsen and Maihle, 2002). Similarly, ras genes encode GTP-binding proteins 
that are involved in cellular signaling. Mutational activation of Ras proteins also facilitates 
invasion and metastasis (Giehl, 2005).  
Alternatively, oncogenes can act as tumor suppressors, such as p53 (Toledo and Wahl, 2006). 
P53 is a transcription factor regulating target genes that induce cell-cycle arrest, apoptosis, 
senescence, DNA repair or alter cell metabolism. P53 is inactivated in 50% of human cancers 
(Soussi, 2005). 
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Oncogenes can also regulate programmed cell death like bcl-2. Bcl-2 functions as an 
oncogene by blocking apoptotic cell death (Piro, 2004; Pattingre and Levine, 2006). However, 
one mutated or activated oncogene is not enough for a cell to become cancerous. Instead 
cancer arises from a stepwise accumulation of genetic alterations in multiple oncogenes, 
resulting in the gradual transformation of a normal cell into malignant derivatives. This multi-
step process always coincides with aneuploidy of the tumor cells. 
Fig. 1.2: The stages of tumor progression. The single stages are described in the text. The figure is taken from 
Fuster and Esko, 2005. 
Aneuploidy indicates abnormal chromosome content. Normally, a healthy human cell has 23 
chromosomes with each chromosome existing as a pair (except sex chromosomes in males). 
During every cell division, each daughter cell receives the exact set of chromosomes of the 
parental cell. Therefore, the separation of the two sister chromatids of one chromosome has to 
be tightly controlled. This control mechanism is called ‘mitotic checkpoint’. A weakening of 
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the mitotic checkpoint can result in aberrant mitosis, premature separation of sister chromatids 
during mitosis, merotelic attachment meaning the attachment of one chromatide to both poles 
and other mitotic checkpoint defects. As a result the cell will end up with irregular 
chromosome content and become aneuploid (Kops et al., 2005). An example of the spectral 
karyotype of an aneuploid tumor cell is displayed in Fig. 1.3. 
Fig. 1.3: Spectral karyotype (SKY) image of an aneuploid tumor cell. The figure is taken from Pollack, 2006.  
Essential for all tumor cells is also the gain of telomerase activity. Telomeres are unique 
structures at the ends of linear eukaryotic chromosomes. They are composed of repetitive G-
rich sequences and are associated with different proteins. Telomeres are responsible for 
preserving chromosome stability, protection of the chromosome ends against degradation and 
prevention of chromosomal end fusion (reviewed in Shay et al., 2001).  
During every replication step, the telomeres shorten due to the ‘end replication problem’ of 
linear DNA (Lingner et al., 1995). Thus, for a continuous cell division the telomeres have to 
be replenished with newly synthesized telomeric repeats, a process, which is accomplished by 
the reverse transcriptase telomerase. Most animal cells – besides germ cells – normally do not 
express telomerase to prevent telomere shortening. As a result, the cell will eventually lose 
telomere length to a point, where the cell cycle arrests and the cell proliferation is stopped. 
This mechanism is not only a sign of ageing, but it is also an effective tumor suppressor. 
Concordantly, a hyper-reactive or constitutively expressed telomerase will ultimately support 
the proliferation of cancerous cells (reviewed in Shay et al., 2001; Bailey and Murnane, 
2006). 
A cell that has become cancerous will proliferate uncontrolled. As such tumors become large, 
they require an adequate supply of oxygen and nutrients. In addition an effective way to 
remove waste products is essential. In a process called angiogenesis, the tumor induces tumor 
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vascularization i.e. the formation of blood vessels that fulfill their tasks as pipelines for 
nutrient and oxygen supply and waste removal. Tumor blood vessels architecturally differ 
from their normal counterparts. They are irregularly shaped, dilated, tortuous and can have 
dead ends. Often they are leaky and hemorrhagic with a loosely associated endothelial lining 
(Papetti and Herman, 2002; Bergers and Benjamin, 2003). 
Several additional mutations will accumulate during tumorigenesis e.g. via mitotic checkpoint 
defects and chromosome instability (Kops et al., 2005). This can lead to the capacity of the 
tumor to degrade basement membranes and extracellular matrix and become invasive. 
Eventually tumor cells will reach the lymph system and the blood stream. Via this system 
they will disseminate throughout the body and aggregate with host cells like platelets and 
lymphocytes and finally lodge in small vessels of distant organs. This will result in the 
formation of secondary tumors or metastases. Metastases represent the major problem for 
tumor therapy. 
1.2 Tumor therapy 
Theoretically, most solid tumors can be removed by surgery. However, surgery is not always 
possible. Tumors might have metastasized to distant organs, where they proliferate although 
the primary tumor has been removed. In other cases, the tumor might be associated with a 
pivotal organ and can therefore not be removed. Thus, the activity of an efficient tumor 
therapy has to be very broad and should reach all tumor cells, including micro-metastases. In 
addition, an ideal tumor therapy would only affect cancerous cells, without side effects on 
normal cells or organs. 
Routinely used therapies are presently far from fulfilling such criteria. On the other hand, 
several novel therapies are considered to date. Accordingly, one could distinguish two kinds 
of tumor therapy: Conventional tumor therapy, which includes surgery, chemotherapy and 
radiotherapy and innovative tumor therapies, which comprise immunotherapy, therapies with 
monoclonal antibodies, gene therapies, as well as all kinds of cancer therapies that are 
presently developed and are not standard in the clinics. 
1.2.1 Conventional tumor therapy 
1.2.1.1 Chemotherapy 
The use of chemotherapy as a remedy for cancer began in the 1940s with the use of nitrogen 
mustard. Based on autopsy findings from soldiers that died of exposure to sulphur mustard 
gas during the First World War, Goodman and Gilman, pharmacologists at the Yale School of 
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Medicine, proposed that this compound might destroy lymphoid tumors. Experiments with 
tumor bearing mice proved them to be right (Gilman, 1963). After a systemic administration 
of nitrogen mustard they could observe a marked level of tumor regression. Unfortunately, the 
remission lasted only a few weeks, but the principle that chemicals can be administered 
systemically to induce tumor regression, was established. Only a few years later, shortly after 
the Second World War, Syndey Farber at the Harvard Medical School used antifolates to 
suppress the proliferation of malignant cells in acute lymphoblastic leukemia (Farber, 1948). 
This was expanded in the following years and decades and a multitude of reagents have been 
found or developed that effectively manipulate the proliferation of malignant cells to suppress 
tumor progression. Besides the discovery of natural products like taxanes, combination 
therapies of different chemotherapeutics have come into focus and have proven to be more 
effective than single agents (Papac, 2001; Chabner and Roberts, Jr., 2005). 
Up to date chemotherapy remains the treatment of choice for most advanced cancers. 
However, chemotherapy does have several major drawbacks. Most chemotherapeutics work 
by impairing mitosis, thereby inhibiting cells that undergo fast proliferation. These are, of 
course, quickly proliferating tumor cells, but also healthy, fast proliferating cells like 
hematopoietic cells, cells in hair follicles or cells in mucous membranes. Hence, strong side-
effects are encountered like hair loss, nausea, diarrhea or anemia. Besides, not all malignant 
cells are affected by a chemotherapeutic drug. Slowly growing solid tumors can hardly be 
treated with chemotherapeutics, especially those tumor cells that are located in the center of 
solid tumors and have stopped division. In addition, some drugs do not have the ability to 
reach the cells in the center of solid tumors. Other disadvantages of chemotherapeutics are the 
development of drug resistant tumor cells that stop responding to the chemotherapeutic 
treatment. This often takes place after repeated treatments with the same drug. In addition, 
most cytotoxic drugs are carcinogenic themselves. Thus, secondary tumors might be induced 
by the treatment. (Lake and Robinson, 2005; Chabner and Roberts, Jr., 2005). 
Taking all the side effects of chemotherapy together and regarding the poor prognosis 
especially for the treatment of solid tumors, it becomes clear that chemotherapy alone cannot 
be the ultimate solution. Other, more specific therapies have to be developed that leave the 
healthy cells of a body unharmed. One such therapy that has made good progress within the 
last couple of years, particularly when it comes to solid tumors, is radiotherapy. 
1.2.1.2 Radiotherapy 
Radiotherapy as a means to treat cancer is even older than chemotherapy. Shortly after 
Wilhelm Conrad Röntgen discovered X-rays in 1895, they were used on tumor patients in the 
clinic. Generally, radiotherapy is the use of direct or indirect ionizing radiation to destroy the 
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DNA of malignant cells and thus control tumor growth. Radiotherapy can be used as primary 
tumor therapy, but in the majority of cases it is used in combination with surgery or 
chemotherapy (reviewed in Bucci et al., 2005). 
However, it has been a long way from the first trials to treat tumors with radiotherapy to what 
is in routine nowadays. After numerous trials with X-rays, γ-rays, electrons (microwave 
technology) and radioactive ‘non-permanent’ implants, some basic rules were defined:  
Firstly, cells that tend to be radiosensitive usually have three properties: they divide rapidly, 
they do have a long dividing future and they do have an unspecialized phenotype. All three 
are properties, which are very common among tumor cells (reviewed in Bernier et al., 2004).  
Secondly, oxygen is important. There is a direct correlation between radiosensitivity and 
oxygen. Cells that are well oxygenated tend to be radiosensitive, while cells that are found in 
hypoxic regions are resistant to radiation. As solid tumors often have a distorted and tortuous 
tumor vasculature, regions of low oxygen or hypoxia are very common, rendering a large part 
of the tumor radioresistant. If such cells re-oxygenate after radiation therapy, the tumors can 
re-grow. This is even more problematic as these are the same cells, that are – due to low 
oxygen and low nutrient supply – slowly proliferating and thus also resistant to chemotherapy  
(Gray et al., 1953; reviewed in Bernier et al., 2004). 
Finally, a fractionated radiotherapy, in which the given dose of ionizing radiation is divided 
into fractions and given at different time intervals, is superior to a single high dose of ionizing 
radiation. As normal, healthy tissue tends to proliferate rather slowly, it has sufficient time to 
repair the damage that is induced by radiation before replication. In contrast, tumor tissue is 
rapidly proliferating and does not have enough time to repair the damage. Therefore, the 
radiation induced DNA-damage can be lethal for tumor cells. In addition, the efficacy of 
fractionated radiotherapy is increased because of differences in progression of cells through 
the cell cycle (redistribution), reoxygenation of the tissues and cell division (repopulation) 
(Withers, 1975; reviewed in Bernier et al., 2004). 
Radiotherapy of solid tumors has improved drastically within the last decades, which is 
mainly due to the rapid development in computer technology that led to three dimensional 
imaging of the tumors within the body. With computed tomography and magnetic resonance 
imaging, it is possible to gain a detailed view of how the tumor is located and shaped. Thus, 
tumors can be treated with exact calculated high doses of radiation with minimized damage of 
adjacent organs and tissues (Blasberg, 2002; Bucci et al., 2005).  
By using hadrons instead of photons, electrons or X- and γ-rays, the outcome of radiotherapy 
could further be enhanced. Hadrons are subatomic particles that are larger than electrons, such 
as protons, neutrons and ions. These hadrons are applied as accelerated particle-beams, which 
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offer an improved dose conformation and a better sparing of normal tissue surrounding the 
tumor, compared to conventional radiation (Suit et al., 2003; Schulz-Ertner et al., 2006).  
However, radiation therapy is still accompanied by side effects. Besides acute, mild side 
effects like nausea, swelling or diarrhea, the long term side effects can manifest themselves 
from fibrosis and permanent hair loss to infertility or secondary radiation induced cancers 
(Bucci et al., 2004; Bentzen, 2006).   
These side effects added to the problem that low oxygenated, slowly growing tumor cells are 
not affected at all clearly point out the need for new or additional cancer therapies. Several 
preclinical and clinical trials are in progress now that investigate innovative tumor therapies, 
as they are called in this work, alone or in combination with chemotherapy, radiotherapy and 
surgery. 
1.2.2 Innovative tumor therapy 
Among the novel tumor therapies that have arisen within the last decades to treat solid tumors 
a very successful type of therapy stands out. This is the use of humanized monoclonal 
antibodies (mAbs) against growth factors or their receptors (Hinoda et al., 2004). 
Trastuzumab (humanized anti-HER2/neu/ErbB-2 mAb) is the first humanized mAb with 
antineoplastic activity that has passed phase III clinical trials. By its trade name Herceptin, it 
is approved for the treatment of solid, metastatic breast cancer (Nahta et al., 2004). 
Bevacizumab (Avastin), which targets vascular endothelial growth factor (VEGF) and inhibits 
angiogenesis, has been licensed in the EU in 2005 and is used to treat metastatic colorectal 
carcinoma (Diaz-Rubio, 2006). Other mAbs on the market are Erlotinib (Tarcerva), which 
inhibits the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) and is 
used for cancers of the lung and of the pancreas or Imatinib (Gleevec), which is used for 
chronic myelogenous leukemia and gastrointestinal stromal tumors. It binds to tyrosine kinase 
domains in the Abelson proto-oncogene (abl), c-kit (CD117) and platelet-derived growth 
factor receptor (PDGF-R) (reviewed in Collins and Workman, 2006)). Several additional 
humanized mAbs are still in clinical development with promising perspectives (Reichert and 
Pavolu, 2004). 
By binding to growth factors or their receptors, the therapeutical principle of the mAbs is to 
shut off the receptor-mediated signaling. Thereby they block cell division and cell growth. 
However, since all these mAbs target self/tumor antigens they can also influence non-tumor 
cells and adverse effects like cardiac dysfunction or thrombotic events have been observed 
(Hinoda et al., 2004). 
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Another special case of innovative tumor therapy is immunotherapy. In general, 
immunotherapy is a treatment to stimulate or restore the ability of the immune system to fight 
infection and disease. A simple method of activating the immune system of a cancer patient is 
the systemic administration of adjuvants, such as the pro-inflammatory cytokines Interleukin 
2 (IL-2) or Interferon-α (IFN-α).  
The administration of IL-2 could dramatically increase clinical regression in of melanomas in 
immunotherapeutic trials (Rosenberg et al., 1998). IL-2 has also been shown to have effects in 
renal cell carcinoma (RCC) (Margolin, 2000).  It is thought that IL-2 facilitates the migration 
of tumor-antigen (TA)-specific T cells to the tumor site by increasing blood vessels 
permeability. It further might induce proliferation and activation of effector functions of CD8+
T cells, but also secondary production of pro-inflammatory cytokines (Wang et al., 2004). 
Similar results have been obtained for IFN-α in melanoma patients (Sabel and Sondak, 2003). 
Impressive anti-tumor activity was also observed with Bacille Calmette-Guerin (BCG) as a 
non-specific immune stimulant for non-invasive bladder cancer and lung cancer (see below) 
(reviewed in Alexandroff et al., 1999; Raez et al., 2005).  
Cell based immunotherapies are also amongst the innovative therapies. Trials have been made 
with so-called lymphokine-activated killer cells (LAK). Peripheral blood cells of patients 
were pulsed with IL-2 in vitro to activate killer cells and re-infused into the patient. While 
LAK-therapy was effective in some melanoma patients, complete responses were rare. In 
addition, such cells are difficult to deliver and the priming steps with IL-2 are rather 
challenging (reviewed in Yannelli and Wroblewski, 2004).  
A more directed, specific immunotherapy is adoptive transfer. This method utilizes specific T 
cells to attack cancer cells via cytotoxic responses. Therefore, T cells that are reactive against 
a patient’s cancer cells are expanded in vitro to be adoptively transferred back into the patient. 
These can be tumor infiltrating lymphocytes from the cancer patient, which do have a natural 
cytotoxic activity, or genetically engineered T cells (Yee, 2006). 
Other approaches aim at the immunization against tumor antigens. Here, tumor lysates or 
irradiated tumor cells are injected into the patient to induce a specific immune response 
against the tumor antigens. A variation of this therapy is the use of dendritic cells (DCs) to 
induce an anti-cancer response. DCs are the best known stimulants of an immune response 
and therefore an obvious choice for specific initiation of an anti-cancer response. In this case, 
DCs from cancer patients are differentiated in vitro and loaded with tumor-specific antigens. 
A common method is the administration of purified tumor-antigens or tumor lysate to the 
DCs. Being loaded with tumor-antigens the DCs are injected into the tumor patients, where 
they present the tumor antigens and activate effector lymphocytes (CD4+ T cells, CD8+
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T cells, B cells and natural killer cells (NK cells)). These cells should migrate to the tumor 
and exert a cytotoxic activity against the tumor cells (Schott, 2006).  
As a special case of immunotherapy, the prophylactic intervention in cancer development 
should be considered here. The introduction of a vaccine against Hepatitis B has dramatically 
reduced the incidence of hepatocarcinomas in some developing countries. Probably the 
continuous inflammation of the liver caused the induction of tumorigenesis (reviewed in 
O'Brien et al., 2004). Unfortunately, a prophylactic vaccination against cancer is not always 
possible. 
Nevertheless, around 20-30% of all cancers are believed to be induced by pathogens. For 
instance chronic infections by bacteria are commonplace. Exemplary are Helicobacter pylori
infections, which are related to the development of gastric cancer (reviewed in Pritchard and 
Crabtree, 2006). Thus, it might be possible to develop prophylactic therapies or vaccines for 
several other types of cancer. On the other hand, antigens of such tumor-causing pathogens 
might represent potential targets for tumor-immunotherapies.  
A case that has drawn attention in 2006 was the approval of two vaccines directed against 
human papilloma virus (HPV), which were designed to immunize against certain sexually 
transmitted diseases, such as cervical cancer and genital warts that are caused by the virus. 
Both vaccines have been shown to offer 100 percent protection against the development of 
cervical cancer. Such an efficiency of a vaccine has rarely been observed so far (Lowy and 
Schiller, 2006; Lollini et al., 2006). However, the success of most of such trials is rather 
scarce up to now. 
Direct gene therapy is also used to treat cancer. One concept of gene therapy is gene transfer, 
in which a foreign gene is transferred and inserted into the cancer cells. These can be genes 
that induce cellular death after expression (suicide genes), genes that inhibit angiogenesis 
(reviewed in Liu et al., 2006) or genes that lead to the expression of immunostimulatory genes 
(reviewed in  Cross and Burmester, 2006). Genes can be delivered into tumor cells via viral 
delivery systems like replication incompetent adenoviruses. Alternatively, non-viral delivery 
systems can be used such as naked DNA that can be transferred into the tumor cells by 
microinjection, particle bombardment, pressure or electroporation but also via polymeric 
delivery systems (Polymer-DNA complexes) and liposomal delivery systems, in which the 
DNA is entrapped in liposomes (reviewed in Patil et al., 2005). These therapies are still highly 
experimental. 
In this context oncolytic virus therapy should be mentioned. Oncolytic viruses have been 
genetically modified to specifically target to and destroy cancer cells. Usually, these vectors 
are designed to infect cancer cells and to induce cell death via virus propagation, expression 
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of cytotoxic proteins and cell lysis. Commonly used are Adenoviruses for prostate cancer. 
Animal experiments have also been performed with influenza virus or new castle disease 
virus amongst others. However, these attempts are still in an experimental stage (reviewed in  
Mullen and Tanabe, 2002;  Hemminki et al., 2003). 
One very promising non-conventional tumor therapy is bacteria-mediated tumor therapy. It 
could be combined with gene therapies and immune therapies and could even be used as gene 
delivery system. Additionally, it specifically aims at the weakly oxygenated, slowly growing 
tumor cells inside solid tumors, which are not well affected by chemo- and radiotherapy. 
1.2.2.1 Bacteria-mediated tumor therapy 
The original idea to use bacteria as an anticancer treatment is rather old. Since the middle of 
the 19th century clinicians have experimented with live bacteria like Streptococci, 
Mycobacteria and Clostridia to treat human cancer. The first reported treatment with living 
bacteria as an anti-cancer agent was done in 1868 by the German physician W. Busch 
(reviewed in Pawelek et al., 2003). He intentionally infected a woman with an inoperable 
sarcoma by cauterizing the tumor and laying the woman into a bed that was previously used 
by a patient with “erysipelas”, a Streptococcus pyrogenes infection. As intended, the woman 
became infected and rapid tumor shrinkage occurred. Unfortunately, the patient died of the 
infection nine days later (reviewed in Van Mellaert et al., 2006). 
30 years later two surgeons, the American William B. Coley and the German Friedrich 
Fehleisen, independently began treating cancer patients with S. pyrogenes after they both had 
observed the cure of cancer or at least remarkable tumor regression by severe erysipelas 
infections. Coley finally dedicated a big part of his life to explore the use of bacteria in anti-
cancer therapy. In his later studies he shifted from injecting live bacteria to injecting bacterial 
extracts that were derived from inactivated Streptococci and Serratia marcescens, a mixture 
that is nowadays known as “Coley’s toxin”, into his patients. He hypothesized that an immune 
reaction against the infectious material crossreacts with the tumor cells and destroys them, 
and thus causes the tumor to shrink. Hence, he could be considered the founder of cancer 
immunotherapy (reviewed in Pawelek et al., 2003; Ryan et al., 2006; Van Mellaert et al., 
2006). 
However, the beginnings of bacteria-mediated tumor therapy can only be regarded as episodic 
and hardly be called successful. Many patients became ill or died in succession of the 
systemic toxicity that was induced by the bacterial infection or the release of necrotic tumor 
debris. In addition, a complete cure of cancer could rarely be obtained, as a persistent outer 
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rim of viable tumor cells after bacterial treatment remains (see below). From this, the tumor 
can re-establish itself (Agrawal et al., 2004). 
Some years ago bacteria as a means for specific tumor therapy had a renaissance, when BCG 
was found to decrease the rates of recurrence of superficial bladder cancer with 70% of the 
patients responding to BCG (Meyer et al., 2002). BCG is a local bacterial tumor therapy, in 
which live attenuated BCG are applied directly into the bladder. Up to now BCG is the only 
bacterial tumor therapy that is successfully used in the clinics. Akaza (1995) showed that 
84.4% of 32 cases with CIS (carcinoma in situ) showed a complete response to BCG. BCG is 
further used for residual papillary tumors to reduce the number and frequency of recurrent 
tumors and to prevent disease progression. The exact mechanism of BCG induced anti-tumor 
response is not completely solved yet. Jackson et al. (1994) suggested the induction of an 
immune response and a tumor response. While the immune response consisted of an 
inflammatory infiltrate and the secretion of cytokines, they also described CD8 T cells killing 
via the induction of apoptosis or necrosis. CD4 T cells contribute to the anti-tumor response 
by the secretion of cytokines leading to the maturation of cytotoxic T cells or possibly more 
specific BCG activated killer cells (BAK) (reviewed in Meyer et al., 2002) .  
Experimentally, bacterial strains of the genera Bifidobacterium, Clostridium, Salmonella and 
even Escherichia coli (E. coli) were found to specifically migrate to and preferentially 
replicate within solid tumors when given systemically (Lemmon et al., 1997; Yu et al., 2004; 
Sasaki et al., 2006). This intrinsic tumor-targeting feature of the bacteria together with the 
tremendous improvements in genetic engineering and genomic sequencing of bacterial 
genomes, have sparked new interests in using bacteria for tumor therapy and opened new 
possibilities for cancer therapies. Thus, bacteria can be exploited not only as anti-cancer 
agents, but also as carriers or transporters that could specifically bring chemotherapeutics, 
toxins, angiogenesis inhibitors and immunotherapeutics like cytokines directly to the place 
where they are needed: into the solid tumor.  
Although many experiments have been performed with different kinds of bacterial strains in 
order to treat solid tumors, it is still not possible to predict, which bacteria will be successful 
as therapeutic agents and which bacteria will fail. Bacterial infections always include 
physiological stress for the host, thus not all bacteria are suitable for tumor therapy. 
1.3 Suitable bacteria for tumor therapy 
Until now, bacteria-mediated tumor therapy has mainly focused on obligate anaerobic species 
of Clostridium and non facultative anaerobic bacteria of the genus Salmonella. Due to the 
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blood vessels in tumors that are structurally and functionally abnormal and result in spatially 
heterogeneous blood flow (Bergers and Benjamin, 2003), solid tumors are known for their 
acute and chronic hypoxic regions. As mentioned before, these regions are problematic in 
chemotherapy and radiotherapy, but they provide optimal growth conditions for anaerobic 
bacteria. A schematic overview of the microenvironmental regions in a centrally necrotic 
tumor is visualized in Fig. 1.4. 
Fig. 1.4: Schematic overview of 3 microenvironmental regions in a centrally necrotic tumor. A spontaneous 
tumor might consist of more than one necrosis. Decreasing magnitude of various physiological 
parameters is indicated as +++, ++, +, +/- and -. The figure is taken from Jain and Forbes, 2001.  
Certainly, being able to live under anaerobic conditions cannot be the single demand for an 
anti-cancer bacterium. But what are the criteria that render a bacterium adequate for anti-
cancer therapy? In summary, an ideal anti-cancer bacterium should (Jain and Forbes, 2001): 
• be non-toxic to the host  
• replicate only within the tumor and spare all the healthy tissues and organs of 
the host 
• be motile and disseminate evenly throughout the tumor, including the hypoxic, 
necrotic and the “healthy” regions of a tumor 
• be easily genetically manipulated and easily and stably transformable 
• kill tumor cells by competition for nutrients or production of cytotoxins for 
instance by therapeutic molecules 
• slowly and completely be eliminated from the host after treatment 
• be of low immunogenicity or non-immunogenic 
None of the bacterial strains that are presently in experimental use fulfills all these criteria.  
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Regarding the requirement for low toxicity for the host, the use of Gram-negative bacteria 
might represent a problem. The administration of high doses of Gram-negative bacteria can 
induce tumor necrosis factor alpha (TNF-α) mediated toxic shock. TNF-α is induced upon 
stimulation with lipid A, a cell wall component of the bacterium. Nevertheless, Gram-
negative bacteria can still be favorable for bacteria-mediated tumor therapy. By disrupting the 
msbB gene of Salmonella, a gene that is involved in the synthesis of lipid A, Low et al. (1999) 
reduced the TNF-α induction, thereby generating an increase of LD50, the dose at which half 
of the infected animals die, by 10,000 fold. While enormously reducing the toxicity of this 
bacterium, the capacity to target into the tumor and suppress tumor growth was retained.   
In addition, highly pathogenic bacteria like Vibrio cholerae or Salmonella typhi, which do 
have the intrinsic ability to target solid tumors (Yu et al., 2004), represent a high risk for the 
patient. Thus, they have to be attenuated in a way that they remain invasive but harmless.  
More problematic is the search for bacteria that exclusively replicate in solid tumors and spare 
all the healthy tissues of a patient. Obligate anaerobic bacteria do fulfill this requirement, but 
they fail in spreading evenly throughout the tumor tissue, as for them well oxygenated areas 
are not supportive. Thus, facultative bacteria like E. coli or some highly attenuated 
S. typhimurium might be more suitable (Forbes et al., 2003; Yu et al., 2004; Saltzman, 2005). 
Similarly, requirements of easy genetic modification and transformation are well met by 
laboratory strains of E. coli or S. typhimurium. Many obligate anaerobic bacteria are more 
difficult to be stably manipulated. However, as long as the bacterium has a high delivery 
capacity for proteins or DNA, it can very likely be genetically modified to satisfy the needs, 
e.g. the production of cytotoxins (Tjuvajev et al., 2001; Theys et al., 2006). The competition 
of nutrients is a requirement that is naturally met by every bacterium. 
The demand for slow and complete elimination of the bacteria from the host can relatively 
easily be overcome by using bacteria that quickly respond to antibiotics or by using 
genetically modified, “conditionally lethal suicide” bacteria that die upon e.g. sugar-induced 
activation of suicide genes (Davison, 2002; Loessner et al., 2006). 
Finally, low immunogenicity of the bacterium used for anti-cancer treatment is required to 
prevent an immune response against the bacterial carrier itself that is independent of an anti-
tumor response. Highly immunogenic bacteria might be eliminated from the host before they 
reach their destination, especially when the same bacteria have to be used for repeated 
treatments. 
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1.3.1 Obligate anaerobic bacteria 
Among the obligate anaerobic bacteria that have been used for tumor-targeting are mainly 
species of the genii Clostridium and Bifidobacterium. 
Clostridia are often found in tumors of patients suffering from colon carcinomas. In fact, 
presence of Clostridia in a patient can be diagnostic for such neoplasia (Myers et al., 1992). 
Experimentally, the first attempts have been performed with spores of the Gram-positive 
bacterium Clostridium tetani (C. tetani) that were injected into normal and tumor-bearing 
mice. All tumor mice died of tetanus poisoning due to toxin production by growing vegetative 
cells, while the healthy control mice remained unaffected. On one hand this had proven that 
the spores required anaerobic conditions to germinate. Such conditions are present only in 
solid tumors. On the other hand it demonstrated the strong selectivity of the spores for 
hypoxic areas of the tumors and its general applicability for tumor therapies (Malmgren and 
Flanigan, 1955). Recent studies explored spores of non-pathogenic Clostridia such as C. 
novyi-NT, a C. novyi strain devoid of lethal toxin or C. sordellii (Dang et al., 2001; Agrawal 
et al., 2004). 
As mentioned already, the spores need low oxygen partial pressure, since they germinate only 
within the hypoxic regions of solid tumors. Thus, colonization by Clostridia is limited to large 
solid tumors, in which blood supply is not sufficient to provide the complete tumor with 
oxygen (Barbe et al., 2006).  
The colonization of the tumor with Clostridia always led to an increase in the size of necrosis. 
This limits tumor growth. However, due to a remaining rim of viable tumor cells, the tumor 
tends to restart growth from such viable tumor cells. To improve bacterial tumor therapy with 
Clostridia, C. novyi-NT has been used in combination with chemotherapeutics (Dang et al., 
2001) and with radiotherapy (Bettegowda et al., 2003). In both cases the supplementary 
treatment with the bacteria leads to an increased anti-tumor activity of the treatment.  
Other approaches utilized living Clostridia that were engineered to produce anti-cancer agents 
such as TNF-α. This cytokine is highly toxic when given systemically. Being encoded under a 
bacterial promoter that is induced by radiation, tumor-specific secretion of TNF-α could be 
demonstrated (Theys et al., 1999).  
C. histolyticum and C. sporogenes were both engineered to carry E. coli cytosine deaminase 
(CD). CD is a so-called prodrug converting enzyme that is able to convert the non-toxic 
prodrug 5-fluorocytosine (5-FC) into the cytotoxic drug 5-fluorouracil (5-FU) (Theys et al., 
2001; Liu et al., 2002). The mechanism of the conversion of 5-FC into 5-FU is depicted in 
Fig. 1.4. Likewise, C. acetobutylicum was engineered to secrete biologically active rat IL-2 as 
an anti-cancer agent. However, this strain has not been tested in vivo yet (Barbe et al., 2005).  
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Fig. 1.5: Schematic representation of bacteria-mediated cytosine deaminase therapy with B. longum as a model 
bacterium. The figure is taken from Fujimori, 2006.
Similar treatments were carried out with the non-pathogenic, Gram-positive domestic 
bacterium Bifidobacterium longum (B. longum). B. longum was shown to colonize large solid 
tumors upon systemic infection, similar to Clostridia. Genetically engineered B. longum were 
successfully used in chemically induced mammary rat tumors (Yazawa et al., 2001). One such 
approach also exploited the enzyme-prodrug therapy with E. coli CD as has been described 
for Clostridia (Sasaki et al., 2006), (compare Fig. 1.5).  
Bifidobacterium adolescence was transformed with a plasmid encoding the endostatin gene. 
Endostatin is a broad spectrum angiogenesis inhibitor that might interfere with angiogenesis 
promoting growth factors such as VEGF (reviewed in Folkman, 2006). This bacterium could 
target subcutaneously implanted Heps liver tumors in BALB/c mice, and inhibited 
angiogenesis and tumor growth (Li et al., 2003a). 
A major disadvantage of such obligate anaerobic bacteria is that they are only able to target 
large solid tumors and leave small tumors and metastases unaffected (Pawelek et al., 2003; 
Ryan et al., 2006). This is due to the fact that small tumors are usually well vascularized and 
hence have no areas of hypoxia and necrosis. Additional measures have to be employed to 
reach the inhibition of angiogenesis and the induction of necrotic areas in smaller solid 
tumors. Therefore, obligate anaerobic bacteria will most likely never be able to distribute 
evenly throughout a solid tumors. If not exclusively designed as a supplementary treatment 
for chemo- or radiotherapy, tumor-targeting bacteria should be able to tolerate various 
conditions. Interestingly, even facultative anaerobic, tumor-targeting species like 
S. typhimurium or E. coli do not settle outside the tumor necrosis although they should not be 
affected by oxygen supply. 
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1.3.2 Facultative anaerobic bacteria 
When looking for an ideal anti-cancer bacterium that is at least theoretically able to meet all 
the mentioned demands for a perfect anti-cancer bacterium, facultative anaerobic bacteria 
seem to be the preferable choice for such therapies. Provided that a strain can be established 
that disseminates throughout solid tumors and fulfills most of the other mentioned criteria. 
Possible facultative anaerobic bacteria as candidates for anti-cancer therapies include E. coli, 
Salmonella species and Shigella flexneri (S. flexneri). 
1.3.2.1 Escherichia coli  
A prime candidate for bacteria-mediated tumor therapy is Escherichia coli. E. coli is a Gram-
negative, rod-shaped, facultative anaerobic bacterium, which belongs to the group of 
enterobacteriaceae (Schlegel, 1992). It was discovered in 1919 by the German Theodor 
Escherich as one of the main species of bacteria that lives in the lower intestines of mammals. 
Today it belongs to the best investigated organisms in the world. Originally, E. coli is a 
commensal bacterium that colonizes the gastrointestinal tract of human infants within the first 
hours after birth, where it coexists with its human host in mutual benefit for decades. Inside 
the gastrointestinal tract it resides in the mucous membrane of the mammalian host (Nataro 
and Kaper, 1998; Kaper et al., 2004). Very rarely commensal E. coli are able to cause disease 
in immunocompromised hosts or when the gastrointestinal barriers break down. On the other 
hand, several highly adapted E. coli strains have evolved that cause a broad spectrum of 
human diseases, characterized by three different clinical syndromes: urinary tract infections, 
sepsis/meningitis and enteric/diarrheal disease.  
Uropathogenic E. coli (UPEC) infect the host via the urethra. They are associated with cystitis 
and pyelonephritis in the normal urinary tract, which include the expression of P fimbriae, 
hemolysin, aerobactin, serum resistance and encapsulation (Manges et al., 2001). 
Meningitis/sepsis-associated E. coli (MNEC) is a pathotype that is the most common cause 
for Gram-negative neonatal meningitis. This strain is spread hematogeneously (Dawson et al., 
1999; Kaper et al., 2004). 
The intestinal pathogens are further divided into six categories: enterotoxigenic E. coli
(ETEC), enterohemorrhagic E. coli (EHEC), enteropathogenic E. coli (EPEC), entero-
aggregative E. coli (EAEC), enteroinvasive E. coli (EIEC) and diffusely adherent E. coli
(DAEC). Each of the diarrheagenic E. coli has unique features in their interaction with 
eukaryotic cells (Nataro and Kaper, 1998; Torres et al., 2005). The unique feature of each of 
these bacteria is shown in Figure 1.6. 
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Fig. 1.6: Pathogenic schemes of diarrheagenic E. coli. The six different categories of enterophatogenic E. coli
use different mechanisms to interact with the host cells. These interactions are described in more detail 
in the text. The descriptions are based on in vitro studies and do not necessarily completely reflect the in 
vivo mechanism. The figure is taken from Nataro and Kaper, 1998. 
ETEC strains adhere to small bowel enterocytes at the surface of the small bowel mucosa and 
induce watery diarrhea via the secretion of heat-labile (LT) and/or heat-stabile (ST) 
enterotoxins (Spangler, 1992; Wolf, 1997).  
EHEC adhere to enterocytes in the colon and destroy the normal microvillar architecture by 
inducing an attaching and effacing lesion. EHEC are further known for the elaboration of 
Shiga toxin as their major virulence factor, which, after systemic absorption, leads to 
potentially life-threatening complications (Reid et al., 2000; Perna et al., 2001).  
EAEC adhere to small and large bowel epithelia as a thick layer of auto-aggregating bacteria 
that deliver secretory enterotoxins and cytotoxins (Hicks et al., 1996; Nataro and Kaper, 
1998).  
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DAEC elicit a characteristic signal transduction effect in small bowel enterocytes that 
manifests as growth of long, finger-like projections, which wrap around the bacteria (Bilge et 
al., 1989; Bernet-Camard et al., 1996). 
Similar to EHEC, EPEC induce the attaching and effacing of lesions in enterocytes, but in the 
small bowel. They destroy the normal microvillar architecture and induce the characteristic 
attaching and effacing lesion (McDaniel et al., 1995; Kenny et al., 1997).  
EIEC actively invade the colonic epithelial cell, lyse the vacuole and move through the cell by 
nucleating actin microfilaments. These bacteria can move laterally through the epithelium by 
direct cell-to-cell spread or by exiting the cell and entering the adjacent cell via the baso-
lateral plasma membrane (Pupo et al., 2000; Sansonetti, 2002; Wei et al., 2003). 
Besides the commensal type in the gut of mammals and the numerous potentially pathogenic 
species, E. coli strains exist, which have beneficial therapeutic effects for their host. One such 
strain is the probiotic E. coli Nissle 1917, which was isolated from the stool of a soldier by 
Dr. Alfred Nissle. This bacterium had prevented the soldier from enteritis, while all the 
comrades of the soldier suffered from the disease (Nissle, 1918). In the meantime, E. coli
Nissle 1917 is applied as Muafluor® for probiotic treatment for diarrhea. It also showed 
success in the treatment of diseases like ulcerative colitis, Crohn’s disease and inflammatory 
bowel disease (Kruis et al., 1997; Malchow, 1997; Kruis, 2004). Recently, E. coli Nissle 1917 
was explored for targeted delivery of molecules to the intestine. When genetically engineered 
to display a model peptide on the bacterial surface, this strain proved to be useful for localized 
delivery of molecules into the intestine in cases where an immune response against the carrier 
strain and its product is undesired (Westendorf et al., 2005).   
Independent of the pathological and probiotic potential of some strains, E. coli has become 
the laboratory microorganism. Having been isolated from the stool of a convalescent 
diphtheria patient in 1922, E. coli K12 was repeatedly passaged for 50 years in the pathology 
department at Stanford University before various strains were typed and categorized 
(Bachmann, 1972; Fux et al., 2005). The genome of an E. coli K12 laboratory strain, which 
had been relieved of the temperate phage lambda by UV irradiation and of the F plasmid by 
acridine orange, has been fully sequenced (Blattner et al., 1997). A plethora of defined 
mutations have rendered this enterobacterium a non-pathogenic tool in the laboratory, which 
is easy to handle and to genetically modify. Besides the described manipulations of E. coli
Nissle 1917, laboratory strains of E. coli were shown to be usable in many clinical 
applications, including anti-cancer therapies.  
In 2004 Yu et al. could demonstrate that the laboratory strain E. coli DH5α was able to home 
to and proliferate within solid tumors of nude mice after a systemic administration. This was 
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extended to tumor-bearing immunocompetent Lewis rats. Similar to systemic infections with 
attenuated S. typhimurium, Vibrio cholerae and Listeria monocytogenes, light-emitting E. coli
were shown to naturally home to primary tumors, but also to small metastatic nodules. The 
authors proposed that all tested bacterial strains enter the tumors through leaky vasculature 
and remain there to escape the host’s immunosurveillance and find refuge in the tumor tissue.  
Half a year later, Critchley et al. (2004) were able to prove in vivo protein delivery of β-
galactosidase, a hydrolase enzyme that catalyzes the hydrolysis of beta-galactosides into 
monosaccharides, by recombinant, invasive E. coli into the tumor cells of a subcutaneous B16 
tumor. These E. coli were expressing invasin from Yersina pseudotuberculosis to selectively 
invade non-phagocytic cells, in which β1-integrin is expressed and accessible. Although 
Critchley et al. injected the recombinant E. coli directly into the tumors of the mice their 
experiments highlighted the possible therapeutic applications for E. coli as drug delivery 
vectors into solid tumors.  
Other E. coli based anti-cancer strategies explored recombinant, invasive E. coli as oral 
vaccines, which are taken up from the intestinal lumen to the Peyer’s Patches, where they co-
localize with DCs and B cells. These bacteria were modified to co-express model antigens, 
which resulted in systemic protection against a lethal challenge with antigen expressing tumor 
cells (Critchley-Thorne et al., 2006). 
1.3.2.2 Salmonella enterica serovar Typhimurium 
A presently often employed candidate for bacteria-mediated anti-cancer therapy is Salmonella 
enterica serovar Typhimurium. S. typhimurium is a facultative anaerobic, Gram-negative, rod-
formed bacterium that belongs to the group of enterobacteriaceae (Schlegel, 1992). The genus 
Salmonella enterica comprises diverse groups of Salmonella, which are the causative agent of 
infections of the lower intestine in animals and man. The severity of the infections varies 
depending on the infecting strain and can result in life-threatening typhus. S. enterica serovar 
Typhimurium serves as experimental mouse model for human typhoid fever. In humans 
typhus is caused by S. typhi (Pang et al., 1998), while S. typhimurium only causes enteritis.   
Being ingested with contaminated food, Salmonellae enter the body by invading the intestinal 
mucosa. Therefore, they have to cross the mucosal surfaces of the gastrointestinal tract. In the 
natural course of infection, Salmonellae target selectively, but not exclusively, M cells, a 
unique epithelial cell type that is specialized for transepithelial transport of macromolecules. 
M cells are located in the follicle associated epithelium (FAE) that covers the small intestine 
and the colon (Clark et al., 1994; Neutra et al., 1996). Here, the Salmonellae cause active 
ruffling of the apical surface of the M cell, which eventually leads to a disassembly of the 
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apical cytoskeleton and the engulfment of the bacteria into membrane bound vesicles, a 
process that is called macropinocytosis (Finlay et al., 1991; Bliska et al., 1993; Jones et al., 
1993; Clark et al., 1994; Jones et al., 1994). In contrast to other enteropathogenic bacteria, 
Salmonellae do survive and replicate within the phagosome, but they are unable to escape this 
compartment. After rapid transcytosis, Salmonellae are transported into the transepithelial 
pocket, where they are taken up by professional phagocytes like macrophages, neutrophils 
and DCs. Within these cells, genes of SPI1, the Salmonella pathogenicity island 1, are 
activated. These genes are representing the invasion system of Salmonella. SPI1 encodes a 
type III secretion system that is able to inject bacterial proteins into the cytosol of the infected 
phagocytic cell (see below). Thereupon caspase-1, a cysteine-aspartic-acid-protease, is 
activated. This results in killing of the infected macrophages in a process similar to apoptosis. 
As a consequence the engulfed bacteria are released and inflammation is initiated. By 
activation of SPI2, another pathogenicity island, which encodes an alternative type III 
secreton, Salmonellae evolved a strategy to survive inside macrophages. This might facilitate 
dissemination of the bacteria in the host. As can be seen in Figure 1.7, Salmonellae are also 
able to infect epithelial cells directly (2) and they can be captured by DCs at the mucosal 
surface and are then transported from the gastrointestinal tract to the bloodstream by 
macrophages (3) (reviewed in Mastroeni and Menager, 2003; Abrahams and Hensel, 2006).  
The gastroenteritis that is associated with Salmonella infections is caused by the irritation of 
the mucous membrane in response to the release of endotoxin, a lipopolysaccharide of the 
bacterial cell wall.  
Beside its pathogenic characteristics during its natural route of infection, Salmonella species 
have been shown to exhibit a promising potential as therapeutic agent for cancer- and 
immunotherapies. As Salmonella species are closely related to E. coli, they can be similarly 
genetically modified like their laboratory relative. Vectors that are designed in E. coli
laboratory strains can be directly transformed into and used by S. typhimurium in the mouse 
model. In addition, the full sequence of S. typhimurium’s genome is known (Sanderson et al., 
1995), which facilitates genetic manipulations. Therefore, Salmonellae have been extensively 
used as a delivery system for heterologous antigens and for the construction of multivalent 
vaccines (Lee et al., 2004; Bauer et al., 2005; Avogadri et al., 2005; Xiang et al., 2005; Lee et 
al., 2005). They can also be manipulated to deliver proteins to host tissues and malignant 
tumors. King et al. (2002) for instance developed an attenuated S. typhimurium strain that 
expresses E. coli CD. This strain accumulates in solid tumors when given systemically. After 
a systemic administration of 5-FC to mice bearing an adenocarcinoma, tumor-specific 
conversion into the cytotoxic drug 5-FU was observed and resulted in inhibition of tumor 
growth. Other researchers (Saltzman et al., 1996; Saltzman et al., 1997) manipulated 
 1 Introduction 22 
attenuated S. typhimurium to express human interleukin 2 (IL-2), a 15 kDa cytokine that was 
described to stimulate the host’s immune system (compare chapter 1.2.2). Naturally it is 
produced by activated CD4+ T cells, promotes lymphocyte killing and enhances the cytolytic 
activity of T cells and NK cells. Systemically administered, high doses of IL-2 caused severe 
toxicities in a number of patients, which include malaise, fever, anasarca, jaundice, renal 
dysfunction and capillary leak syndrome (Kintzel and Calis, 1991; Saltzman, 2005). In 
contrast, local production of IL-2 by attenuated S. typhimurium inside solid tumors did – at 
least in animal models – cause only diminished toxicities. At the same time significantly 
fewer neuroblastoma metastases were found and significantly smaller neuroblastomas 
(Saltzman et al., 1996). 
Fig. 1.7: Salmonella routes for crossing the intestinal barrier in the course of an oral infection. The single steps 
are described in the text. The figure is taken from Sansonetti, 2002. 
The fact that S. typhimurium can easily be genetically modulated and manipulated can be 
favorable for tumor therapies. As described above, by deleting the gene for msbB, an altered 
LPS is present in the cell wall of this strain. This did not alter the tumor targeting behavior, 
but resulted in lower TNF-α stimulation and thus in lower toxicity (Low et al., 1999; Toso et 
al., 2002; Rosenberg et al., 2002). 
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As mentioned before, S. typhimurium theoretically meets the majority of the demands for an 
ideal anti-cancer bacterium. It can grow under aerobic and anaerobic conditions, it has the 
ability to survive in many of different host cells, including epithelial cells, macrophages and 
dendritic cells and it has the intrinsic property to preferentially invade solid tumors at tumor-
liver ratios of 250:1 – 9000:1 (Pawelek et al., 1997). In contrast to obligate anaerobic bacteria 
like Clostridia, S. typhimurium does not only colonize big solid tumors with a huge hypoxic 
core. Rather they can even accumulate in micro-metastases after systemic administration (Yu 
et al., 2004). Nevertheless, several animal studies revealed that S. typhimurium although being 
able to live under aerobic conditions, still favors the necrotic tumor tissue, leaving the viable 
tumor cells intact. According to the study from Kasinskas and Forbes (2006), quiescent cancer 
cells produce compounds that specifically chemoattract the bacteria into the quiescent and 
necrotic tumor tissue. This results in the accumulation and proliferation of the bacteria inside 
the necrosis. Interestingly, although the initial attraction of S. typhimurium towards the 
necrotic area inside a solid tumor might partially be solved, the reason why they do not 
colonize the whole tumor and distribute evenly throughout the tumor tissue remained unclear 
thus far.  
Concordantly, first clinical trials with an attenuated S. typhimurium in a Phase I study did not 
show the desired results. While most patients could tolerate the intravenous infection with the 
bacteria and some exhibited bacterial colonization of the tumor, only one patient responded to 
the treatment completely and was tumor free three months after infection. In all other patients, 
tumor growth was not retarded and the tumor biopsies of the examined tumors showed only 
focal colonization by bacteria. The authors mainly attributed the poor outcome of their study 
to the inability of the bacteria to fully colonize the tumors despite of the administration of a 
high dose (Toso et al., 2002; Heimann and Rosenberg, 2003). 
1.3.2.3 Shigella flexneri  
A third potential candidate for bacteria-mediated tumor therapy is Shigella flexneri
(S. flexneri), another member of the family of Enterobacteriaceae (Jennison and Verma, 
2004). S. flexneri is a Gram-negative, facultative anaerobic, non-sporulating pathogen that is 
the cause for bacillary dysentery and shigellosis in man. Shigellosis is a bloody diarrhea that 
is caused by the invasion of the colonic and rectal mucosa by S. flexneri. Here, it leads to 
severe inflammation, which eventually results in the destruction of the mucosa (Sansonetti 
and Egile, 1998).  
S. flexneri belongs to the genus Shigella, which comprises the four species S. boydii, 
S. dysenteriae, S. sonnei and S. flexneri, respectively. According to biochemical differences 
and variations in their O-antigens, which are the antigenic, polysaccharide (O) side chains of 
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the lipopolysaccharide (LPS) molecule in the intact bacterial cell of Gram-negative bacteria, 
these species are further divided into serotypes. Based on this classification scheme, the 
species S. flexneri can be divided into 13 different serotypes (Jennison and Verma, 2004).   
S. flexneri is a highly infectious pathogen, as the uptake of 100 bacteria can be enough to 
cause shigellosis in adult humans (DuPont et al., 1989). This low infective dose is mainly due 
to S. flexneri’s ability to survive the low acidity in the host stomach by upregulating acid 
resistance genes like rpoS, the growth phase-dependent sigma factor sigma38 (Small et al., 
1994). 
During its natural course of infection, S. flexneri enters the body via the mucosal epithelium. 
Since S. flexneri is unable to invade epithelial cells through the apical route, this bacterium 
circumvents the apical entry by exploiting M cells in the FAE to enter into the colonic 
epithelium (Wassef et al., 1989). As a result, the majority of S. flexneri invade the epithelial 
cells through the basolateral pole of the colonic epithelial cells (Mounier et al., 1992). The 
reason for this detour via M cells and the resulting infection of epithelial cells via the 
basolateral pole still remains unclear. One possibility is that the mucin layer of colonic 
epithelial cells acts as a physical barrier to prevent the physical contact of the bacteria with 
the host cells, which is necessary for the bacterial entry into the cells. The second possibility 
is that the basolateral site of the epithelial cells displays molecules not present on the apical 
site, which function as receptors for bacterial cell entry.  
Shigellae appear to enter the M cells via a process called “membrane ruffling” (Sansonetti and 
Phalipon, 1999). Although the translocation of Shigella through M cells has been observed 
and documented repeatedly (Sansonetti et al., 1996; Sansonetti and Phalipon, 1999), no 
specific adherence system that mediates the interaction between Shigella and the luminal side 
of M cells has been identified so far. As invasive Shigella translocate much more efficiently 
through M cells than non-invasive mutants, the invasive phenotype seems to play a major role 
in this process.  
Upon internalization into an endocytic vacuole of the M cell, the bacteria are moved rapidly 
through the cell into the transepithelial pocket. Here, they are quickly phagocytosed by 
resident macrophages and dendritic cells. In order to obtain access to the basal side of the 
epithelial cells, S. flexneri cause apoptosis of the macrophages (Zychlinsky et al., 1992). 
Macrophages, which undergo Shigella-induced apoptosis, activate caspase-I, which 
eventually leads to the release of the two inflammatory cytokines. These are interleukin 1β
(IL-1β) and interleukin 18 (IL-18) (Sansonetti et al., 2000). Both cytokines cause 
inflammation; the release of IL-1β additionally recruits polymorphonuclear cells (PMNs) to 
the site of infection (Zychlinsky et al., 1994). Once released into the sub-mucosa, S. flexneri
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invade the epithelial cells through a macropinocytic process, in which bacteria-induced 
rearrangements of the cytoskeleton (“membrane ruffling”) engulf the bacteria into a vacuole.  
The uptake of S. flexneri into non-phagocytic cells like epithelial cell is in part conferred by 
products of the “invasion genes”, which are encoded on a 210-230 kb virulence plasmid 
(Sansonetti et al., 1982; Hale and Keren, 1992; Schuch and Maurelli, 1997; Dorman and 
Porter, 1998). Many of these plasmid encoded virulence factors are located within a 31-kb 
“invasion region”, which includes more than 30 genes (Maurelli et al., 1984; Sasakawa et al., 
1988). Inside this invasion region, two loci are crucial for the uptake of S. flexneri into 
epithelial cells: the ipa locus and the mxi-spa locus. While the ipa locus encodes the “invasion 
plasmid antigens” IpaA, IpaB, IpaC and IpaD, which are the effectors of bacterial cell entry, 
the mxi-spa locus encodes the components of a type III secretion system, a needle-like 
structure that is used to deliver proteins from the bacterial cytoplasm to the cytoplasmic 
membrane or into the cytosol of the host cell (Tamano et al., 2000). The detailed mechanism 
by which the Ipa proteins cause bacterial cell entry has not completely been solved. Upon 
contact of the bacteria with the host cell, Ipa proteins are secreted. IpaB, IpaC and IpaD form 
a complex that has been shown to bind α5β1 integrin that are present on the basolateral site of 
the epithelial cell (Watarai et al., 1996). Since β1-inegrins interact with the actin cytoskeleton, 
these integrins might induce the observed “membrane ruffling”. In addition, Tran et al. (1999) 
reported the activation of host cell Rho GTPases by IpaC, which triggers the actin 
polymerization and filopodial extensions in the vicinity of the bacteria.  
A second receptor, CD44, is also expressed on the basolateral site of the epithelial cells and 
binds not only to hyaluronan, a component of the extracellular matrix, but also to an IpaB-
IpaC complex (Skoudy et al., 1996a). The cytoplasmic domain of CD44 interacts with ezrin, a 
member of a protein family that crosslinks the plasma membrane with the actin cytoskeleton. 
Ezrin has been shown to be enriched in cellular protrusions that engulf invading Shigella
(Skoudy et al., 1996b) and is thought to play an important role in the regulation of Shigella
entry. In non-phagocytic cells, IpaC and IpaA seem to engineer the cytoskeletal 
rearrangements that are necessary for the uptake of the bacterium into the host cell (Tran et 
al., 1997; Bourdet-Sicard et al., 2000). 
Inside the host cell cytoplasm Shigellae lyse the membrane-bound vacuole by the invasin 
IpaB and escape into the cytoplasm (High et al., 1992). Here, the bacterium is able to replicate 
and to directly spread from one epithelial cell to the other. The intracellular, actin-based 
motility and the cell-to-cell spread are directed by the outer membrane protein IcsA 
(Bernardini et al., 1989). IcsA is expressed on the surface of the bacteria, with the greatest 
concentration on the “old” pole of the bacterium. The unipolar localization of IcsA is essential 
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for intracellular movement of the bacterium and seems to be dependent on the structure of 
LPS (Goldberg et al., 1993; Sandlin et al., 1995; Charles et al., 2001). 
The infection of the epithelial cells leads the activation of NF-κB, which ultimately results in 
the secretion of IL-8. Like IL-1β that is secreted by the infected macrophages IL-8 is a 
chemoattractant for neutrophils. As Shigellae are unable to escape the phagocytic vacuole of 
neutrophils, they are killed inside the phagosomes (Mandic-Mulec et al., 1997). Besides, 
leukocytes produce a host defense protein, neutrophil elastase (NE), which is capable to 
degrade Shigella virulence proteins within 10 minutes (Weinrauch et al., 2002). Thus, 
neutrophils obviously play an important role in controlling a Shigella infection. 
Unfortunately, neutrophils also migrate through epithelia, where they open the intercellular 
junctions between the epithelial cells and break the intact epithelial barrier. As result, 
Shigellae are now able to migrate directly to the basolateral site of the epithelial cells, sparing 
the detour via M cells and macrophages (Sansonetti et al., 1999; Philpott et al., 2000). A 
summary of the epithelial infection by S. flexneri is displayed in Figure 1.8. 
Fig. 1.8: S. flexneri routes for crossing the intestinal barrier during in the course of an oral infection. The single 
steps are described in the text. The figure is taken from Sansonetti, 2002. 
In 2002, Lan and Reeves reported that Shigella, although it still stands as a genus with four 
species, belongs in fact to the heterogeneous species of E. coli. A comparative analysis of 36 
housekeeping genes of E. coli K12 and S. flexneri 2a had revealed an average distance 
between the two species of 1.12%. This is within the range reported for E. coli. In addition, 
Shigella strains and EIEC strains share the presence of a large virulence plasmid and their 
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ability to induce their entry into epithelial cells and spread from cell to cell (Jin et al., 2002); 
(Parsot, 2005). 
Being that closely related to E. coli, S. flexneri is not only a pathogen, but its attenuated forms 
can easily be used as vaccines, or as tools for gene transfer or protein delivery. In September 
2000, Koprowski et al. reported the development of an attenuated S. flexneri 2a vaccine strain 
that expresses the colonization factor I antigen and mutant LT from ETEC. As intended, their 
prototype Shigella-ETEC hybrid vaccine could encode multiple ETEC antigens on a single 
plasmid in an attenuated Shigella vaccine strain and engender immune responses against the 
heterologous antigens, as well as against antigens of the vector strain.  
Other vaccination strategies aim directly at the protection against Shigellosis, or more exact, 
at protection against multiple serotypes of S. flexneri. As immunity to S. flexneri is serotype-
specific, the vaccination against one serotype will only provide protection against infections 
by the homologous serotype. The combination of several S. flexneri serotypes into a vaccine 
cocktail should make a cross-protection against most S. flexneri serotypes possible. 
Interestingly, a vaccine cocktail consisting of serotypes 2a and 3a could actually confer 
significant protection against challenges with the serotypes 1b, 2b, 5b and Y in guinea pigs 
(Noriega et al., 1999). Clinical trials with subunit Shigella vaccines revealed that proteosomes 
comprising native S. flexneri 2a LPS complexed to meningococcal outer membrane proteins 
were capable of generating a serotype-specific immune response in humans after intranasal 
administration (Fries et al., 2001). Similarly, S. flexneri LPS that had been attached to proteins 
and delivered parenterally was safe in humans and induced strong serum antibody responses 
(Cohen et al., 1996; Ashkenazi et al., 1999).  
In summary, attenuated strains of S. flexneri have been widely used as direct vaccines against 
Shigellosis or as vectors for the delivery of DNA vaccines to mucosal tissues. Although many 
experiments and clinical trials have been carried out, which exploit S. flexneri as vaccine, 
S. flexneri have not been used as an anti-cancer bacterium so far. S. flexneri has not yet been 
reported to have intrinsic tumor targeting ability. Indeed S. flexneri did not specifically target 
into solid tumors in our own experiments. This might be attributed mainly to the fact that 
S. flexneri is a human pathogen that is not pathogenic in mice. Thus, most of the inoculum 
might be cleared almost immediately from the mice. Nevertheless S. flexneri strains were still 
able to migrate to and settle inside solid tumors after systemic administration of attenuated 
S. flexneri strains (unpublished data). However, one should keep S. flexneri in mind when 
looking for a suitable bacterium for anti-tumor therapy. As S. flexneri is that closely related to 
E. coli, it might be manipulated as easily and the same plasmids can be used for manipulating 
E. coli and S. flexneri. In addition, S. flexneri has repeatedly been shown to mediate gene 
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transfer into mammalian cells. This makes them an interesting option for transporting 
therapeutic molecules encoded as eukaryotic genes on plasmids into mammalian tumor cells.  
Taken together, the investigation of the bacterial settlement inside solid tumors and the 
interaction of the bacteria with the tumor cells, as well as with different immune effector cells 
remains a major task in order to understand the preferential accumulation of facultative 
anaerobic bacteria like inside solid tumors. This knowledge would help to improve bacteria-
mediated tumor therapies. 
1.4 Bacteria-mediated tumor therapy 
As described above, upon colonizing tumors, bacteria lead to increased necrosis and 
inhibition of tumor growth. The remaining viable cells at the tumor rim regrow thus resulting 
only in partial remission. Therefore, an important feature of anti-cancer bacteria is the 
possibility to exploit them as transport vehicles for therapeutic macromolecules. The selective 
accumulation of the bacteria results in transport of the therapeutic molecules into the solid 
tumor, exactly to the place, where they should fulfill their therapeutic effect.  
Basically, there are three types of macromolecules that could be transported into solid tumors 
with bacteria as vehicles. (I), DNA, which is released into the cytosol of the infected 
mammalian tumor cells and is then translocated into the nucleus where the DNA is 
transcribed into mRNA. Thus, tumor cells express the therapeutic molecule themselves that 
should eventually lead to tumor destruction. (II), RNA that is delivered into the cytosol of the 
tumor cells, to be either translated into the encoded therapeutic molecule or to inhibit the 
expression of mammalian genes, e.g. by RNA interference. (III), therapeutic proteins, which 
are expressed by the bacteria. These proteins could remain in the bacteria, they could be 
secreted into the extracellular space in the tumor or they could be secreted into the cytosol of 
the tumor cell with the aid of appropriate secretion systems.  
1.4.1 Bacteria-mediated gene transfer 
One very exciting bacterial anti-cancer strategy is the transfer of eukaryotic expression 
plasmids via bacterial carriers into mammalian tumor cells. A schematic overview of bacteria-
mediated gene-transfer is depicted in Figure 1.9. 
Around 25 years ago, in 1980, Walter Schaffner (Schaffner, 1980) was the first to report 
direct transfer of plasmid-encoded Simian virus 40 (SV 40) DNA from E. coli into monkey 
cells. At that time, it was known that DNA can be transferred from one organism to the other 
within a kingdom, but gene transfer between prokaryotes and mammals was rather 
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unexpected. Thus far, the only well documented gene transfer between prokaryotes and 
eukaryotes had been the induction of crown gall tumors in higher plants by the non-invasive 
bacterium Agrobacterium tumefaciens. In the meantime, several attenuated, invasive bacterial 
strains including the Gram-negative bacteria Salmonella typhimurium, Shigella flexneri, 
invasive Escherichia coli, but also the Gram-positive species Listeria monocytogenes have 
been shown to efficiently mediate gene transfer into mammalian cells in vitro and in vivo
(Sizemore et al., 1995; Courvalin et al., 1995; Darji et al., 1997; Hense et al., 2001; reviewed 
in Dietrich et al., 1999). 
Fig. 1.9: Schematic overview of bacteria-mediated gene transfer into mammalian host cells. The basic principle 
of bacteria-mediated gene transfer is described in the text. The figure is taken from Weiss et al., 2001. 
Even though the discovery of bacteria-mediated gene transfer into mammalian cells has been 
reported repeatedly, the exact mechanism of how the bacteria release their plasmid load and 
how the plasmid reaches the nucleus is still unknown. Basically there are two ways how 
bacteria can deliver their plasmid into the cytosol of the host cell. Invasive, intracellular 
bacteria like S. flexneri and L. monocytogenes are able to escape from the phagolysosome into 
the cytoplasm of the host cell. After escape into the cytosol these bacteria die either because 
of an attenuation that makes them auxotrophic for the production of essential proteins, 
nucleotides or cell wall components that cannot be supplied by the host cell (Sizemore et al., 
1995; Courvalin et al., 1995), or they die by inducible autolytic systems or antibiotics that are 
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used to kill the bacteria inside the cytosol (Dietrich et al., 1998; Hense et al., 2001; Weiss and 
Krusch, 2001). The lysis of the bacteria results in the release of their plasmid load. In case of 
L. monocytogenes the bacterial escape out of the vacuole was shown to be essential for 
efficient gene transfer (Hense et al., 2001).  
Interestingly, other bacteria like S. typhimurium or invasive E. coli that are unable to escape 
out of the phagosome and hence die within the vacuole, are still able to release their plasmid 
out of the vacuole into the cytosol (Darji et al., 1997; reviewed in Grillot-Courvalin et al., 
1999). The mechanism of how plasmid DNA is transported into the cytosol remains unclear. 
In both cases the plasmid is transferred into the nucleus of the host cell, where it is transcribed 
into mRNA. The transport mechanism of the plasmid DNA into the host’s nucleus is not yet 
solved. Finally, the mRNA is transported back into the cytoplasm and translated. The 
transgenic protein can be detected in the host cell.  
Unfortunately, bacteria-mediated gene transfer per se is not very efficient as only a low 
percentage of infected eukaryotic cells will express the transgenic protein. In 2005 Zelmer et 
al. published a study in which they investigated the limiting step during bacteria-mediated 
gene transfer. According to their studies the bacterial plasmids are not simply released upon 
lysis, but remain associated with high molecular weight components. By further investigating 
the molecular mechanisms of plasmid transfer, bacterial gene transfer should become 
increasingly more efficient in the future.  
When exploiting bacteria as vehicles for gene therapy the intended application is important. 
Not every bacterium that is capable of gene transfer is suitable for every application. Based on 
different host cell preferences, different bacteria naturally infect different host cells. 
Salmonella species for example transfect primarily murine and human macrophages and 
dendritic cells. This property most likely renders them highly suitable for genetic vaccinations 
(Gentschev et al., 1995; Darji et al., 1997; Catic et al., 1999; Grillot-Courvalin et al., 2002).  
Contrary to Salmonellae, other bacteria like L. monocytogenes, invasive E. coli and S. flexneri
have been shown to infect and transfect a broader range of cell lines, preferably epithelial cell 
lines. Even the transfer into primary cells has been reported (Grillot-Courvalin et al., 2002). 
Therefore, these bacteria might be more suitable for gene therapies other than vaccination, 
e.g. bacterial anti-cancer therapies. Furthermore, L. monocytogenes and S. flexneri are able to 
spread from cell to cell and might therefore spread inside the infected tissue (e.g. the tissue of 
a solid tumor) and transfect cells that are not accessible for other ways of gene therapy. Even 
Salmonellae have been shown to transfect different types of cell lines in vitro after the 
successful introduction of the poreforming toxin Listeriolysin O (LLO) from 
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L. monocytogenes into a Salmonella strain (Gentschev et al., 1995). However, this strain 
would still lack the advantage of cell to cell spreading. 
Notwithstanding the low efficiency, bacterial transfection has been proven to be a useful tool 
in tumor therapy in mice. Lee et al. (2005) reported a successful transgene expression in 
murine melanomas after systemic administration of Salmonella choleraesuis, which was 
carrying a plasmid encoding thrombospondin-1. Thrombospondin-1 inhibits angiogenesis and 
modulates endothelial cell adhesion, motility and growth. Tumor-bearing mice that were 
treated with this Salmonella strain showed a significantly retarded tumor growth and a 
prolonged survival. The same group reported efficient gene transfer into murine melanoma 
and bladder tumors by S. choleraesuis carrying an endostatin expression vector, which exerts 
tumoricidal and anti-angiogenic activities (Lee et al., 2004).  
Other approaches aim at bacteria-mediated DNA vaccination against specific tumor antigens 
(Weth et al., 2001; Niethammer et al., 2001; Xiang et al., 2001; Pertl et al., 2003; Souders et 
al., 2006) and at the additional stimulation of the anti-tumoral immune response by 
coexpression of cytokines (Luo, 2004) or CD40-ligand (Xiang et al., 2001). 
All these reports highlight a noticeable effect that is caused by bacterial gene transfer. 
However, there is still one obvious limitation associated with such studies, namely the 
instability of the transfectants used. It is known, that high copy plasmids are quickly lost by 
the bacterial vehicle in vitro and especially in vivo, as a high number of plasmids represent a 
burden for the bacterium (Togna et al., 1993; Glick, 1995). In 2005 Bauer et al. circumvented 
this problem by designing low copy plasmids, which were dramatically more stable both in 
vitro and in vivo and resulted in improved immune responses. 
Recently Giacalone et al. (2006) presented an interesting new approach, in which they used 
protoplasted, achromosomal bacterial minicells to transfer plasmid DNA into eukaryotic 
Cos-7 cells. Minicells are small, achromosomal vehicles that are produced through ectopic 
septation during cell division and contain all molecular components of the parent cell minus 
the chromosome (Khachatourians et al., 1973). The use of bacterial mini cells that mainly 
consist of the bacterial envelope and the plasmid that has to be transferred might be a future 
direction of bacteria-mediated gene transfer. Minicells are almost as easy to manipulate as 
bacteria, they are smaller and their plasmid load is stable. They show no toxicity to cultured 
cell lines (Giacalone et al., 2006) and the co-transfer of DNA of the bacterial chromosome 
that might generate a problem is avoided. 
Taken together, the use of bacteria as transfer vehicles for plasmid DNA still remains a 
promising tool for successful cancer therapy in the future. 
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1.4.2 Bacteria-mediated RNA transfer  
A novel approach for bacteria-mediated tumor therapy is the use of tumor-targeting bacteria 
as carriers for RNA. Thus far, two different applications for bacterial RNA transfer into 
eukaryotic cells have been reported: the delivery of functional mRNA (Schoen et al., 2005; 
Loeffler et al., 2006) and the delivery of short hairpin RNA (shRNA) that elicits RNA 
interference in mammals (Xiang et al., 2006). Schoen et al. (2005) used a self-destructing 
L. monocytogenes strain to efficiently deliver translation-competent mRNA into the cytosol of 
epithelial cells, macrophages and dendritic cells in vitro. The method was further improved by 
Loeffler et al. (2006), who used the same bacteria in vivo, where they successfully delivered 
the model antigen ovalbumin (OVA). This resulted in the presentation of OVA in the context 
of major histocompatibility complex (MHC) class I molecules and to induction of a specific 
CD8 T-cell response. The way from the described vaccination strategies to the use of bacteria 
to transfer mRNA in anti-cancer therapies is rather obvious. 
In contrast, Xiang et al. (2006) used non-pathogenic, invasive E. coli to transcribe shRNAs 
against catenin β-1 from a plasmid, which induced significant gene silencing in the intestinal 
epithelium and in human colon cancer xenografts in mice. This approach has the potential to 
be further developed to clinically compatible RNAi-based anti-cancer therapies. 
Both forms of bacterial RNA transfer can be seen as potential alternatives to bacteria-
mediated DNA transfer as they have the advantage to lack the limiting step that impairs 
bacterial DNA transfer, i.e. the transport of the plasmid into the nucleus. On the other hand, 
only transient effects can be obtained with this approach. 
1.4.3 Bacteria-mediated delivery of therapeutic proteins 
A second alternative to bacteria-mediated gene transfer is to utilize tumor-targeting bacteria 
for the delivery of proteins. In fact, the delivery of therapeutic proteins by bacteria will in all 
probability become the dominant first generation of applications of bacterial therapies. Due to 
its importance, a detailed description is given here. 
As mentioned above, there are three different mechanisms via which bacteria can deliver 
therapeutic proteins: The proteins can remain in the bacteria, they can be secreted into the 
extracellular space in the tumor, or, they can be secreted into the cytosol of the tumor cell. 
The most difficult objective is to find a suitable expression system that is optimal for the 
intended application. 
An example for a therapeutic protein that remains inside the bacteria is CD. As described 
before, a plasmid with the gene that expresses the E. coli enzyme CD has successfully been 
 1 Introduction 33 
introduced into different tumor-targeting bacteria, including Clostridia, Bifidobacteria and 
Salmonellae (Fox et al., 1996; King et al., 2002; Liu et al., 2002; Fujimori, 2006; Sasaki et al., 
2006). By expressing functional CD intracellularly, the bacteria can transform the non-toxic 
prodrug 5-FC into the cytotoxic drug 5-FU (compare Fig. 1.4). An alternative enzyme would 
be nitroreductase, which converts the prodrug CB1954 to a highly toxic bifunctional 
alkylating agent. This enzyme has been used in animal experiments with Clostridia already 
(Minton et al., 1995). 
A simple possibility to release intracellular proteins from the bacteria into the extracellular 
space exists by the induction of bacterial lysis. Recently, the lytic gene E from bacteriophage 
ΦX174 could be shown to be expressed in tumor-targeting Salmonellae upon induction of an 
L-arabinose controlled promoter. Additionally, this promoter could successfully be induced 
inside tumor-residing Salmonellae (Loessner et al., 2007). Other approaches that aim at the 
release of intracellular proteins into the extracellular space utilize particular metabolic 
attenuations. The release of intracellular macromolecules could be shown for a Salmonella
mutant that is defective in asd, an essential enzyme in cell wall synthesis (Loessner et al., 
2006). However, this approach has many limitations like the uncontrolled release of 
additional bacterial products. 
In contrast, the exploitation of special bacterial secretion systems facilitates a controlled 
release of proteins from bacteria. Secretion systems are available that can be used to deliver 
proteins either into the extracellular space or into the cytosol of the adjacent cell.  
Many Gram-negative bacteria use the so-called type I secretion systems (type I SS) to 
translocate proteins like pore-forming toxins, proteases, lipases or S-layer proteins across their 
inner and outer membranes into the extracellular surroundings. The prototypical and best 
characterized type I SS is the E. coli α-hemolysin (Hly) secretion system. A topological 
model of the hemolysin secretion system is depicted in Fig. 1.10.  
Type I secretion systems characteristically contain only three different transport components, 
HlyB, HlyD and TolC. HlyB and HlyD are located in the inner membrane (IM) and are 
specific for the passenger protein that is to be translocated across the membrane, while TolC 
forms a pore in the outer membrane (OM) (reviewed in Gentschev et al., 2002). During the 
translocation process, these three proteins form a tunnel that links the IM and the OM. As a 
result, the passenger proteins are secreted directly into the extracellular medium. Type I SS 
recognize a secretion signal (HlyA), which is located at the carboxyl terminus of the secreted 
proteins and is usually not cleaved off after secretion. 
 1 Introduction 34 
Fig. 1.10: Topological model of hemolysin secretion. In response to HlyA engagement, a HlyD trimer interacts 
with the trimeric TolC protein to form a continuous transperiplasmic export channel. The Figure is 
taken from Gentschev et al., 2002. 
Some of the gene clusters encoding such secretion systems are already located on plasmids 
and are therefore easy to be modified genetically, a sincere advantage of type I SS (Binet et 
al., 1997). In addition, the plasmids carrying the Hly system of E. coli have been shown to 
replicate stably in other Gram-negative bacteria, including Vibrio cholera and various species 
of Salmonella and Shigella (Spreng et al., 1999). This secretion system also appears to 
support the secretion of heterologous proteins independent of their size (Hahn and von 
Specht, 2003). Thus, it can be modified to express and secrete proteins of potential therapeutic 
value in the course of bacteria-mediated anti-cancer therapy.  
However, the Hly secretion system also has its limitations. The amount of recombinant 
protein that is secreted under in vitro conditions is rather low (Li et al., 2000; Li et al., 2002). 
Besides, the secretion is tightly coupled to bacterial growth and the accumulation of HlyA 
fusion proteins occurs only in the early and mid-exponential growth phase (Felmlee et al., 
1985; Li et al., 2000). The impact of bacterial growth inside solid tumors on the secretion of 
such fusion proteins is yet unknown, as the knowledge about growth phases of bacteria inside 
solid tumors is scarce.  
The secretion of HlyA-fusion proteins was further found to be oxygen dependent. As small 
culture volumes resulted in higher final protein concentrations (Hahn and von Specht, 2003), 
aeration seemed to negatively affect the secretion of HlyA fusion proteins. Ironically, what is 
detrimental in vitro might be beneficial for in vivo applications. If this observation is 
confirmed in in vivo studies, it might become an advantage for bacterial anti-cancer therapies 
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in solid tumors, which are known to have large necrotic areas, in which the bacteria 
preferentially accumulate.  
Another limitation of HlyA secretion systems is the relatively large secretion signal sequence, 
which consists of 60 amino acids and is not removed after translocation. This signal sequence 
might influence the correct folding of the recombinant protein and lead to the secretion of 
non-functional proteins. In addition, Hly-mediated secretion is greatly impaired for proteins 
that contain extended β-sheet regions (Hahn and von Specht, 2003).  
However, Hahn et al. (1998) were able to secrete functional, bioactive human interleukin 6 
(hIL-6) via this secretion system with S. typhimurium. Several years later, Li et al. (2003b) 
reported an optimized hIL-6 secreting S. typhimurium strain that could increase systemic IgG 
and IgA responses against bacterial LPS upon oral administration of vaccine strains in vivo. In 
the meantime Hly secretion systems have been used to successfully secrete several different 
vaccine antigens (Gentschev et al., 1994; Hess et al., 1996; Gentschev et al., 1998; Hess et al., 
2000; Spreng et al., 2000) mucosal adjuvant proteins like the subunits of choleratoxin (CT) 
and the tetanus toxin fragment C (Harokopakis et al., 1997; Lee et al., 2000) as well as 
cytokines including the interleukins IL-4, IL-5 and IL-6 (Denich et al., 1993; Dunstan et al., 
1996; Whittle et al., 1997). 
In contrast to the hemolysin secretion system, bacterial secretion systems exist, which 
transport the protein of interest directly into the cytosol of the tumor cell. One such system is 
the type III secretion system (type III SS). The name “type III secretion system” refers to a 
secretion pathway, which is common to the flagellae of eubacteria and the injectisomes of 
some Gram-negative bacteria (reviewed in Journet et al., 2005). While flagellar secretion 
results in the transport of the protein into the extracellular space, injectisomes release the 
protein into the cytosol of the cell. A model of an injectisome is shown in Fig. 1.11. 
The flagellum is a motility organelle that – besides its function as a rotary motor for bacterial 
movement – contains a built-in secretion apparatus for the export of the hook and filament 
components (Macnab, 2003). In 2005 Majander et al. were able to explore the flagellar 
secretion apparatus of E. coli for extracellular secretion of several polypeptides and 
eukaryotic GFP at high concentrations. This secretion system was claimed to be only 
dependent on the 5’ untranslated region (5’UTR) plus an N-terminal secretion signal of 20 
amino acids resulting in a significantly smaller fusion protein compared to HlyA-fusion 
proteins. However, contrary to the findings of Majander et al. (2005), Gal et al. (2006) and 
Vegh et al. (2006) reported a 5’UTR independent protein secretion in S. typhimurium and a 
flagellum specific secretion signal confined to a 22-amino acid sequence in the N-terminal 
region of Salmonella flagellin. 
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Fig. 1.11:  Representation of a type III secretion system (injectisome) modeled from isolated needle structures 
observed by electron microscopy and genetic and biochemical data. The figure is taken from Thomas 
and Brett, 2003. 
Injectisomes are needle-like structures that allow the bacteria to deliver proteins across the 
two bacterial membranes and the eukaryotic membrane into the host cell’s cytosol. Although 
similar between different species, every bacterial species has a slightly different type III SS 
with different secretion signals in each species. Usually the secretion systems are not 
transferable from one species to another and thus have to be designed specifically for the 
favored species for each application.  
Up to now, type III SS have mainly been used to secrete vaccines (Russmann et al., 1998; 
Russmann et al., 2002). Nishikawa et al. (2006) and Panthel et al. (2006) were even able to 
deliver anti-tumor antigens via the Salmonella typhimurium type III SS. In the first case, this 
resulted in CD8+ T cell induced tumor regression. In the second case, prophylactic cytotoxic 
effector and memory CD8+ T cell responses against a murine fibrosarcoma were induced.  
In 2002 Russmann et al. reported the successful secretion of proteins using the InvI/InvJ type 
III secretion system of S. typhimurium. According to their studies, as little as 7 amino acids at 
the N-terminus of the secretion sequence were necessary and sufficient to correctly secrete the 
fusion protein. 
Theoretically all kinds of proteins can be secreted via a type III SS. Besides their use for the 
secretion of antigens, they should also be suitable to release therapeutic molecules for anti-
cancer therapies. Many type III systems seem to be more efficient regarding protein 
concentration and length of signal peptide compared to type I SS. On the other hand, type III 
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SS are very complex and consist of at least twenty different proteins, which render them 
difficult to genetically manipulate. Besides, not all proteins are secreted efficiently. Disulfide 
bonds cannot be built correctly. They cannot be transferred from one species to another and 
they still result in the release of fusion proteins that might be incorrectly folded (reviewed in 
Journet et al., 2005).  
Type IV secretion systems (type IV SS) are similar to type III SS in assembly, function and in 
their limitations. These secretion systems are involved in horizontal gene transfer to other 
bacteria and eukaryotic cells. The prototypical type IV SS is the Agrobacterium tumefaciens
T-DNA (transfer DNA) transfer machinery, which delivers the T-DNA into plant cells and 
results in the development of crown-gall tumors. Other bacteria, such as Helicobacter pylori, 
use it for the injection of protein virulence factors into the host’s cytosol. However, this 
system has not been used for the transport of therapeutic proteins yet (reviewed in Backert 
and Meyer, 2006).  
An alternative type of secretion system that might be suitable for the application in bacterial 
anti-cancer therapies are autotransporters of the type V secretion systems (type V SS). 
Autotransporters are proteins that contain all of the information required for traversing the 
bacterial membrane system and routing to the bacterial cell surface. This indicates that they 
are characterized by an outer membrane translocator module representing the C-terminal 
domain of the transported protein itself. Different to the above mentioned secretion systems, 
the signal peptide can be cleaved off after transport, provided that an appropriate motif is 
included. Thus, the folding of the heterologous protein is not impaired by an additional signal 
peptide (Konieczny et al., 2001). One prominent member of the autotransporter family is the 
AIDA autotransporter, which is a bacterial adhesin associated with some diarrheagenic E. coli
(Benz and Schmidt, 1992; Sherlock et al., 2004). The AIDA system consists of a translocator 
subunit that forms a β-barrel porin in the outer membrane through which the adhesin moiety 
gains access to the surface (Maurer et al., 1999). Up to now, autotransporters have mainly 
been used for vaccination strategies (Rizos et al., 2003; Kramer et al., 2003; Casali, 2003). 
Like the other described secretion systems they do have the potential for a future use as 
secretion system of therapeutic molecules in bacteria-mediated anti-cancer therapy. 
Additional secretion systems exist for various applications, e.g. for the secretion of 
recombinant antibodies. While Gram-negative bacteria like E. coli secrete the proteins mostly 
into the periplasm (reviewed in Ward, 1993) and thus have to be lysed in order to release the 
protein into the extracellular space, Jordan et al. (2007) exploited the Gram-positive 
bacterium Bacillus megaterium for the production of recombinant antibody fragments, which 
were successfully secreted into the growth medium. Although a tumor targeting ability of this 
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bacterium has not been tested yet, it might have chances as therapeutic vehicle in anti-cancer 
therapies.   
In general, all described secretion systems could be simply applied for vaccination strategies, 
in which functionally folded proteins are not essential. In contrast, the secretion of 
biologically active proteins, such as cytokines or cytotoxins, requires correct folding and is 
therefore more prone to failure. As a prediction of the most adequate secretion system that is 
working for the given protein is not possible, different secretion systems will have to be tested 
systematically in each case. 
1.5  Bacterial interactions with the immune system in tumor therapies 
The immune system of vertebrates is a remarkable adaptive system of defense. It has evolved 
to protect the host from invasive microorganisms and includes an extraordinary huge number 
and variety of cells and molecules that are able to specifically detect and eliminate foreign 
invaders. All these cells and molecules cooperate in a unique, dynamic network, whose 
complexity is still far from being understood (reviewed in Delves and Roitt, 2000a; Delves 
and Roitt, 2000b). 
In general, one can distinguish the immune reactions that are initiated upon contact with a 
pathogen into adaptive and innate immunity. The adaptive immunity is only activated if the 
invading microorganisms have not been eliminated by the innate immune system already. It is 
based upon the production of antibodies by B cells and effector functions of T cells. The 
adaptive immune response often leads to a lifelong immunity against infections by the same 
microorganism. Thus, the activation of the adaptive response during bacteria-mediated tumor 
therapy might prevent repeated administration of the therapeutic bacteria (reviewed in 
Medzhitov and Janeway, Jr., 1998). 
As the adaptive immune response is activated at later times during an infection and only in 
cases where the innate immune system was not able to eliminate the intruding bacteria, it 
should only play a minor role at the early times of bacteria-mediated tumor therapy. Thus, to 
investigate the immediate impacts of bacterial colonization of solid tumors on the immune 
system, the major focus should lie on the immediate innate immune response, i.e. the first line 
of defense. Depending on the type of bacterial tumor therapy, the natural activation of the 
immune system by the bacterial carrier might not necessarily be beneficial. Some tumor 
therapies might actually require an inducible suppression of the host’s immune system or the 
stimulation and shaping of the immune answer of the host according to the therapeutic needs.  
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1.5.1 First line of defense 
Innate immunity comprises four different defense mechanisms, which protect the host from 
bacterial, viral, fungal and parasite infections. These defense mechanisms comprise physical 
barriers like the skin or the surface of mucous membranes that keep pathogens from invading 
the body mechanically, physiological barriers, phagocytic or endocytic barriers and 
inflammatory barriers (reviewed in Medzhitov and Janeway, Jr., 2000; Janeway, Jr. and 
Medzhitov, 2002). For intended infections in the course of bacteria-mediated tumor therapies 
physical barriers should not play a role, as the bacteria are injected intravenously and 
naturally find their way into the tumor tissue or are even injected directly into the tumor. The 
same is true for physiological barriers. As bacterial tumor therapy vectors are applied 
according to the therapeutic needs, physiological barriers like the low pH of the stomach or 
the mucus and digestive enzymes in the upper intestinal tract, amongst others, are simply 
circumvented. In addition, therapeutic bacteria are especially chosen to find optimal growth 
conditions inside the tissue of solid tumors and are therefore well adapted to their host and to 
their target tissue in particular. Thus, barriers that do influence bacterial tumor therapy and 
might even direct the outcome of the therapy are inflammatory barriers and phagocytic or 
endocytic barriers.  
If a pathogen has breached the physical and physiological barriers and escaped into the host’s 
body during a natural occurring infection, the innate immune system of the host tries to 
eliminate the intruder immediately or to retain the pathogen locally.  
Activation of innate defense mechanisms are due to various pathogen associated molecular 
patterns (PAMPs) that distinguish microorganisms from multicellular organisms. 
Correspondingly, the innate immune system has evolved “pattern recognition receptors”. 
Among these microbial patterns that are specific for bacteria are peptidoglycan, 
lipopolysaccharide and lipoteichoic acid (Kimbrell and Beutler, 2001).  
The activation of the pattern recognition receptors, which include the entire toll like receptor 
family (TLRs) amongst others, results in a cellular signaling cascade that ultimately leads to 
the secretion of inflammatory and chemoattractant proteins like cytokines and chemokines 
(Penate and Pena, 2001). This causes an inflammatory reaction that is characterized by 
swelling, redness, heat and pain (Bloom and Ahmed, 1998) and leads to an enlargement of the 
local blood vessels. As a consequence, the local blood flow is increased while the velocity of 
the blood flow decreases and the tissue becomes red and warm. The infiltration of 
professional phagocytes like macrophages and neutrophilic granulocytes is initiated by the 
expression of adhesion molecules on the surface of the endothelial lining. Simultaneously the 
permeability of the blood vessels is increased as the joining of the endothelial cells that line 
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the blood vessels loosens. Monocytes, NK cells and granulocytes that patrol the blood to 
detect pathogens are entering into the infected tissue accompanied by liquid and antimicrobial 
proteins. This causes the swelling and pain. The phagocytes like neutrophilic granulocytes 
and macrophages that accumulate inside the infected tissue will eventually take up and 
destroy the pathogenic invaders by a process called phagocytosis (reviewed in Aderem and 
Underhill, 1999). 
1.5.2 Neutrophilic granulocytes 
Neutrophilic granulocytes, so-called neutrophils, belong to the class of polymorphonuclear 
leukocytes, whose name is based on the multilobulated shape of their nuclei. Leukocytes in 
general comprise macrophages, granulocytes and dendritic cells. The group of granulocytes 
can further be divided into basophilic, eosinophilic and neutrophilic granulocytes or 
neutrophils. The latter represent 50-60% of the total circulating leukocytes and are the first 
cells to be recruited to the site of infection during an inflammatory reaction. Being active 
phagocytes, neutrophils target bacteria, viruses, fungi, protozoa, virally infected cells and 
tumor cells.  
Like other cells of the immune system, neutrophils are derived from pluripotent stem cells in 
the bone marrow (Baum et al., 1992). During granulopoiesis the hematopoietic stem cells give 
rise to unipotent myeloblasts, which subsequently differentiate via five further morphological 
stages into segmented neutrophils (Cline and Golde, 1975). The development in the bone 
marrow takes about two weeks. During this time the cells sequentially acquire the receptors 
and proteins that are needed for their role in the first line of defense. Once they are mature, 
they are released into the bloodstream, where they circulate with a half life of 6-8 hours 
before they migrate into tissues. Here they can survive for 1-2 days (Kobayashi et al., 2005).  
Neutrophils are actively recruited to the sites of infection in response to host- or pathogen-
derived chemotactic factors such as the chemokine IL-8 in humans (Godaly et al., 1997) and 
its murine homologue MIP-2 (macrophage-inflammatory protein-2) (Tekamp-Olson et al., 
1990) or bacterial products like N-formylated peptides. Many of these chemoattractants can 
prime neutrophils to enhance their function, which improves host defense. They might be 
primed for enhanced adhesion, phagocytosis and production of reactive oxygen species 
(ROS), cytokine secretion, leukothriene synthesis, degranulation and bactericidal activities. 
Neutrophil priming agents include host-derived cytokines, chemokines, growth factors and 
lipid-derived signaling molecules, but also all kinds of microbial products, cell-cell contact 
and the adhesion to cell receptors (reviewed in Kobayashi et al., 2005). Priming of neutrophils 
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mobilizes secretory vesicles and induces the secretion of cytokines to promote an efficient 
clearance of the invading pathogen.  
At the site of infection neutrophils bind and ingest the invading microbes via phagocytosis. 
The binding of PAMPs to pathogen-recognition receptors like TLRs and CD14 activates 
signaling pathways that lead to the above mentioned effects of priming.  
Microorganisms could be opsonized, i.e. covered with activated serum complement 
components or specific antibodies. Such microbes are recognized and bound via complement 
receptors and Fc receptors that bind to the constant part (Fc region) of the antibodies. This 
process drives the mechanism of phagocytosis in which the microorganisms are internalized 
and sequestered within a phagosome. 
Fig. 1.12:  Neutrophil phagocytosis and activation of microbicidal systems. The exact mechanisms are described 
in the text. The figure is taken from Kobayashi et al., 2005. 
Inside the phagosome the microbes are killed by two independent mechanisms, an oxygen-
dependent and an oxygen-independent mechanism. In the first mechanism, neutrophils 
undergo a so-called “respiratory burst” during which the NADPH oxidase complex assembles 
at the phagosomal membrane and produces O2¯ . This is converted into ROS such as 
hydrogen peroxide, hypochlorous acid, hydroxyl radical and chloramines, all of which are 
potent antimicrobial agents (Hampton et al., 1998; Chapman et al., 2002).  
In the oxygen-independent mechanism, specific cytoplasmic granules that contain anti-
microbial peptides and proteins like α-defensins, cathepsins, proteinase-3, elastase, azurocidin 
and lysozyme, fuse with the bacteria-containing phagosomes (Flodgaard, 2003). The content 
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of the granules is released and consequently the phagosome is enriched with microbicidal 
proteins and peptides that degrade bacterial proteins or disrupt the anionic bacterial surfaces 
(Borregaard and Cowland, 1997). These described mechanisms are illustrated in Figure 1.12.  
In 2003 Reeves et al. proposed a convincing concept that combines the two mechanisms. If 
ROS recruit K+ ions into the phagolysosome, the potassium ions can further allow cationic 
proteases of the azurophilic granules to convert from a highly organized intracellular structure 
in a soluble form. This will result in the fusion of the granules with the bacteria-containing 
phagosomes and the bacteria are destroyed by the released microbicidal proteins. (Reeves et 
al., 2003) 
Recently Brinkmann et al. (2004) and Fuchs et al. (2007) reported a novel mechanism 
whereby neutrophils can kill bacteria. By releasing granule proteins and chromatin into the 
extracellular medium, neutrophils generate extracellular fibers or “neutrophil extracellular 
traps” (NETs) that bind Gram-positive and -negative bacteria. These NETs degrade virulence 
factors and kill bacteria extracellularly. Besides the antimicrobial properties, NETs might 
serve as physical barriers that prevent the spreading of the microorganisms throughout the 
body. An electron microscopical image of such NET-generating neutrophils with Shigellae
entrapped in the NETs can be seen in Fig. 1.13. 
Fig. 1.13:  Electron microscopy of a NET-generating neutrophil. Shigellae are entrapped by the neutrophils. The 
figure is taken from Zychlinsky, 2006. 
As counterattack to strategies of the immune system, bacteria have developed own strategies 
to outflank the defense mechanisms of this system. These strategies include avoidance of 
neutrophil contact, the prevention of phagocytosis, the survival within the neutrophils, the 
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killing of neutrophils and the avoidance of being killed in neutrophil NETs (Urban et al., 
2006). 
Neutrophils have been repeatedly reported to infiltrate bacteria-infected solid tumors in the 
course of a bacteria-mediated anti-tumor therapy. Once they have migrated into the 
hypoxic/necrotic regions of the tumor, their functions appear to be inhibited (Bjerknes et al., 
1990). The same has been shown for other immune cells (macrophages and T cells) under 
hypoxic conditions (Siegert et al., 1999; Robbins et al., 2005).  
Nevertheless, the above mentioned interactions between neutrophils and bacteria could play a 
major role in tumor therapy and influence the outcome of the anti-cancer therapy in a 
beneficial or detrimental way. 
1.5.3 Macrophages and the stimulation of the specific immune system 
The second type of leukocytes are macrophages. Macrophages are an extremely 
heterogeneous population of cells. They develop in bone marrow and migrate through the 
blood as monocytes. In the tissue they develop into mature macrophages, which can become 
extremely long-lived. Similar to neutrophils, macrophages are actively recruited to the site of 
infection upon stimulation with chemotactic factors. Being professional phagocytes, 
macrophages can phagocytose bacteria, viruses or proteins upon contact with the foreign 
antigen. Having bound the antigen with one of the different receptors such as mannose-, 
scavenger- or Fc-receptor on the surface of the phagocyte, phagocytosis is initiated (Pontow 
et al., 1992; Ravetch, 1997).  
Macrophages are activated by phagocytosis. The activation can be enhanced by cytokines that 
are released by other immune cells, e.g. activated TH-cells (Aderem and Underhill, 1999). 
Activated macrophages are more effective in killing and eliminating pathogens than resting 
macrophages. They are able to secrete a number of cytotoxic proteins that kill virus-infected 
cells, tumor cells or intracellular bacteria (Gordon, 2003). 
Characteristic for activated macrophages is the upregulation of MHC (major 
histocompatibility complex) class II molecules on their surface. These molecules present 
antigens to TH-cells of the specific immune system. In case of a bacterial infection these 
antigens are polypeptides that resulted from the lysis of the phagocytosed bacterium. Thus, 
macrophages are not only part of the host’s first line of defense, but they can also induce 
secondary immune responses by stimulating the specific immune system (Margulies, 1997).  
The role of macrophages in bacteria-mediated anti-tumor therapy is yet unknown. However, 
an influence of macrophages on bacterial dissemination and on the recruitment of different 
immune cells to the tumor upon bacterial infection cannot be excluded.  
 1 Introduction 44 
DCs, the third member of leukocytes, were long considered to be macrophages. Now it is 
clear that they are an independent cell lineage. They are essential for the induction of a 
specific immune response, but at the present state of knowledge they are irrelevant for 
bacterial tumor therapy.  
1.6 Aim of this work 
Several obligate and facultative anaerobic bacterial strains are known to preferentially 
accumulate and proliferate inside solid tumors when given systemically (Yu et al., 2004). 
Their ability to naturally target to and accumulate in solid tumors suggests their use as 
transport vehicles that carry therapeutic molecules directly into solid tumors. Thereby it could 
be possible to limit side effects that are caused by non-directed, systemic treatments by 
commonly used anti-cancer therapeutics.  
At present only little is known about the mechanisms that lead to bacterial settlement in solid 
tumors and about bacteria-host interactions inside the tumor. In addition, the majority of 
tumor-targeting bacteria show poor dissemination inside solid tumors as they accumulate 
exclusively inside large necrotic areas, and spare a rim of viable tumor cells (Vassaux et al., 
2006). The reason for the limited dissemination is still little understood. 
The present work deals with several aspects of early bacterial tumor colonization and the 
impacts of bacterial settlement inside solid tumors. It focuses on the use of three different 
facultative anaerobic bacteria, namely S. flexneri, S. typhimurium and E. coli, as vehicles for 
bacteria-mediated tumor therapy. The investigations of this work should reveal new 
informations about tumor composition and the infiltration of primary immune cells, about the 
interactions of the bacteria with these immune cells and about influences of tumor 
composition and tumor microenvironment on the bacteria and their behavior. 
One aspect of this work was to establish an S. flexneri strain, as an in vivo system for bacteria-
mediated gene transfer into solid tumors. As Gram-negative bacteria are able to use the 
mammalian CMV promoter for gene expression (Goussard et al., 2003) an intron should be 
integrated into a reporter gene. This should allow to ultimately distinguish eukaryotic from 
bacterial gene expression and to manifest the proof of principle of in vivo bacterial gene 
transfer as a means for tumor therapy.  
A second aspect of this work was the characterization of early bacterial settlement inside solid 
tumors. This included the characteristic dissemination of the above mentioned facultative 
anaerobes in a model tumor and the impact of bacterial colonization inside solid tumors on the 
infiltration and distribution of immune cells. Histological analysis of bacteria-colonized 
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model tumors at early times post infection, ranging from 30 min p.i. to 2 days p.i., should 
clarify how the bacteria escape from the blood stream into the solid tumor and how they start 
to colonize and disseminate throughout the solid tumor. Such analyses should further give 
information about the chronology of bacterial tumor colonization after systemic infection and 
the associated effects on the host’s immune system. The results obtained from histology 
should be confirmed and extended with electron microscopy of infected model tumors. 
Especially the question whether the bacteria reside intra- or extracellularly should be 
answered here. 
These investigations led to the final issue of the present work. As the majority of tumor-
targeting bacteria show poor dissemination inside solid tumors, the improvement of bacterial 
spreading in solid tumors to vital parts of the tumor should be addressed. This should result in 
a homogeneous distribution of the bacteria and of therapeutic factors that are to be carried by 
the tumor-targeting bacteria.  
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2 Material and Methods 
2.1 Material 
2.1.1 Mouse strain 
6 week old, female BALB/c mice (Harlan, Borchen, Germany) were used for all animal 
experiments. 
2.1.2 Cell lines and culture conditions 
BHK-21 (ATCC CCL-10), TS/A (Nanni et al., 1983), CT26 (ATCC CRL-2638) and HEp-2 
cells (ATCC CCL-23) were cultured in IMDM (Gibco BRL, Eggenstein, Germany) 
supplemented with 10% heat inactivated FCS (Integro, Zaandam, The Netherlands) and 
0.25 mM β-mercaptoethanol (Serva, Heidelberg, Germany). Cells were cultured at 37°C and 
5% CO2 in a humidified atmosphere. 
2.1.3 Antibodies  
DRAQ5 (Biostatus, Leicestershire, United Kingdom) 
Donkey-anti-goat-cy3 (R&D Systems GmbH, Wiesbaden, Germany) 
goat-anti-E. coli (Biomol, Hamburg, Germany), 
goat-anti-luciferase (Promega, Madison, USA) 
goat-anti-rabbit Alexa 488 (Sigma-Aldrich, Deisenhofen, Germany) 
rabbit-anti-goat Alexa 488 (Invitrogen, Karlsruhe, Germany) 
rabbit-anti-S. flexneri (Biomol, Hamburg, Germany), 
rabbit-anti-S. typhimurium (Sifin, Berlin, Germany) 
rat-anti-CD11b PE (eBioscience, San Diego, USA) 
rat-anti-mouse Fc receptor (Pharmingen, San Diego, USA), 
rat-anti-mouse Gr-1 biotinylated (Pharmingen, San Diego, USA), 
Streptavidin-cy5 (Invitrogen, Karlsuhe, Germany), 
Phalloidin Alexa Fluor 594 (Invitrogen, Karlsruhe, Germany) 
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* rat-anti-Gr1 (RB6-8C5) 
* rat-anti-Gr1 biotin (RB6-8C5) 
* rat-anti-Gr1 FITC (RB6-8C5) 
* The three latter antibodies were isolated from culture supernatants and biotinylated or FITC-
conjugated according to standard procedures. 
All other materials will be described within the methods. 
2.2 Methods 
2.2.1 Molecular biological methods 
2.2.1.1 Bacterial strains and growth conditions 
The E. coli strains TOP10 and DH5α were purchased from Invitrogen (Karlsruhe, Germany). 
Both bacterial strains were used for general cloning and were grown in Luria-Bertani medium 
(LB) supplemented with the appropriate antibiotics and with 15 g/l agar, where appropriate 
(Sambrook, 1989). Bacteria were grown at 37°C in liquid medium with vigorous shaking. For 
infection experiments, E. coli TOP 10 was grown in LB broth supplemented with 30 µg/ml
streptomycin (Sigma, Taufkirchen, Germany) or on LB agar plates supplemented with 
30 µg/ml streptomycin at 37°C. 
S. typhimurium strain SL7207 (hisG, ∆aroA) was kindly provided by Dr. Stocker (Hoiseth 
and Stocker, 1981). It was grown in LB medium supplemented with 30 µg/ml streptomycin at 
37°C with vigorous shaking or on LB agar plates with 30 µg/ml streptomycin at 37°C. 
S. flexneri strains S. flexneri M90T (Serotyp 5, ∆dap) and S. flexneri (Serotyp 2a, ∆aroD) 
were kindly provided by Dr. Sansonetti (Sansonetti et al., 1982). Shigellae were grown in 
tryptic soy broth (TSB) or on TSB-agar plates (Beckton Dickinson, Heidelberg, Germany) 
supplemented with 200 µmol/l Congo red (Serva, Heidelberg, Germany) at 37°C. Medium for 
S. flexneri ∆dap was additionally supplemented with 30 µg/ml kanamycin, 100 µg/ml DAP 
(Fluca, Buchs, Switzerland). Ampicillin was added at 50 µg/ml where indicated. 
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2.2.1.2 Expression plasmids 
pCMVβm2A 
pCMVβm2A is a eukaryotic expression plasmid that was constructed by exchanging the pUC 
replicon of the high copy number plasmid pCMVβ (Clontech, Palo Alto, USA) with the low 
copy replicon pMB1. It is a reporter plasmid with the gene encoding β-galactosidase under 
the control of the cytomegalovirus immediate early promoter (CMV IE).  Its construction was 
described in Bauer, 2004 and Bauer et al., 2005. 
pCMVlucm2A 
The eukaryotic expression plasmid pCMVlucm2A is a reporter plasmid for the expression of 
firefly luciferase in mammalian cells driven by the CMV IE promoter. Besides the promoter 
and the firefly luciferase gene, it contains a splice donor/splice acceptor site (SV40 SD/SA), a 
polyadenylation signal from simian virus 40 (SV40 late polyA), the low copy number pMB1 
replicon from pBR322 (pMB1ori) (Sutcliffe, 1979) and an ampicillin resistance gene 
(AmpR). Its construction is described in Zelmer, 2005. 
Fig. 2.1: Plasmid map of pCMVlucm2A. This reporter plasmid mediates the expression of the firefly luciferase 
gene via the eukaryotic CMV promoter. 
pCMVluc-λ2In-m2A  
Since the CMV promoter can be used by several Gram-negative bacteria (Goussard et al., 
2003), an intron was introduced into the firefly luciferase of pCMVlucm2A, to be able to 
distinguish eukaryotic from bacterial gene expression. Therefore, the intron from the VJ gene 
pCMVlucm2A
5182 bp
luciferasepMB1ori
SV 40 SD/SA
SV40 late polyA
CMV IE
AmpR
EcoRI (2)
PstI (24)
XhoI (641)
XhoI (837)
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segment of the λ2 immunoglobulin gene of the mouse (Wu et al., 1982) was amplified and 
introduced via fusion PCR into the firefly luciferase gene of plasmid pCMVlucm2A. The 
exact mechanism and procedure of the fusion PCR is explained in chapter 2.2.3.1. The PCR 
product was then ligated into pCMVlucm2A via restriction sites SfuI/BsrGI. 
Fig. 2.2: Plasmid map of pCMVluc-λ2In-m2A. In this plasmid the firefly luciferase gene is interrupted by an 
intron of the λ2 immunoglobulin gene of the mouse to ensure the expression of luciferase exclusively in 
eukaryotic cells. 
2.2.1.3 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction allows the selective amplification of DNA fragments between 
two regions of known sequence. Two oligonucleotides are used as primers, which bind to the 
complementary strands in opposite directions and, using a heat-stabile polymerase, the 
flanked DNA sequence can be amplified exponentially by repetitive cycles of denaturation 
and elongation. 
Reaction mix:  1.0 µl primer 1 (10 pmol/µl) 
   1.0 µl primer 2 (10 pmol/µl) 
   1.0 µl template DNA 
   2.0 µl 10x PCR buffer 
   0.4 µl nucleotide mix (10mM each nucleotide) 
   0.1 µl AmpliTaq Gold™ (5U/µl) 
            14.4 µl H2O 
pCMVluc-λ2In-m2A
5080 bp  
pMB1ori
AmpR
CMV IE
EcoRI (2)
PstI (24)
SV40 late polyA
Luciferase-Exon2
    λ2-Intron
Luciferase-Exon1
XhoI (641)
PstI (1014)
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The reaction was conducted in 200µl reaction tubes (Applied Biosystems, Hamburg, 
Germany) in a primus 96 thermocycler from MWG-biotech (Ebersberg, Germany). 
Standard PCR conditions:  
After a 10 min activation of the AmpliTaq Gold™ polymerase (Applied Biosystems, 
Darmstadt, Germany) at 37°C, 30 cycles of amplification with a denaturation temperature of 
94°C (30 sec), an annealing temperature of 58°C (30 sec) and an elongation temperature of 
72°C (30 sec) were performed. The PCR was finished with a final extension at 72°C for 5 
min. 
Fusion PCR 
To introduce a functional intron into the luciferase reporter gene, three requirements had to be 
fulfilled: 1. the intron had to be inserted at the beginning of the luciferase gene to ensure the 
expression of a nonsense protein in bacteria, which are unable to splice the two exons. 2. The 
number of nucleotides in the intron had to be not divisible by three, to ensure a frameshift and 
thus the expression of a nonsense protein, if the gene is not spliced correctly. 3. The intron 
had to contain the splice donor/splice acceptor site, which additionally should be flanked by 
the last two nucleotides of the preceding exon and the first two nucleotides of the succeeding 
exon.  
As the original λ2-intron is flanked by the nucleotides AG and GA, respectively, the cDNA of 
the luciferase gene in pCMVlucm2A was screened for an AGGA-sequence that is framed by 
two single cutters for easier handling of the fragments. After the discovery of an AGGA-
sequence that was framed by the two single cutters SfuI and BsrGI, respectively, the 
following four primers were constructed:  
Lambda2In1-for:   5’-GAGTACTTCGAAATGTCCGTT-3’; 
Lambda2In1-rev:  5’-GCAAATCGAGAGACAAGATGTGTATTGTTGCATACCCACTGC 
AGTGTAGAAAGGCTGCTGACCGATAAATAACGCGCCCAA-3’; 
Lambda2In2-for: 5’-CAATACACATCTTGTCTCTCGATTTGCTACTGATGACTGGATT 
TCTTACCTGTTTGCAGGAGTTGCAGTTGCGCCCGCG-3’; 
Lambda2In2-rev: 5’-CGAACGTGTACATCGACTGAA-3’; 
The first primer binds to the luciferase gene and includes the restriction site for SfuI. The 
second primer is a reverse primer that includes the first two-thirds of the sequence of the λ2-
intron. The third primer is a forward primer and includes the last two-thirds of the λ2-intron-
sequence. The last primer is a reverse primer that binds to the luciferase gene and includes the 
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BsrGI restriction site. As the original λ2-intron consists of 93 bp and is thus divisible by 
three, one extra nucleotide was inserted into the sequence, which is marked in red. Two 
standard PCRs were performed with plasmid DNA from pCMVlucm2A as a template and 
with primers 1 and 2 for the first PCR, with primers 3 and 4 for the second PCR. After a gel-
purification of the amplified PCR-fragments on a 2% (w/v) agarose gel, a third PCR, the 
fusion PCR, was performed. This PCR was accomplished with primers 1 and 4 and with the 
two gel-purified PCR-products as templates. The thermocycler conditions were always 
standard PCR conditions. Fig. 2.3 shows a schematic overview of the fusion PCR. 
Fig. 2.3: Schematic overview of the fusion PCR. The exact mechanism is described in the text. 
2.2.1.4 Agarose gel electrophoresis 
DNA is negatively charged in aqueous solutions due to the ionization of its phosphate 
residues. Thus, linear, double-stranded DNA-fragments can be separated in an electric field 
according to the molecular size of the fragments. In this study agarose gels (SeaKem® LE 
Agarose, Cambrex) were used at concentrations of 0.8% and 2% (w/v), respectively. The gels 
were running in 1xTAE buffer at 110-120 V. DNA fragments were stained with ethidium 
bromide and visualized using the Herolab GmbH software. 
AGGT 
BsrGI
Luciferase-
cDNA from 
pCMVlucm2A
1650 bp
SfuI BsrGI
 321 bp
SfuI
Primer 1 
 Primer 4
AGGA 
AGGA
λ2-Intron 
Primer 2 
Primer 3 
  ~30 bp 
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50x TAE:  242 g Tris 
   57.1 ml acetic acid 
   100 ml 0.5 M EDTA (pH 8.0) 
   Filled up with H2O to 1l and autoclaved 
DNA marker:  SmartLadder SF, 100bp-1kb (Eurogentec)
mixture of HindIII-digested l-DNA and HaeIII-digested pFX174-DNA 
(MBI-Fermentas, St. Leon-Rot, Germany) 
Electrophoresis was conducted using the Horizon 11.14 system (Gibco BRL, Eggenstein, 
Germany) 
Isolation of DNA from agarose gels 
The extraction of DNA fragments from agarose gels for the later ligation was performed with 
the “QIAquick Gel Extraction Kit” from QIAGEN according to the manufacturer’s protocol. 
DNA was always eluted in 50 µl water and stored at –20°C until use. 
2.2.1.5 Molecular cloning 
Molecular cloning comprises the cleavage of plasmid DNA with restriction enzymes and 
joining to foreign DNA fragments by the use of ligase. The resulting recombinant plasmids 
are then used to transform bacteria. 
Cleavage of DNA with restriction enzymes 
Restriction endonucleases recognize short specific DNA sequences, generally ranging 
between 4 and 8 nucleotides, and cleave the DNA in this region. Digestion of DNA was 
carried out using optimal buffer and temperature conditions for each enzyme according to the 
manufacturer’s protocol. Finally, an aliquot of the digestion mix was analyzed by agarose gel 
electrophoresis for complete digestion. 
Ligation of DNA 
Ligation of a foreign DNA fragment to a linearized plasmid vector involves the formation of 
phosphodiester bonds. T4 DNA ligase (Gibco BRL, Eggenstein, Germany) was used to 
catalyze the formation of a phosphodiester bond between juxtaposed 5’phosphate and 
3’hydroxyl termini in doublestranded DNA. Re-circularization of vector DNA can be limited 
by performing the ligation reaction with an excess of foreign DNA and a comparatively low 
concentration of the plasmid vector. Thus, vector and fragment, which were previously 
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digested with the same or compatible restriction enzymes, were ligated in a molar ratio of 
1:10 and incubated at room temperature for 60 minutes. 
2.2.1.6 Transformation of bacteria 
Different methods of transformation were carried out to introduce plasmid DNA into bacteria.
Transformation of chemically competent E. coli  
Chemically competent E. coli (Invitrogen, Karlsruhe, Germany) were thawed on ice, mixed 
with 10 µl of the ligation reaction or with 1 µl of plasmid DNA by gently tapping and were 
incubated for 30 minutes on ice. After a subsequent incubation for 30 seconds at 42°C, the 
bacteria were immediately placed back on ice for 5 min. 250 µl of SOC medium (supplied 
with the bacteria) were added to the bacteria and the suspension was incubated at 37°C and 
180 rpm for one hour. Afterwards the bacteria were plated on LB plates containing the 
appropriate antibiotics and the plates were incubated at 37°C over night. The next day, single 
colonies were picked and cultivated in LB medium containing the appropriate antibiotics. The 
liquid cultures were incubated at 180 rpm and 37°C for 6 to 8 hours. Afterwards the clones 
were analyzed by plasmid isolation and restriction digestion.  
Transformation of electrocompetent S. flexneri 
The electrocompetent bacteria were thawed on ice, mixed with 2 µl of the desired plasmid 
solution by gently tapping and incubated for 1 minute on ice. The suspension was transferred 
into a cuvette and electroporation was carried out (parameters 2.5 kV, 25 µF, 200Ω) with a 
Gene Pulser (Biorad). Immediately, 900 µl of TSB medium (+ DAP for S. flexneri ∆dap) were 
added to the cuvette. The suspension was transferred to a tube and was incubated at 180 rpm 
at 37°C for one hour before plating on TSB plates containing the appropriate antibiotics. The 
plates were incubated at 37°C over night. Picking of colonies was performed as described 
above. 
2.2.1.7 Isolation of plasmid DNA 
Depending on the required amount of plasmid DNA, mini or maxi plasmid preparations were 
performed to isolate plasmids from bacteria. To purify plasmid DNA from E. coli strains, the 
“GFX Micro Plasmid Prep Kit” (Amersham Biosciences) was used for analytical and the 
"Qiagen Plasmid Maxi Kit“ (Qiagen, Hilden, Germany) for preparative purposes. The 
“Qiagen Plasmid Mini Kit” (Qiagen, Hilden, Germany) was employed for purification of 
plasmid DNA from Shigella strains. 
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2.2.1.8 Optical determination of DNA concentration 
For optical determination of the DNA concentration, the extinction of a sample was measured 
at 260 nm. The OD260 of 1 corresponds (at a diameter of the cuvette of 1 cm) to a DNA 
concentration of 50 µg/ml. 
Photometer:  BioPhotometer (Eppendorf, Hamburg, Germany) 
2.2.1.9 Long-term storage of bacteria 
For the long-term storage of bacteria 700 µl of a fresh bacterial culture were mixed with 
300 µl of 50% glycerin and stored at –80°C. 
50% glycerin:  50% (v/v) glycerin in H20, filter sterilized and stored at 4°C.
2.2.2 Tissue culture 
2.2.2.1 Determination of viable cells 
An aliquot of a cell suspension was diluted 1:1 with 0.5% (w/v) trypan blue in PBS and 
counted into a Neubauer chamber. 0.1mm/0.025mm2 (Brand, Wertheim, Germany). Only 
viable cells, whose plasma membranes are, unlike dead cells, not leaky for trypan blue and are 
therefore not stained, were considered. 
2.2.2.2 Propagation of adherent cells 
For transfer of adherent growing cells to new culture flasks, cells were washed once with 
PBS, removed enzymatically from the substrate by adding trypsin-EDTA solution (TE) and 
incubated at 37°C in a humified atmosphere until the cells were detached. TE was inactivated 
by addition of FCS containing medium. The cells were harvested by centrifugation, washed 
once with PBS and resuspended in medium. 
PBS:  137 mM NaCl; 2.6 mM KCl; 6.4 mM Na2HPO4 x 2 H2O; 1.4 mM 
KH2PO4; in H2O (pH 7) 
TE:    0.5 g/ml trypsin; 0.2 g/ml EDTA; in PBS 
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2.2.2.3 Cryoconservation of mammalian cells 
Cells from a dense growing 12- or 6-well plate were taken in 0.5 ml ice-cold freezing 
medium. The cell suspension was temporarily frozen at -70°C and finally stored in liquid 
nitrogen. 
Freezing medium:  10 % (v/v) dimethylsulfoxide (Merck, Darmstadt, Germany) in FCS 
2.2.2.4 Thawing of cells 
The frozen cells were thawed at 37°C in a water bath and the cell suspension was taken up in 
medium. Afterwards, the cells were harvested by centrifugation, washed once and 
resuspended in medium. 
2.2.3 Calcium phosphate transfection 
Transfection represents a method for the transfer of DNA into cell culture cells. The principle 
of calcium phosphate precipitation is based on the formation of an insoluble precipitate of 
calcium phosphate, to which the DNA can be adsorbed. These calcium phosphate-DNA-
complexes are taken up by the cells via endocytosis. The DNA reaches the nucleus, where it 
can be transcribed (transient transfection). Some of the DNA can be integrated into the 
genome of the recipient cell (stable transfection), which can subsequently transmit this DNA 
segment to the next cell generation. Practically: 3x105 adherent cells per 25 cm2 culture flask 
were seeded the day before. The medium was exchanged for 5 ml of fresh medium 4 h before 
transfection. For preparation of the calcium phosphate/DNA coprecipitate, 250 µl of the 
CaCl2- DNA-mixture were added drop by drop under gentle mixing to 250 µl HEBS-buffer 
(2x) and incubated for 30-60 min at room temperature. The precipitate was then added to the 
medium above the cells and the transfected cells were cultured at 37°C. Excess of precipitate 
was removed the next day by exchange of medium. 24 h after exchange of the medium, 
transgene expression was analyzed (chapter 2.2.6). 
HEBS-buffer (2x):  280 mM NaCl; 50 mM HEPES; 1.5 mM Na2HPO4 x 2 H2O; 
add 100 ml; adjust with 5 M NaOH to pH 7,1; sterile filtering, 
aliquots stored at -20°C 
CaCl2-DNA-mixture:  25 µl CaCl2 (250 mM); 10 µg co-transfer-DNA; H2O add 250 µl 
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2.2.4 S. flexneri-mediated transfer of eukaryotic expression plasmids to 
mammalian cells 
Cells were seeded 24 h before infection in 24-well plates at a density of 5x104 cells/well, 
resulting in approximately 1x105 cells/well at the time of infection. Overnight cultures of 
S. flexneri strains were diluted 1:50 in the corresponding medium and grown at 37°C and 
180 rpm for 2.5 hours. After washing once with PBS, bacteria were added to cell cultures at 
the indicated multiplicity of infection (MOI) and in a total volume of 200 µl medium. For 
S. flexneri ∆dap, PBS and culture medium were supplemented with 100 µg/ml DAP. 
Subsequently, infection cultures were centrifuged to enhance invasion and incubated for 
1.5-2 hrs at 37°C. Cells were then washed twice with PBS and cultured in medium 
supplemented with 50 µg/ml gentamycin to kill extracellular bacteria. Cells were incubated 
for the indicated time periods at 37°C and transient transgene expression was analyzed 
(chapter 2.2.6).  
2.2.5 Infection of tumor-bearing BALB/c mice with S. flexneri, S. typhimurium
and E. coli 
6 week old, female BALB/c mice (Harlan, Borchen, Germany) were subcutaneously 
inoculated at the abdomen with 5x105 cells of the colon adenocarcinoma cell line CT26 or 
with 1x106 cells of the adenocarcinoma cell line TS/A. Mice bearing tumors of approximately 
5-7 mm diameter (day 10 post infection) were intravenously injected with 5x106 CFU of 
S. typhimurium or E. coli suspended in phosphate-buffered saline (PBS) and intratumorally 
with 1x107 S. flexneri ∆dap suspended in PBS with 100 µg/ml DAP, respectively. At the 
indicated time points mice were sacrificed and their tumors and spleens were transferred into 
1 ml, livers were transferred into 2 ml of sterile ice-cold PBS containing 0,1% (v/v) Triton X-
100. Tissues were homogenized by using a Polytron PT3000 homogenizer (Kinematica).  
For determination of total CFU per organ, bacteria homogenates were serially diluted in PBS, 
in case of Shigella they were serially diluted in PBS with 100 µg/ml DAP, plated with the 
required antibiotics and colonies were counted.  
For transgene analysis, the tissue homogenates were analyzed as described in chapter 2.2.6. 
2.2.6 Quantitation of luciferase expression
To detect luciferase, the Dual Glo luciferase assay system (Promega, Mannheim, Germany) 
was used according to the manufacturer’s recommendations. 10 µl of each sample were 
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measured and luminescence was recorded for 10 s using a Lumat LB9507 luminometer 
(Berthold Technologies, Bad Wildbad, Germany). 
2.2.7 Immunological methods 
2.2.7.1 Neutrophil depletion 
For depletion of neutrophils, mice received three doses of 25 µg monoclonal rat-anti-Gr1 
(RB6-8C5) antibody diluted in 100 µl PBS intraperitoneally (i.p.) 1 day before, 
simultaneously and 1 day after infection. Depletion was controlled by taking blood samples 
from the treated mice and analyzing the blood via flow cytometry. 
2.2.7.2 Flow cytometry of blood samples 
Erythrocytes of 50 µl blood were lysed in 1.5 ml erythrocyte lysis buffer (ELB), vortexed, 
incubated for 5 min at room temperature (RT) and centrifuged for 5 min at RT. This 
procedure was repeated once in 1 ml ELB. Cell pellets were then washed once with PBS and 
stained with rat-anti-Gr1 FITC and rat-anti-CD11b PE for 20 min on ice. Afterwards, cells 
were washed once with PBS and analyzed on the FACSCalibur (Beckton Dickinson, 
Heidelberg, Germany). Data were then analyzed with CellQuestPro software (Becton 
Dickinson, Heidelberg, Germany). 
ELB: 2.06 g Tris (HCl); 7.49 g NH4Cl; filled up to 1l with H2O (pH 7.2)  
2.2.7.3 Histology 
Tumors were removed from sacrificed mice and snapfrozen in Tissue-Tek OCT Compound 
(Sakura Finetek, Zoeterwoude, The Netherlands). Cryosections of 10 µm were cut with a 
microtome-cryostat (Cryo-Star HM560V, Microm, San Marcos, USA) and placed onto slides. 
Slides were air dried at room temperature overnight and fixed in acetone at -20°C for 3 min. 
Slides were rehydrated in PBS, blocked with 50 µg/ml BSA and 1 µg/ml FcR blocker (rat-
anti-mouse CD16/CD32), and stained with the following reagents: polyclonal rabbit-anti-
S. typhimurium, polyclonal goat-anti-rabbit Alexa 488, polyclonal rabbit-anti-S. flexneri, 
polyclonal goat-anti-E. coli, polyclonal rabbit-anti-goat Alexa 488, rat-anti-Gr1 biotin, 
Streptavidin-cy5, rat-anti-CD11b PE, goat-anti-luciferase, donkey-anti-goat-cy3, Phalloidin 
Alexa Fluor 594 and DRAQ5. After staining, the slides were washed and dried, mounted with 
mounting medium (Neomount, Merck, Darmstadt, Germany) and analyzed using a laser 
scanning confocal microscope (LSM 510 META, Zeiss). Images were processed with LSM5 
Image Browser (Zeiss) and Adobe Photoshop 7.0.  
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For paraffin sections, tumors were fixed in 10 % (v/v) paraformaldehyde and embedded in 
paraffin wax. 5 µm sections were mounted on starfrost slides and stained with hematoxilin 
and eosin. The stained paraffin sections were analyzed with an Olympus BX51 microscope 
and pictures were taken with an Olympus U-CMAD3 camera. 
PBS/BSA buffer:  0.05% BSA in PBS, pH 7.2
2.2.8 Electron microscopy 
2.2.8.1 Transmission electron microscopy 
Tumors were fixed in 5% formaldehyde and 2% glutaraldehyde, cut into cubes with an edge 
length of 3-5 mm and contrasted in 1% aqueous osmium tetroxide. Subsequently, the samples 
were dehydrated with a graded series of acetone (10, 30, 50, 70, 90, 100%) on ice for 30 min 
per step. The dehydrated samples were infiltrated with an epoxy-embedding resin (described 
by Spurr, 1969) (1 part acetone/1 part resin; 1 part acetone/2 parts resin, pure resin 
alternating). The infiltrated samples were polymerized at 70°C for 10 h and cut into ultrathin 
sections with a diamond knife. The sections were picked up with Formvar-grids and 
contrasted with uranylacetate and lead-citrate. Finally the samples were analyzed with a 
transmission electron microscope (TEM910 Zeiss, Germany) at an acceleration voltage of 80 
kV. 
2.2.8.2 Scanning electron microscopy 
Tumors were fixed in 5% formaldehyde and 2% glutaraldehyde in cacodylate buffer. 
Afterwards they were washed three times in cacodylate buffer and dehydrated with a graded 
series of acetone (10, 30, 50, 70, 90, 100%) on ice for 30 min per step. After a double wash 
with 100% acetone at RT for 30 min a critical-point drying with liquid CO2 was performed. 
The dried samples were fixed on sample brackets. A second sample bracket was applied and 
pressed slightly against the sample. By uncompressing the brackets, the samples were broken. 
The fractured surface was sputtered with a thin gold layer. Finally, the samples were analyzed 
with a Zeiss field emission scanning electron microscope DSM 982 Gemini at an acceleration 
voltage of 5 kV. Images were digitally stored on MO-disks. 
Cacodylate buffer: 0.1 M cacodylate; 0.01 M CaCl2; 0.01 M MgCl2; 0.09 M saccharose; 
pH 6.9 
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3 Results 
The transfer of eukaryotic expression plasmids from intracellular invasive bacteria into 
mammalian host cells in vitro and in vivo has been reported repeatedly (Sizemore et al., 1995; 
Courvalin et al., 1995; Darji et al., 1997; Hense et al., 2001). Regarding tumor therapy, most 
in vivo approaches that exploit bacteria-mediated gene-transfer generally aim at the induction 
of immune responses against tumor antigens and at the development of cancer vaccines. Even 
though bacterial gene transfer has often been proposed as a means to deliver therapeutic 
molecules – or more exact, to deliver plasmids that encode therapeutic molecules – into solid 
tumors, no such system has been described yet.  
In the present work two attenuated S. flexneri strains were explored to deliver a plasmid 
encoding luciferase as a reporter gene into different cancer cell lines in vitro and into an 
established solid carcinoma in vivo. Although the in vitro results obtained from infection 
studies with different cancer cell lines were very promising, subsequent in vivo experiments 
gave fluctuating results.  
The in vivo delivery of plasmids into mammalian tumor cells appears to be more complex and 
includes unknown variables such as efficient tumor colonization by bacteria, impact of tumor 
microenvironment on bacteria, interactions of bacteria and of tumor cells with the immune 
system, etc. Hence, it became clear that for the establishment of an efficient bacteria-mediated 
plasmid delivery system, all such variables had to be considered and their possible influence 
on bacterial gene transfer needed to be investigated. Therefore, the intratumoral settlement 
and the physiological state of S. flexneri, but also of S. typhimurium and E. coli, the 
concomitant intratumoral changes like infiltration of primary immune cells and their impact 
on bacterial colonization bacteria were studied in the present work. 
3.1 Shigella flexneri-mediated gene transfer into solid tumors  
Attenuated S. flexneri strains were amongst the first intracellular invasive bacteria to be 
shown to transfer eukaryotic expression plasmids into mammalian cells (Hone et al., 1988; 
Sizemore et al., 1995; Sizemore et al., 1997). The typical eukaryotic expression plasmid, 
which was also used by Sizemore et al. amongst others, encodes the gene of interest, which 
could be a therapeutic gene or a reporter gene, under the control of the immediate early 
promoter and enhancer of the human cytomegalovirus (CMV promoter). The CMV promoter 
has been proven to be a strong, constitutive promoter that allows high-level expression of 
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recombinant genes in a wide range of mammalian cells. In 2003 Goussard et al. found that the 
CMV promoter can also direct protein synthesis in Gram-negative bacteria such as Shigellae, 
Salmonellae and E. coli. Thus, whenever studying gene transfer from Gram-negative bacteria 
to mammalian cells using genes that are under the control of the CMV promoter, the results 
have to be interpreted with caution, unless eukaryotic expression is unequivocally 
demonstrated (Darji et al., 1997; Hense et al., 2001). 
3.1.1 The CMV promoter directs protein synthesis in S. flexneri M90T 
Serotyp 5, ∆dap and S. flexneri Serotyp 2a, ∆aroD 
In order to test whether the two employed S. flexneri strains, S. flexneri M90T Serotyp 5, 
∆dap (S. flexneri ∆dap) and S. flexneri Serotyp 2a, ∆aroD (S. flexneri ∆aroD), were able to use 
the CMV promoter for protein synthesis, both strains were transformed with the 
pCMVlucm2A plasmid (Fig. 2.1). In this eukaryotic expression plasmid the luciferase 
reporter gene is under the control of the CMV promoter. After overnight growth in TSB 
medium with the appropriate supplements at 37°C and aeration at 180 rpm, the overnight 
cultures were serially diluted, the bacteria were lysed and bacterial luciferase expression was 
measured. In concordance with the results from Goussard et al. (2003), both S. flexneri strains 
did use the CMV promoter to direct the transcription of the reporter gene luciferase. As can be 
seen in Fig. 3.1, the basal reporter gene expression in S. flexneri ∆aroD was higher than for S. 
flexneri ∆dap for reasons unknown. In both strains, especially in S. flexneri ∆aroD, the 
bacterial luciferase expression might be high enough to be mistaken for successful bacteria-
mediated gene transfer and expression in host cells.  
3.1.2 Distinction between eukaryotic and bacterial gene expression 
To overcome this problem and to be able to ultimately distinguish bacterial from eukaryotic 
gene expression, an intron was cloned into the luciferase reporter gene. In contrast to bacterial 
genes, the genes of eukaryotic cells are often interrupted by introns, which are non-coding 
sections of DNA. In the course of eukaryotic transcription, the whole eukaryotic genes, 
including the non-coding introns and the exons, i.e. the coding sections, are transcribed into 
pre-mRNA. From these primary transcripts the introns are spliced out to generate the mature 
mRNA. This mRNA is then translated into polypeptides. As the genes of prokaryotes are not 
interrupted by introns, they do not need to build spliceosomes, the ribo-protein complexes that 
perform the splicing process. Being unable to build spliceosomes, prokaryotes cannot splice 
introns. 
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Fig. 3.1: The CMV promoter can direct protein synthesis in S. flexneri M90T Serotyp 5, ∆dap and S. flexneri
Serotyp 2a, ∆aroD. Both bacterial strains were transferred with the eukaryotic expression plasmid 
pCMVlucm2A. Luciferase expression was measured in serially diluted bacterial fractions after 
overnight growth. (A) Basal luciferase expression in S. flexneri ∆dap. (B) Basal luciferase expression in 
S. flexneri ∆aroD. The graphs show mean values of at least three independent experiments. 
Thus, by cloning a functional intron into the luciferase reporter gene, only eukaryotic cells 
should be able to express functional luciferase, while the expression by bacteria should result 
in a nonsense protein, which does not give a positive luciferase signal. To ensure correct 
splicing in mammalian cells and the expression of a nonsense protein in bacteria, the intron 
had to fulfill several requirements. It should be short because short fragments are easier to 
handle in fusion PCRs during the cloning procedure (compare p.50). Further, it should contain 
a number of nucleotides, which is not divisible by three, and thus result in a frameshift 
mutation and a nonsense protein in bacteria upon translation. For the same reason it should be 
inserted at the upstream region of the luciferase gene. Finally it should contain the splice 
donor/splice acceptor site, which additionally should be flanked by the last two nucleotides of 
the preceding exon and the first two nucleotides of the succeeding exon. The intron was 
selected from the VJ gene segment of the λ2 immunoglobulin gene of the mouse (Wu et al., 
1982). As this 93 bp-intron is divisible by three, one extra nucleotide was inserted into the 
intron. The modified intron was cloned into pCMVlucm2A and resulted in the new plasmid 
pCMVluc-λ2In-m2A (Fig. 2.2). 
First, the functionality of this plasmid had to be tested, i.e. whether mammalian cells were 
able to splice the λ2-intron and express functional luciferase, while no luciferase should be 
detected in the two S. flexneri strains. Therefore, mammalian BHK-21 cells were transfected 
with pCMVluc-λ2In-m2A via calcium phosphate precipitation including pCMVβm2A and 
pCMVlucm2A as negative and positive controls, respectively. 48 h after transfection, the cells 
A B
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were harvested, lysed and 10 µl of undiluted lysate were tested for enzymatic activity of 
luciferase. Simultaneously, 1 ml of either of the overnight cultures of the two S. flexneri 
strains that were transformed with pCMVluc-λ2In-m2A was centrifuged, the bacteria were 
lysed and luciferase activity was determined. Fig. 3.2 shows that BHK-21 cells transfected 
with the intron-containing expression plasmid expressed higher activity of luciferase than 
BHK-21 cells transfected with the original plasmid. It is known that many genes are better 
expressed in eukaryotic cells when they contain an intron. This might also apply for 
luciferase. Transfection of BHK-21 cells with a control plasmid that encoded β-galactosidase 
instead of luciferase did not show any luciferase activity and marks background levels. No 
luciferase activity could be revealed for the two S. flexneri strains that were transformed with 
the newly constructed pCMVluc-λ2In-m2A plasmid. Both bacterial strains were not able to 
produce functional luciferase from this plasmid, although they could express luciferase from 
the initial expression plasmid (compare Fig. 3.1). 
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Fig. 3.2: Luciferase expression in BHK-21 cells 48 h after calcium phosphate transfection. BHK-21 cells were 
transfected with pCMVluc-λ2In-m2A, pCMVlucm2A and pCMVβm2A, respectively. The cells are 
able to express high amounts of functional luciferase from the λ2-intron containing reporter gene. 
Luciferase expression in S. flexneri strains that were transformed with pCMVluc-λ2In-m2A 
corresponds to background levels. The results show mean values of at least three independent 
experiments. Error bars show standard deviations. 
Thus, pCMVluc-λ2In-m2A meets all the demands of a delivery vector for bacteria-mediated 
gene transfer into mammalian cells. It was therefore useful as a reporter-plasmid for bacterial 
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gene transfer experiments, as it allows the unequivocal distinction between mammalian and 
bacterial protein expression. 
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Fig. 3.3: In vitro bacteriofection of different tumor cell lines with attenuated S. flexneri strains carrying the 
expression plasmid pCMVluc-λ2In-m2A. Luciferase expression was determined 24 h after 
bacteriofection. Enzymatic activity of luciferase was determined in CT26 cells (A) and HEp-2 cells (C) 
that were bacteriofected with S. flexneri ∆dap and in CT26 cells (B) and HEp-2 cells (D) that were 
bacteriofected with S. flexneri ∆aroD, respectively. Data show mean values of at least three independent 
experiments. Error bars show standard deviations. 
3.1.3 In vitro gene transfer into different tumor-cell lines 
After plasmid pCMVluc-λ2In-m2A had proven its functionality, it was used in vitro for 
bacterial gene transfer experiments into the mammalian tumor cell lines CT26 and HEp-2. To 
this end, tumor cells were infected with plasmid-bearing bacteria at an MOI of 250. Two 
hours after infection the culture medium was exchanged and Gentamycin was added to kill 
extracellular bacteria. 24 hours after infection, the cells were harvested, lysed and luciferase-
expression was measured.  
 C  D 
 A  B 
3 Results 64 
As expected, bacteria-mediated gene transfer into both tumor cell lines could be observed 
(Fig. 3.3). While uninfected tumor cells and both Shigella strains alone showed only 
background activity, both tumor cell lines did express luciferase 24 hours after infection with 
pCMVluc-λ2In-m2A-bearing Shigellae. HEp-2 cells (Fig 3.3 C and D) exhibited a luciferase 
activity that was 10-fold higher than CT26 cells (Fig. 3.3 A and B).  
When comparing gene transfer efficiency between S. flexneri ∆dap (Fig. 3.3 A and C) and 
S. flexneri ∆aroD (Fig. 3.3 B and D), the first strain transferred plasmids noticeably more 
efficient than the second strain, resulting in luciferase activities in the tumor cells that were 
100-fold higher. This phenomenon might be due to the fact that S. flexneri ∆dap is impaired in 
its cell wall synthesis and is not able to replicate without supplementary diaminopimelic acid 
(DAP) in the medium. As DAP is not produced by the tumor cells, the bacteria should lyse 
quickly inside the cells and release their plasmid load into the cytosol (Loessner et al., 2006). 
Probably, these bacteria release plasmids more efficiently into the cytoplasm than S. flexneri
∆aroD, whose cell wall synthesis is not impaired.  
3.1.4 In vivo gene transfer into solid CT26 tumors 
Having shown promising results in vitro, the S. flexneri-mediated plasmid transfer was tested 
in vivo. As S. flexneri ∆dap was more efficient in gene transfer experiments in vitro than 
S. flexneri ∆aroD, all in vivo experiments were performed with S. flexneri ∆dap.  
Studies of Zelmer (2005) revealed that S. flexneri do not preferentially accumulate in solid 
tumors when given systemically. Thus, they had to be administered directly into the tumor. 
Accordingly, 5x106 S. flexneri ∆dap carrying the eukaryotic expression plasmid pCMVluc-
λ2In-m2A were intratumorally injected into CT26 tumor-bearing BALB/c mice. Two days 
and three days after infection, mice were sacrificed, tumor, spleen and liver were removed, 
homogenized and luciferase activity in the tissue homogenates was measured. The results are 
summarized in Fig. 3.4. The experiment was repeated twice with similar results. The data 
shown represent mean values of luciferase activity of 3-4 mice per value.  
Two days and three days after bacteriofection, eukaryotic transgene expression could be 
observed in CT26 tumors. Expression could also be detected in spleen and liver albeit to a 
lesser extend. The detection of luciferase activity in organs different from the tumor is not 
astonishing, as this Shigella strain had been shown to disseminate to spleen and liver after 
intratumoral administration and persists for at least 4 days post administration (Zelmer, 2005). 
As Shigellae are invasive and induce their own uptake into cells, they should be able to infect 
various cell types, i.e. cells of different organs, into which they could transfer their expression 
plasmids. 
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Fig. 3.4: In vivo bacteriofection of subcutaneous CT26 tumors (T), spleen (S) and liver (L) with attenuated 
S. flexneri ∆dap carrying the expression plasmid pCMVluc-λ2In-m2A. Luciferase expression was 
determined 2 days and 3 days after bacteriofection. Data show mean values of 3-4 mice. Error bars 
show standard deviations. Experiments were repeated with identical results. 
In general, the luciferase activity appears to be higher at later times post infection. Obviously, 
over time higher numbers of cells will become infected resulting in higher numbers of cells 
expressing the transgene after Shigella-mediated transfer of the expression plasmid. This 
showed that in vivo gene transfer into immunocompetent mice mediated by S. flexneri ∆dap + 
pCMVluc-λ2In-m2A after intratumoral infection is generally possible. 
However, after this initial series of functional in vivo gene transfer of pCMVluc-λ2In-m2A 
from S. flexneri ∆dap into the cells of solid CT26 tumors, spleen and liver, fluctuating results 
were obtained. In the majority of cases in vivo gene transfer into the tumor cells was not 
successful, while spleen and liver sometimes displayed low positive luciferase activity. 
Intensive error analysis that aimed at improving gene transfer efficiency of the bacteria did 
not change the outcome of these experiments.  
One characteristic of S. flexneri is its large virulence plasmid, which confers the invasive 
properties to these bacteria. As plasmids always represent a burden for the microorganism, 
S. flexneri tend to quickly lose this plasmid unless under appropriate selection pressure. One 
simple way to distinguish virulent from avirulent Shigella strains is their ability to bind Congo 
red. Avirulent clones, which have lost their virulence plasmid, fail to bind Congo red, while 
virulent clones do (Payne and Finkelstein, 1977). By strictly cultivating the bacteria in the 
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presence of Congo red, a clone containing up to 99% virulent bacteria could be obtained. 
These bacteria showed improved gene transfer in vitro, but could not influence the outcome of 
the in vivo results (data not shown).  
In vitro systems represent highly artificial systems with a defined number of cell types – in 
this case only one – in which all the parameters can be controlled and optimized. In contrast, 
in vivo systems are extremely more complex with only limited options to optimize the 
different parameters. As the in vitro gene transfer constantly gave positive results, while in 
vivo gene transfer experiments transformed in parallel failed, the limiting steps had to be 
found in the mouse, especially in the interactions of tumor and immune cells with the bacteria.  
Thus, when trying to establish a therapeutic method like bacteria-mediated gene therapy of 
solid tumors it is essential to know as many details of the system as possible. However, only 
few details are known of this experimental system. Bacterial distribution, influences of 
bacteria on the tumor and on the host’s immune system as well as interactions of the bacteria 
with different host cells have not been described until now. Consequently, to understand the 
failure of bacteriofection of CT26 tumors in vivo, tumors of S. flexneri-infected and 
uninfected mice were analyzed and compared. 
3.2 Distribution of Shigella flexneri ∆dap in solid CT26 tumors 
In order to determine where Shigellae are located inside solid tumors, CT26 tumor-bearing 
BALB/c mice were intratumorally infected with S. flexneri ∆dap. Two days after infection 
tumors were removed, snapfrozen and cut into 10 µm sections. The cryosections were stained 
with Alexa 488-labeled antibodies that detect the bacteria, Phalloidin, which stains the 
cytoplasm and DRAQ5, which stains the DNA. Fig. 3.5A gives an overview of an 
intratumorally S. flexneri ∆dap-infected CT26 tumor. The majority of bacteria accumulate 
inside a large area with loosely attached cells. This area was shown to be largely necrotic 
(compare Fig. 3.22). Bordering this area a layer of densely packed cells surrounding the 
necrosis was observed. Here, most of the Shigellae were located, as shown in Fig. 3.5 A. The 
Shigellae appear to form a ring that is associated with the densely packed cells. Fig. 3.5 B 
displays a higher magnification of this region. 
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Fig. 3.5: Distribution of S. flexneri ∆dap in solid CT26 tumors 2 days post intratumoral infection. Bacteria are 
stained in green, DNA is stained in blue and the cellular actin is stained in red. (A) Low magnification 
overview of an S. flexneri colonized tumor. (B, C) Higher magnifications of the border between 
viable and necrotic tumor tissue. (D) High magnification of the bacteria-colonized, necrotic region. 
The white box in A indicates the area of enlargement in C, while the white box in C indicates the area 
of enlargement in D. The white bars represent 100 µm (A and B) and 10 µm (C and D), respectively. 
The pictures are representative for at least 3 different S. flexneri ∆dap infected CT26 tumors from 
independent experiments. 
In Fig. 3.5 C the transition between the necrotic region (right) and the densely packed region 
(left) is more enlarged, demonstrating the accumulation of bacteria between the necrotic cells 
and the densely packed cells. Most of the necrotic cells still have an intact nucleus while only 
little of the cytoplasm is left. Fig. 3.5 C is a magnification of the white box indicated in Fig. 
A B
C D
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3.5 A. Fig. 3.5 D is a magnification of the white box in Fig. 3.5 C, which shows single 
bacteria in the necrotic tumor tissue.  
Only very few bacteria could be detected in vital tumor tissue, distant from the necrotic area. 
However, some bacteria could also be found to accumulate in larges clusters directly below 
the skin spanning the tumor (Fig. 3.6). 
Fig. 3.6: Accumulation of S. flexneri ∆dap directly below the skin of CT26 tumors. Bacteria are stained in green, 
cellular actin is stained in red. (A) and (B) show high magnification images of bacterial accumulation in 
two different CT26 tumors. The white bars represent 10 µm. The pictures are representative for at least 
three different S. flexneri ∆dap infected CT26 tumors from independent experiments.
The accumulation of bacteria directly under the skin might not be astonishing and could be 
explained by the route of infection. Since the tissue of uninfected, solid CT26 tumors is rather 
dense, only very small volumes (10-20 µl) can be injected intratumorally. Despite of careful 
injection, small amounts of the inoculum will leak out of the tumor through the injection 
channel when the needle is removed and some of the bacterial suspension will remain in the 
space directly below the skin. As a result, a significant number of bacteria should accumulate 
directly below the skin. 
The inhomogeneous distribution of S. flexneri ∆dap inside the solid tumors was rather 
surprising. Being an invasive facultative anaerobic bacterium, S. flexneri ∆dap was expected 
to spread all over the tumor. Hypoxic areas should be colonized but also oxygenated areas and 
Shigella’s ability to actively spread from cell to cell should facilitate the dissemination. In 
contrast, Shigellae were almost exclusively found inside the large necrotic area and directly 
below the skin. Occasionally, bacteria were found in vital tumor tissue, associated with living 
A B
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cells. Such bacteria might be the initiators for gene transfer that was occasionally observed, as 
gene transfer can only occur, when the bacteria are infecting living cells. The reason for the 
observed inhomogeneous distribution remained unclear at this time. However, the question 
arose, whether this kind of distribution inside a solid tumor was characteristic for S. flexneri, 
or whether different bacteria, e.g. naturally tumor-targeting bacteria behave similarly.  
3.3 Distribution of Salmonella typhimurium SL7207 and Escherichia coli 
TOP10 in solid CT26 tumors 
To confirm the tumor-targeting ability of the two strains S. typhimurium SL7207 and E. coli
TOP10, BALB/c mice bearing a CT26 tumor were intravenously infected with either of the 
two strains. Two days after infection, tumor, spleen and liver were homogenized and the CFU 
per tissue were determined. Both bacterial strains exhibited a strong preference for the solid 
tumor (Fig. 3.7 A and 3.7 B). While the number of Salmonellae in the tumor was 50-100 
times higher than in other tissues (Fig. 3.7 A), the E. coli strain used showed an even stronger 
preference for the tumor. Here, 50-100,000 times more bacteria were found in the tumor in 
comparison to other organs (Fig. 3.7 B). 
In order to determine, where the bacteria accumulate inside the CT26 tumor, the tumors were 
removed two days p.i., snapfrozen and cut into 10 µm sections. Fig. 3.8 shows the distribution 
of S. typhimurium SL7207 two days after i.v. infection. Fig. 3.8 A gives an overview of the 
infected tumor tissue, while Fig. 3.8 B shows an enlargement of necrotic tumor tissue. Here, 
the loose association between tumor cells inside the necrosis is clearly visible. Again, most 
nuclei appear to be intact, while the cytoplasm is largely disintegrated. Fig. 3.7 C is a 
magnification of the white box marked in Fig. 3.7 A and highlights the border between viable 
(V) and necrotic (N) tumor cells. Fig. 3.7 D is an enlargement of the white box in Fig. 3.7 C 
and shows single bacteria in the necrotic tumor tissue. 
Interestingly, S. typhimurium were found only inside the necrotic tumor tissue or at the rim 
between necrotic and viable tumor cells and showed a similar distribution pattern as 
S. flexneri. However, S. typhimurium could not be detected under the skin covering the solid 
CT26 tumor. S. typhimurium entered the solid tumor via the tumor vasculature and were not 
directly administered into the tumor like S. flexneri. Thus, they have no direct access to the 
skin. The route of administration might also explain why Salmonellae were never found to be 
associated with viable cells distant from necrotic areas.  
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Fig. 3.7: Bacterial colonization in different tissues. Tumor bearing mice were i.v. infected with S. typhimurium
SL7207 (A) and E. coli TOP10 (B), respectively. Two days p.i. tumor, spleen and liver were 
homogenized and plated and CFU per organ were determined. Results are representative for at least 
three independent experiments. Error bars show standard deviations. 
The distribution of E. coli TOP10 in CT26 tumors two days after i.v. infection is generally 
comparable to the distribution of S. typhimurium SL7207. Like Salmonellae, E. coli were 
found only inside large necrotic areas, while no bacteria could be detected under the skin 
covering the solid tumors or inside viable tumor tissue. This is shown in Fig. 3.9. Fig. 3.9 A 
displays an overview of the infected tumor tissue and Fig. 3.9 B shows the border between 
viable (V) and necrotic (N) tumor tissue in enlargement. As for S. flexneri, the necrotic, 
loosely associated cells inside the necrosis were bordered by a region of densely packed cells 
with irregularly shaped nuclei. The E. coli were either found inside the necrosis or in close 
contact to those densely packed cells. Fig. 3.9 C is a magnification of the white box marked in 
Fig. 3.9 A and displays the bacteria inside the necrotic area. In Fig. 3.9 D, the white boxed 
part of Fig. 3.9 C is displayed in a higher magnification. 
Comparing the distribution of S. typhimurium and E. coli to the distribution of S. flexneri
inside solid CT26 tumors, it becomes clear that all tested bacterial strains accumulate 
preferably, if not exclusively, inside large necrotic areas (compare Fig. 3.22) leaving a rim of 
viable, non-infected tumor cells. The accumulation of bacteria inside the tumor was always 
associated with a macroscopic visible blackening of the surface of the subcutaneous tumors 
and the tumor growth was retarded or stopped. Sometimes, even shrinkage of the tumor could 
be observed. However, when the experiment was extended over the described two days, the 
viable cells of the tumor rim rapidly proliferated and the tumor started to regrow. 
A B
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Fig. 3.8: Distribution of S. typhimurium SL7207 in solid CT26 tumors two days after intravenous infection. 
Bacteria are stained in green, DNA is stained in blue and the cellular actin is stained in red. (A) Low 
magnification overview of an S. typhimurium colonized tumor. (B) Higher magnification of the necrotic 
tumor tissue. (C) Higher magnification of the border between necrotic and vital tumor tissue. (D) High 
magnification of the bacteria-colonized, necrotic region. The white box in A indicates the area of 
enlargement in C, while the white box in C indicates the area of enlargement in D. The white bars 
represent 100 µm (A) and 10 µm (B, C, and D), respectively. The pictures are representative for at least 
three different S. typhimurium SL7207 infected CT26 tumors from independent experiments. 
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Fig. 3.9: Distribution of E. coli TOP10 in solid CT26 tumors two days after intravenous infection. Bacteria are 
stained in green, DNA is stained in blue and the cellular actin is stained in red. (A) Low magnification 
overview of an E. coli colonized tumor. (B) Higher magnification of the border between necrotic and 
vital tumor tissue. (C) Higher magnification of the necrotic tumor tissue. (D) High magnification of the 
bacteria-colonized, necrotic region. The white box in A indicates the area of enlargement in C, while 
the white box in C indicates the area of enlargement in D. The white bars represent 100 µm (A) and 10 
µm (B, C, and D), respectively. The pictures are representative for at least three different E. coli TOP10 
infected CT26 tumors from independent experiments. 
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Together, the depicted accumulation of the employed facultative anaerobic bacteria inside a 
large necrosis is independent of the route of infection. The infection itself cannot be sufficient 
to stop tumor growth since the bacteria are not able to kill all the viable, proliferating tumor 
cells. 
3.4 Dramatic influx of neutrophils to the site of infection 
All the bacteria strains tested so far were mainly restricted to the necrotic area although their 
growth characteristics should have allowed them to spread over the entire tumor. Hence, it 
was postulated that immune cells inside the tumor might be responsible for the bacterial 
distribution. To test this hypothesis, 10 µm cryosections of infected and uninfected tumors 
were stained with fluorescently conjugated antibodies against various immune cells. This 
revealed a tremendous influx of neutrophils to the site of infection.  
Fig. 3.10 shows low magnification overviews of three different, uninfected control CT26 
tumors. In all such tumors, neutrophilic granulocytes, which are double positive for the 
markers Gr1 and Mac1 and thus appear pink, are scattered as single cells or in small clusters 
all over the solid tumor. Sometimes, as can be seen in Fig. 3.10 C, the neutrophils appear 
accumulated in bigger clusters, usually at places of small necroses. All tumor cells seem to 
express low amounts of Mac1, as the whole tumor is faintly stained blue. The Mac1 staining 
is more intense at the rim of the solid tumors. In general it is known that Mac1 can be 
expressed on macrophages, granulocytes and on dendritic cells.  
Two days after infection neutrophils had invaded the tumor in large numbers. They are 
located at the border between the “healthy” tumor tissue at the outer rim and necrosis that is 
populated by the bacteria at the inner rim (Fig. 3.11, Fig. 3.12, Fig 3.13 and Fig. 3.14). The 
necrotic part of the tumor is neither stained by Gr1 nor Mac1. Here, most of the bacteria can 
be found. This necrotic area is bordered by a thick layer of Gr1/Mac1 double positive 
neutrophils, the majority of which is in close contact with bacteria. The vital tumor tissue that 
is neighboring the neutrophil border is positive for Mac1. This could be due to an infiltration 
of Mac1-positive macrophages, but also because of the low expression of Mac1 on the vital 
CT26 cells. 
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For S. flexneri ∆dap (Fig. 3.10), the restriction to the necrotic tissue is not as strict as for 
S. typhimurium (Fig. 3.12) and E. coli (Fig. 3.13). As can be seen in Fig. 3.11 E, S. flexneri
could sometimes be found in viable tumor tissue. As proposed before, the occurrence of 
S. flexneri in vital tumor tissue might – at least in part – be due to the different infection route. 
Even here, the bacteria are in close contact with neutrophils.   
S. flexneri can also be applied systemically. Since they do not represent a pathogen in the 
mouse, only few bacteria survive after administration. Nevertheless, some of them can be 
found in the tumor, although they do not have a strong intrinsic tumor-targeting ability 
(Zelmer, 2005). Interestingly, the Shigellae found in tumors after systemic application are also 
located inside necrotic areas (Fig. 3.12). In these cases, the bacteria-containing necroses are 
Fig. 3.10: 
Distribution of neutrophils in three different 
uninfected 10-12 day old CT26 tumors. Gr1-positive 
cells are stained in red, Mac1 (CD11b)-positive cells 
are stained in blue. (A-C) Low magnification 
overviews of neutrophil-distribution in uninfected 
control tumors. (A and B) Neutrophils are scattered 
in small clusters all over the tumor or (C) 
accumulated at places of small necroses. The white 
bars represent 100 µm.  
A B
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surrounded by numerous neutrophils that migrate into the tumor upon invasion, similar to 
intratumoral application of Shigellae.  
Contrary to i.t. injected S. flexneri, S. typhimurium SL7207 was strictly found inside the 
necrosis (Fig. 3.13 A-C) or associated with neutrophils bordering the necrosis (Fig. 3.13 C 
and D). No Salmonellae could be detected in vital tumor tissue. Similar results were obtained 
for E. coli TOP10. No E. coli were found in viable tumor tissue, while most bacteria had 
disseminated inside the large necrosis (Fig. 3.14 D).  
Together, the cellular arrangement inside bacteria-colonized tumors suggests that the 
microorganisms are kept from spreading homogenously over the solid tumor by neutrophils 
that are attracted after bacterial colonization and migrate towards the necrosis not only to 
remove the dead, necrotic cells but also to inhibit the bacteria from further spreading into 
healthy tissue. The inhibition of bacterial distribution into vital tumor tissue might be the 
reason for the low gene transfer efficiency with S. flexneri ∆dap in solid CT26 tumors 
observed before.  
To investigate whether Shigella-mediated gene transfer could be observed in cryosections of 
CT26 tumors that were colonized by S. flexneri ∆dap carrying the reporter plasmid pCMVluc-
λ2In-m2A, 10 µm cryosections of these tumors were stained with antibodies directed against 
luciferase, the reporter protein. In addition, the tumor sections were stained with antibodies 
directed against Shigellae and against Gr1-positive cells in order to localize bacteria, 
neutrophils and necrosis.  
As can be seen in Figure 3.15, the majority of cells did not express luciferase. Only very few 
cells are brightly stained for the enzyme. These luciferase expressing cells are magnified in 
3.15 B and 3.15 C. According to the enlarged images, luciferase expressing cells (marked by 
arrow heads) were in areas, in which bacteria (marked by arrows) and neutrophils are located. 
Such rare luciferase expressing cells were only found in vital tumor tissue (V), distant from 
the large necrosis (N). The number of luciferase expressing cells per section was very scarce. 
This might explain the failure of detecting luciferase activity reproducibly in tumor 
homogenates.  
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Fig. 3.11:  
Massive infiltration of neutrophils into CT26 tumors 
2 days after i.t. infection with S. flexneri ∆dap. 
Bacteria are stained in green, Gr1-positive cells in red 
and Mac1-positive cells in blue. (A and B) Low 
magnification overviews of neutrophil distribution in 
CT26 tumors 2 days after intratumoral application of 
S. flexneri ∆dap. (C and D) Higher magnifications of 
the neutrophilic border between vital and necrotic 
tumor tissue. (E) High magnification of neutrophils 
associated with S. flexneri ∆dap in vital tumor tissue. 
The white bars represent 100 µm (A, B and C) and 
10 µm (D and E), respectively.  
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Fig. 3.12: Massive infiltration of neutrophils into CT26 tumors two days after intravenous infection with 
S. flexneri ∆dap. Bacteria are stained in green, Gr1-positive cells are stained in red and Mac1-positive 
cells are stained in blue. (A and B) Low magnification overviews of neutrophil distribution in CT26 
tumors 2 days after intravenous infection with S. flexneri ∆dap. (C and D) Higher magnification of the 
neutrophilic border between vital and necrotic tumor tissue (D). The white bars represent 100 µm (A-
C) and 10 µm (D), respectively. The pictures are representative for at least three different tumors from 
independent experiments.
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Fig. 3.13: Massive infiltration of neutrophils into CT26 tumors two days after intravenous infection with 
S. typhimurium SL7207. Bacteria are stained in green, Gr1-positive cells are stained in red and Mac1-
positive cells are stained in blue. (A) Low magnification overview of neutrophil distribution in CT26 
tumors 2 days after intravenous infection with S. typhimurium SL7207. (B-D) Higher magnifications 
of the neutrophilic border between vital and necrotic tumor tissue. The white bars represent 100 µm 
(A and B) and 10 µm (D and E), respectively. The pictures are representative for at least three 
different tumors from independent experiments.
A B
C D
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Fig. 3.14: Massive infiltration of neutrophils into CT26 tumors two days after intravenous infection with E. coli 
TOP10. Bacteria are stained in green, Gr1-positive cells are stained in red and Mac1-positive cells are 
stained in blue. (A) Low magnification overview of neutrophil distribution in CT26 tumors 2 days 
after intravenous infection with E. coli TOP10. (B and C) Higher magnifications of the neutrophilic 
border between vital and necrotic tumor tissue. (D) High magnification of E. coli TOP10 inside the 
necrosis. The white bars represent 100 µm (A and B) and 10 µm (D and E), respectively. The pictures 
are representative for at least three different tumors from independent experiments. 
A B
C D
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As depicted in Fig. 3.11-3.14, the bulk of bacteria were enclosed by neutrophils inside a large 
necrosis, associated with dead, necrotic cells into which gene transfer is not possible. The fact 
that most of the Shigellae were accumulated inside the necrosis and only few bacteria were 
found in vital tumor tissue is very likely one cause for the low bacterial gene transfer 
efficiency in vivo.  By extrapolation, this might also apply to other bacterial transfer systems 
like L. monocytogenes, where similar failure of gene transfer was accounted (Zelmer, 2005). 
Generally, in an ideal bacteria-mediated tumor therapy, the bacteria should be homogenously 
distributed over the tumor and reach all cells of a tumor, including well oxygenated, vital cells 
but also hypoxic and necrotic areas. In this respect, the “border of neutrophils” might be 
keeping the bacteria from homogeneous dissemination throughout the solid tumors. 
Therefore, the depletion of neutrophils or the prevention of an infiltration of neutrophils 
Gr1
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Fig. 3.15: 
Luciferase-expressing cells in cryosections of CT26 
tumors 2 days after i.t. infection with S. flexneri ∆dap 
+ pCMVluc-λ2In-m2A. Bacteria are stained in green, 
Gr1-positive cells are stained in red and luciferase is 
stained in blue. (A) Low magnification overview of 
an infected tumor. (B and C) Higher magnifications 
of luciferase expressing cells. (C) Arrow heads 
highlight typical cells in which the cytoplasm is 
stained for luciferase. The white arrows indicate 
single bacteria in (B and C). The white bars represent 
100 µm (A) and and 10 µm (B and C), respectively.  
V
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towards the infection should improve bacterial dissemination inside solid CT26 tumors and 
might enhance gene transfer efficiency. 
3.5 Depletion of host neutrophils 
The hypothesis that the neutrophil border has an impact on the spreading of the bacteria 
throughout the tumor and their invasion into viable tumor tissue was tested by depleting 
neutrophils from the mice. This was accomplished by triple i.p. injections of 25 µg and 
100 µg anti-Gr1 antibody, respectively. The antibody was injected 1 day before bacterial 
infection (-1), simultaneously with infection (0) and 1 day after infection (1). All mice 
survived the antibody-treatment and the concomitant infection without obvious impairments 
in health. Two days after infection the efficiency of the depletion was controlled via flow 
cytometry of blood of treated and control mice. As can be seen in Fig. 3.16, a triple treatment 
with 25 µg anti-Gr1 was sufficient to reduce the number of neutrophils in the blood to 4% of 
the number found in untreated control mice. A higher dosage of the antibody resulted only in 
slight enhancement of the depletion (down to 3%). Thus, all further experiments were 
performed with a triple dose of 25 µg anti-Gr1. 
ctrl 25µg anti-Gr1
(-1,0,1)
100µg anti-Gr1
(-1,0,1)
100%
80%
60%
40%
20%M
ea
n
pe
rc
en
ta
ge
o
f n
eu
tr
o
ph
ils
 
[%
]
M
ea
n
pe
rc
en
ta
ge
o
f n
eu
tr
o
ph
ils
 
[%
]
Fig. 3.16: Neutrophil depletion in the blood of BALB/c mice. Neutrophils were depleted by triple i.p. injections 
of 25 µg and 100 µg anti-Gr1, respectively, one day before (-1), simultaneously (0) and one day after 
(-1) infection. Two days post infection, blood samples were taken and analyzed by flow cytometry. 
The percentage of neutrophils in the blood of neutrophil depleted mice was normalized to the 
percentage of neutrophils in non-depleted tumor bearing control mice. 
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3.5.1 Stronger accumulation of bacteria inside the tumor after depletion of 
neutrophils
Two days after infection tumor-bearing mice that were either depleted of neutrophils or not 
were sacrificed and the CFU per tissue were determined (Fig. 3.17 A-C). To ensure successful 
depletion of neutrophils in every experiment, the depletion was controlled via flow cytometry 
of blood, as described above. As displayed in Fig. 3.17 A, the depletion of neutrophils lead to 
a colonization of S. typhimurium in all tested tissues that was approximately 4-5 times higher 
than in non-depleted, infected control mice. Thus, a depletion of neutrophils has a strong 
influence on bacterial colonization of solid tumors. However, at the same time the bacterial 
numbers in all other organs tested was also increased, resulting in a higher total bacterial 
burden of the mice.  
Regarding E. coli TOP10 (Fig. 3.17 B), this effect was more diversified. Here, the number of 
bacteria inside the tumor was about 7 times higher in depleted compared to non-depleted 
mice. In contrast, the other organs were only slightly more affected in depleted mice, if at all, 
compared to non-depleted mice. Thus, E. coli primarily leads to higher bacterial numbers in 
the tumor without a concomitant increased bacterial burden in the other organs.   
S. flexneri ∆dap (Fig. 3.17 C) basically show the same pattern as S. typhimurium and E. coli
although the differences between the bacterial load inside the tumor of neutrophil-depleted in 
comparison to non-depleted mice are not as distinct. This might, again, be due to the way of 
bacterial administration. The small volume of the i.t. application might render this route of 
infection more error prone than i.v. infections. Small deviations of the intended injection 
volume will result in significant alterations in bacterial numbers in the tumor two days later. 
Therefore, the effect of the neutrophil depletion on the CFU in tumors might be obscured by 
the large standard deviation in non-depleted mice. 
Different to the intratumoral colonization with S. flexneri ∆dap, the number of Shigellae in 
other organs seems not to be influenced by the depletion. As mentioned before (chapter 
3.1.4), S. flexneri are able to spread from the tumor into distant organs. This spreading is 
obviously not affected by the presence or absence of neutrophilic granulocytes. 
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Fig. 3.17: Bacterial accumulation in different tissues with or without neutrophil depletion. Tumor-bearing, anti-
Gr1 treated and non-treated mice were infected i.v. with S. typhimurium SL7207 (A), E. coli TOP10 
(B) or infected i.t. with S. flexneri ∆dap (C). Neutrophils were depleted by triple i.p. injections of 
25 µg anti-Gr1, on day -1, 0 and 1. Two days post infection, tumor, spleen and liver were 
homogenized and plated and the CFU per tissue were determined. The black bars represent the CFUs 
in non-depleted mice while the grey bars represent the CFUs in neutrophil-depleted, infected mice. 
The error bars show standard deviations. Results are representative for at least 2 independent 
experiments with 3-5 mice.
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3.5.2 Bacteria are found in vital tumor tissue of neutrophil-depleted mice 
In parallel to plating tissue homogenates, tumors from neutrophil-depleted mice were 
snapfrozen and analyzed by histology, as before. Fig. 3.18-3.19 demonstrate that most of the 
Gr1/Mac1 double-positive neutrophils in the tumor were depleted, as intended. Remarkably, 
under these conditions all bacteria tested were able to disseminate into vital tumor tissue (Fig. 
3.18 D, Fig. 3.19 D, Fig. 3.20 D). However, the majority of bacteria still remained inside the 
necrosis. 
Fig. 3.18 A and Fig. 3.18 B show low magnification overviews of S. typhimurium-infected, 
neutrophil-depleted, CT26 tumors two days p.i.. In both experiments, few neutrophils 
remained that were clustered in a small layer. Obviously, such few neutrophils were not 
sufficient to keep the bacteria from spreading into vital tumor tissue, as Salmonellae could be 
found on both sites of this neutrophil border. In Fig. 3.18 B S. typhimurium appear to migrate 
around the few remaining neutrophils. Fig. 3.18 C shows an enlargement of the remaining 
neutrophil border and of Salmonellae settling on both sites of neutrophils. Fig. 3.19 D 
highlights Salmonellae inside vital tumor tissue. 
In the overviews of neutrophil-depleted, E. coli TOP10-infected tumors (Fig. 3.19 A and Fig. 
3.19 B) no such remaining neutrophil border could be observed. Obviously the treatment was 
more efficient in this case. Fig. 3.19 C shows a higher magnification of E. coli inside the 
necrosis. One can clearly see the destruction of the necrotic tissue. The necrotic cells stick to 
each other and appear to form a mesh of sticky necrotic cells. Up to now it is unclear, whether 
this is caused by the cutting process, or whether the mesh-like structure is also found in the 
intact tumor. However, it is obvious that the cells in this structure are dead. Fig. 3.19 D 
highlights vital tumor tissue. Contrary to Fig. 3.19 C, the cells inside vital tissue are 
interconnected with each other and form a smooth layer of cells. Similar to the results 
obtained for S. typhimurium in neutrophil-depleted mice, bacteria can now be found inside 
vital tumor tissue. Single E. coli are marked with white arrows.  
The distribution of S. flexneri ∆dap (Fig. 3.20) in neutrophil-depleted CT26 tumors two days 
after infection resembles the distribution of S. typhimurium and E. coli. However, in contrast 
to these other strains, the structure of S. flexneri ∆dap infected, neutrophil-depleted tumors 
seems to be more amorphic. Differences between vital and necrotic tumor tissue are hardly 
visible and the majority of the tumor appears to be necrotic. In Fig. 3.20 C the transition from 
highly colonized, clearly necrotic tumor tissue to less colonized, vital tumor tissue is enlarged. 
Fig. 3.20 D finally shows single S. flexneri in tumor tissue that is mostly vital. The bacteria 
are marked with white arrows. 
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Fig. 3.18: Cryosections of CT26 tumors from S. typhimurium SL7207-infected, neutrophil-depleted mice were 
prepared two days p.i. Gr1-positive cells are stained in red, Mac1-positive cells are stained in blue and 
bacteria are stained in green. (A) and (B) Low magnification overviews; a small border of neutrophils 
can still be seen, which is apparently bypassed by the bacteria. (C) Higher magnification of the 
neutrophil border that remained. Bacteria can be seen on both sides of the neutrophils. (D) High 
magnification of S. typhimurium in vital tumor tissue. The white bars correspond to 100 µm in A and 
B and to 10 µm in C and D, respectively. Pictures are representative for 3-5 tumors from at least two 
independent experiments. 
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3 Results 86 
  
Fig. 3.19: Cryosections of CT26 tumors from E. coli TOP10-infected, neutrophil-depleted mice were prepared 
two days p.i. Gr1-positive cells are stained in red, Mac1-positive cells are stained in blue and bacteria 
are stained in green. (A) and (B) Low magnification overviews; almost no neutrophils can be detected 
inside the tumor. (C) High magnification of bacteria inside the necrosis. (D) High magnification of 
E. coli in vital tumor tissue. Some single bacteria are indicated by white arrows. The white bars 
correspond to 100 µm in A and B and to 10 µm in C and D, respectively. Pictures are representative 
for 3-5 tumors from at least two independent experiments. 
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Fig. 3.20: Cryosections of CT26 tumors from S. flexneri ∆dap-infected, neutrophil-depleted mice were prepared 
two days p.i. Gr1-positive cells are stained in red, Mac1-positive cells are stained in blue and bacteria 
are stained in green. (A and B) Low magnification overviews; almost no neutrophils can be detected 
inside the tumor. The tumor architecture has become less structured. Differentiation between viable 
and necrotic tumor tissue has become very difficult. (C) High magnification of the border between 
necrotic and vital tumor tissue. (D) High magnification of S. flexneri in mostly vital tumor tissue. 
Some single bacteria are indicated by white arrows. The white bars correspond to 100 µm in A and B
and to 10 µm in C and D, respectively. Pictures are representative for 3-5 tumors from at least two 
independent experiments. 
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Taken together, the depletion of neutrophils via triple injections of anti-Gr1 leads to an 
increased dissemination of all bacterial strains tested inside solid CT26 tumors and most 
impressively, to a spreading of the bacteria into vital tumor tissue. 
3.5.3 Depletion of neutrophils leads to increase of necrosis 
Analysis of the cryosections under the various conditions described above had also suggested 
that the size of necrosis was increased in bacteria-colonized tumors of depleted mice. To 
determine the exact size of necrosis under various conditions, tumors were removed and fixed 
in paraformaldehyde. The fixed tumors were embedded in paraffin, cut into 5 µm sections and 
stained with hematoxylin and eosin. The size of the necrosis of a tumor was evaluated by 
examining every fifth section of the tumor from different locations i.e. from the center or the 
rim. This was accomplished with the cell^D software from Olympus, which allows the 
calculation of marked areas inside a histological section. The normalized results are displayed 
in Table 3.1. According to these evaluations, the size of necrosis clearly increased from 
around 10% in non-infected tumors to up to 60%-70% in infected tumors. After depletion of 
neutrophils, the size of necrosis increased even further and could reach to up to 90% of the 
entire tumor tissue. Increase in the size of necrosis is slightly more developed in S. flexneri-
colonized tumors in comparison to tumors that were infected with the two other bacteria. The 
cause of this difference between the single bacterial strains is presently unclear. Figures 3.21-
3.23 show representative data Table 3.1 is based upon. 
Table 3.1: Size of necrosis in infected and uninfected CT26 tumors with and without depletion of neutrophils 
85-90% 
65-70% 
80-85% 
60-65% 
75-85% 
60-65% 
5-15% 
Percentage 
Necrosis 
  + S. flexneri ∆dap 
  – S. flexneri ∆dap
  + E. coli TOP10 
  – 
E. coli TOP10
  + 
S. typhimurium
SL7207 
  – 
S. typhimurium
SL7207 
  –
Not infected 
CT26 
     anti-Gr1 Bacteria Tumor 
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The increase of necrosis two days after infection with any of the three bacterial strains in 
CT26 tumors can be seen when comparing Fig. 3.21 and Fig. 3.22. Necrosis is marked with 
N. In uninfected tumors (Fig. 3.21) several very small necroses could be detected Fig. 3.21A. 
In the necrotic cells, the nuclei were either very compressed or they had dissolved (Fig. 
3.21B). Hardly any neutrophils could be detected in the surrounding of a necrosis in 
uninfected tumors (Fig. 3.21 and data not shown). 
  
Fig. 3.21: HE staining of uninfected CT26 tumors. Nuclei are stained in violet/blue and the cytoplasm is stained 
in red/pink. Necrosis is marked with N. (A) Low magnification overview of an uninfected CT26 
tumor. (B) Magnified image of a small necrosis. The black bars represent 500 µm in A and 50 µm in 
B, respectively.  
In contrast, all examined CT26 tumors colonized by bacteria were dominated by one large 
necrosis, which was surrounded by a border of densely packed cells (compare Fig. 3.22 A, C 
and E). Even at first glance, the size of necrosis appeared dramatically enlarged. Higher 
magnifications of these densely packed cells revealed them to be neutrophils, as can be 
recognized by the multilobulated shape of their nuclei (Fig. 3.22 B, D and F). The basic 
structures of S. typhimurium-infected CT26 tumors Fig. 3.22 A and Fig. 3.22 B, E. coli-
infected tumors Fig. 3.22 C and Fig. 3.22 D and S. flexneri-infected tumors Fig. 3.22 E and 
Fig. 3.22 F resemble each other and are therefore not bacteria-specific.   
Taken together these data absolutely correspond with the data from the cryosections. All 
tested bacterial strains lead to a tremendous infiltration of host neutrophils, which migrate 
towards the necrosis and separate the bacteria-containing necrosis from vital tumor tissue. 
When depleting the neutrophilic granulocytes by triple injections of 25 µg anti-Gr1 
simultaneously to the bacterial infections, the border of densely packed neutrophils had 
disappeared (Fig. 3.23). 
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Fig. 3.22: HE staining of infected CT26 tumors. Nuclei are stained in violet/blue and the cytoplasm is stained in 
red/pink. The necrosis is marked with an N. (A, C and E) Low magnification overviews of 
S. typhimurium- (A), E. coli- (C) and S. flexneri- (E) infected CT26 tumors. (B) Magnified images of 
the neutrophilic border between necrosis and vital tumor tissue of S. typhimurium- (B), E. coli- (D) 
and S. flexneri- (F) infected CT26 tumors. The black bars represent 500 µm in A, C and E and 50 µm 
in B, D and F, respectively. The black arrows in B, D and F indicate single neutrophils. 
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Fig. 3.23: HE staining of infected, neutrophil-depleted CT26 tumors. Nuclei are stained in violet/blue and the 
cytoplasm is stained in red/pink. The necrosis is marked with N. (A, C and E) Low magnification 
overviews of S. typhimurium- (A), E. coli- (C) and S. flexneri- (E) infected CT26 tumors. (B) 
Magnified images of the border between necrosis and vital tumor tissue of S. typhimurium- (B), 
E. coli- (D) and S. flexneri- (F) infected, neutrophil-depleted CT26 tumors. The black bars represent 
500 µm in A, C and E and 50 µm in B, D and F, respectively.  
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Fig. 3.24: Cryosections of TS/A tumors from S. flexneri ∆dap-infected mice and from S. flexneri ∆dap-infected 
neutrophil-depleted mice were prepared two days p.i. Gr1-positive cells are stained in red, Mac1-
positive cells are stained in blue and bacteria are stained in green. (A) Low magnification overview of 
neutrophil dissemination in TS/A tumors 2 days after i.t. infection with S. flexneri ∆dap. (B) Higher 
magnification of bacteria inside the necrosis. (C) Low magnification overview of a neutrophil-
depleted, S. flexneri ∆dap-infected TS/A tumor. (D) High magnification of S. flexneri in vital tumor 
tissue of a neutrophil-depleted TS/A tumor. The white bars correspond to 100 µm in A and C and to 
10 µm in B and D, respectively. Pictures are representative for three tumors from at least two 
independent experiments. 
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Fig. 3.25: Cryosections of TS/A tumors from S. typhimurium SL7207-infected mice and from S. typhimurium 
SL7207-infected neutrophil-depleted mice were prepared 2 days p.i. Gr1-positive cells are stained in 
red, Mac1-positive cells are stained in blue and bacteria are stained in green. (A) Low magnification 
overview of neutrophil dissemination in TS/A tumors 2 days after i.v. infection with S. typhimurium 
SL7207. (B) Higher magnification of the neutrophil border between vital and necrotic tumor tissue. 
(C) Low magnification overview of a neutrophil-depleted, S. typhimurium SL7207-infected TS/A 
tumor. (D) High magnification of S. typhimurium SL7207 in vital tumor tissue of a neutrophil-
depleted TS/A tumor. The white bars correspond to 100 µm in A and C and to 10 µm in B and D, 
respectively. Pictures are representative for three tumors from at least two independent experiments. 
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Fig. 3.23 A, C and E show overviews of S. typhimurium- (Fig. 3.23 A), E. coli- (Fig. 3.23 C) 
and S. flexneri (Fig. 3.23 E)-infected, neutrophil-depleted CT26 tumors. All these tumors lack 
the thick blue border of neutrophils that could be observed in colonized tumors of non-
depleted mice (Fig. 3.22). When enlarging the border between necrotic and viable tumor 
tissue in Gr1-depleted tumors (Fig. 3.23 B, D and F) the first impression obtained from the 
overviews was confirmed. No more neutrophils were detectable between viable and necrotic 
tissue. This can be seen by the missing multilobulated nuclei of the cells. Instead, the necrosis, 
which is more reddish, directly borders the violet stained, vital tumor tissue. As mentioned 
before, not only the neutrophilic border had disappeared, but also the necrosis had apparently 
increased. 
These results were confirmed with a second subcutaneously injected solid tumor, the 
adenocarcinoma TS/A. Pictures of stained cryosections of these tumors after infection with 
S. typhimurium SL7207 and with S. flexneri ∆dap, respectively, with or without neutrophil 
depletion are shown in Fig. 3.24 and Fig. 3.25.  
Regarding gene transfer with S. flexneri carrying the reporter plasmid pCMVluc-λ2In-m2A, 
the depletion of neutrophils did not increase efficiency (data not shown). For optimal gene 
transfer conditions, the bacteria have to infect viable tumor cells. However, the depletion of 
neutrophils also leads to an increase in the size of necrosis and thus to an increased number of 
bacteria that are associated with necrotic, non-viable tumor cells. This is most likely the 
reason why gene transfer efficiency could not be enhanced. 
As the total number of bacteria as well as the spreading of bacteria inside solid tumors could 
be remarkably improved, other bacteria-mediated tumor therapies, like the delivery of 
therapeutic proteins via bacterial secretion systems, might be strongly supported by the 
depletion of neutrophils.  
In summary, depletion of neutrophils in the course of bacteria-mediated tumor therapy leads 
to an enhanced dissemination of bacteria inside solid tumors. Besides a noticeable higher total 
number of bacteria inside the tumor, an increase of the size of necrosis is observed and most 
remarkably the migration of bacteria into the vital tumor tissue. The border of host neutrophils 
that obviously trap the bacteria inside the necrosis had disappeared and the few neutrophils 
that were left could be circumvented by the bacteria. 
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3.6 Kinetics of bacterial colonization of solid CT26 tumors 
The tremendous influx of neutrophils to the site of infection and the enormous increase of the 
size of necrosis two days after bacterial infection suggested a closer investigation of the early 
times of bacterial colonization. Up to now it was claimed that tumor-colonizing bacteria are 
attracted to hypoxic, especially necrotic areas of solid tumors. The necrosis satisfies the needs 
of the bacteria in terms of sufficient supply of nutrients, optimal pH and optimal temperature. 
However, the dramatic increase of the size of necrosis after colonization with facultative 
anaerobic bacteria suggests that the bacteria themselves induce necrosis after having 
successfully escaped from the blood into the solid tumor. 
In order to investigate, how and when the bacteria start colonizing the tumor and when the 
infiltration of neutrophils takes place, CT26 tumor-bearing BALB/c mice were intravenously 
infected with S. typhimurium SL7207. At different times after infection, ranging from 30 min 
to 18 h, tumors were removed and snapfrozen. Cryosections of 10 µm diameters were stained 
with fluorescently labeled antibodies against Salmonellae, neutrophilic granulocytes and 
CD31, a cluster of differentiation molecule that is normally found on endothelial cells. As the 
blood vessels are lined with endothelial cells, it should highlight their distribution and their 
course.  
As early as 30 minutes after infection, single bacteria could be found inside blood vessels of 
CT26 tumors (Fig. 3.26 A and B). The single bacteria are marked with white arrows. 
Sometimes, it even appears as if a bacterium has escaped a blood vessel (compare the upper 
left bacterium in Fig. 3.26 A). This situation did not change much over the first six hours after 
infection (Fig. 3.26 C – E). Most of the bacteria that could be detected were located inside or 
in close contact to blood vessels and they were isolated. Rarely, tiny clusters or colonies of 
Salmonellae could be detected 6 hours p.i. as depicted in Fig. 3.26 F. Between 6 hours and 15 
hours post infection, the tumors were macroscopically becoming dark red, as if blood was 
flowing in. This phenomenon was analyzed in more detail via hematoxilin/eosin stainings 
(Fig. 3.28) and is further described below.  
Twelve hours post infection these tiny bacterial clusters could be observed more frequently 
(Fig. 3.26 G and H). They could be found at different places scattered all over the tumor. 
Often the bacterial colonies were still associated with or in close contact to blood vessels 
(compare left arrow in Fig. 3.26 G). 
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Fig. 3.26: Early times of bacterial colonization of solid CT26 tumors. S. typhimurium is stained in green, 
neutrophils (Gr1) are stained in red and the endothelial cells of blood vessels (CD31) are stained in 
blue. (A and B) 30 min post infection. (C and D) 2 h post infection. (E and F) 6 h post infection. (G
and H) 12 h post infection. (I and J) 15 h post infection. (K and L) 18 h post infection. The white 
arrows in A – E indicate single bacteria. The white arrow in G indicates a bacterial colony inside a 
blood vessel. The white bars represent 10 µm. 
Fifteen hours post infection the scattered bacterial colonies had become significantly larger 
(Fig. 3.26 I and J) and the single bacteria were starting to localize at places distant from blood 
vessels. Eighteen hours post infection (Fig. 3.26 K and L) the situation looked similar to the 
distribution of bacteria and neutrophils two days p.i.. At this time the bacteria were scattered 
inside large necrotic areas, which were surrounded by infiltrated neutrophils. Although the 
bacteria were not as dense as two days post infection and the amount of infiltrated neutrophils 
was lower, the basic distribution of bacteria and neutrophils was the same. In Fig. 3.26 K and 
L, the beginning establishment of the border of neutrophils that surrounds the necrotic area 
and keeps the bacteria from spreading into vital tumor tissue is enlarged. As seen before, 
Salmonellae are found inside the unstained necrotic areas, or in close contact with neutrophils.  
Overviews of the infected CT26 tumors revealed that as long as the bacteria had not started to 
disseminate throughout the tumor neutrophils were scattered all over the solid tumor with a 
slightly stronger accumulation at the tumor rim. This is visualized in Fig. 3.27 A, which 
shows neutrophil distribution of blood vessels two hours p.i.. As soon as the bacteria form 
colonies and start spreading, they seem to induce necrosis, which in turn leads to a stronger 
influx of neutrophils. Twelve hours p.i. (Fig. 3.27 B) and fifteen hours p.i. (Fig. 3.27 C) the 
neutrophils migrated towards the infected tissue, which could be seen by an increased 
accumulation of neutrophils throughout the tumor. At eighteen hours p.i. a small border of 
neutrophils could be observed that apparently shielded the vital tumor tissue from the quickly 
multiplying Salmonellae (Fig. 3.27 D). The basic pattern of a neutrophil border surrounding 
the bacteria-colonized necrosis, which had been observed before at two days p.i., could 
already be seen after 18 h, albeit less pronounced.
As mentioned before, the colonization of solid CT26 tumors with bacteria and the concomitant 
infiltration of neutrophils to the place of infection that could be observed microscopically, were 
always associated by a macroscopic reddening of the solid tumor, suggesting a strong influx of 
blood into the infected tissue.  
3 Results 99 
Fig. 3.27: Low magnification overviews of early times during bacterial colonization of solid CT26 tumors. S. 
typhimurium is stained in green, neutrophils (Gr1) are stained in red and the endothelial cells of blood 
vessels (CD31) are stained in blue. (A) 2 h post infection. (B) 12 h post infection. (C) 15 h post 
infection. (D) 18 h post infection. The white bars represent 100 µm. 
To investigate this phenomenon in more detail, 5 µm paraffin sections of infected CT26 
tumors that had been infected with S. typhimurium twelve hours before were stained with 
hematoxylin/eosin and analyzed (Fig. 3.27). It became clear that as soon as twelve hours after 
infection, it is possible to tell where the necrosis is beginning to develop and where the rim of 
vital tumor tissue will remain. I.e. the bluish violet area directly below the skin, indicated with 
V in Fig. 3.28 will remain vital. Neighboring this area is a huge, more reddish stained area, 
which will become necrotic (N). The border of the area that most likely will remain vital and 
the area that will become necrotic is enlarged in Fig. 3.28 B. Further enlargement of the 
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“necrosis-to-be”-area (Fig. 3.28 C and D) revealed the reason for the reddish staining. This 
area is filled with erythrocytes. Thus, as assumed because of the macroscopic reddening of the 
solid tumor between six hours and fifteen hours p.i., the tumor is indeed filled up with blood. 
This is very likely a mechanism via which the neutrophilic granulocytes that have been shown 
to control intratumoral infections acquire access to the tumor tissue and prevent further 
spreading of the bacteria. It is conceivable, that blood borne bacteria can also be flushed into 
the tumor this way.  
  
  
Fig. 3.28: HE stainings of S. typhimurium S7207-infected CT26 tumors 12 h p.i.. Nuclei are stained in 
violet/blue and the cytoplasm is stained in red/pink. The developing necrosis is marked with N, the 
tissue that remains vital is marked with V. (A) Low magnification overview. (B) Higher magnification 
of the border between the developing necrosis and the tissue that remains vital. (C and D) High 
magnification of erythrocytes that have infiltrated the tumor. The black bars represent 500 µm in A, 
200µm in B and 50 µm in C and D. 
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3.7 Salmonella typhimurium SL7207 resides mainly extracellularly inside 
solid CT26 tumors 
An additional important aspect of bacterial settlement inside solid CT26 tumors is the 
clarification of the question, whether the invasive tumor-colonizing bacteria invade tumor 
cells, or whether they remain extracellularly. 
Therefore, 2µm paraffin sections of S. typhimurium-infected CT26 tumors were prepared two 
days after bacterial infection. The bacteria were stained by a standard silver staining and 
should appear black. The nuclei were counterstained with Kernechtrot and should appear 
purple. The cytoplasm should appear pink and the cellular junctions should be obvious as 
black irregular lines. As demonstrated in Fig. 3.29 A, the bacteria are mainly found in 
extracellular, unstained white spaces. Fig. 3.29 B shows a part of the viable tumor tissue of 
the same tumor, in which no Salmonellae reside. The insets magnify parts of each picture by 
2.5 fold. 
  
Fig.3.29: Silver staining of histological sections of S. typhimurium-infected CT26 tumors two days p.i. Bacteria 
and cellular junctions appear black. Nuclei are counterstained with Kernechtrot and appear purple. (A) 
Extracellular bacteria at the rim of necrosis. (B) Area without bacteria in viable tissue of the same 
tumor. The insets show 2.5 fold magnifications of a part of each picture. The black bars represent 
20 µm.  
These results suggested that the majority of the bacteria reside extracellularly. However, an 
explicit answer to the question whether all bacteria are extracellular or if some bacteria are 
still able to infect cells and can be found intracellularly could not be established this way.  
Therefore, Salmonella-infected tumors were analyzed by electron microscopy. CT26 tumors 
from S. typhimurium infected BALB/c mice were removed two days p.i., fixed and prepared 
A B
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for electron microscope analysis. Fig. 3.30 shows transmission electron micrographs of 
Salmonellae residing in CT26 tumors. Fig. 3.30 A and Fig. 3.30 B clearly show that 
S. typhimurium reside extracellularly. No bacterium could be found to be in direct contact 
with the cytoplasm. Besides the extracellular occurrence of the bacteria, S. typhimurium
appears to be encapsulated, as can be seen by the unstained surrounding of the bacteria.  
Fig.3.30: S. typhimurium reside extracellularly inside CT26 tumors. Transmission electron micrographs of 
S. typhimurium SL7207 infected CT26 tumors two days p.i.. The small dark grey particles are  
Salmonellae are indicated by black arrows. Nuclei are marked with N. A and B highlight different 
places of Salmonella colonization inside CT26 tumors. Salmonellae are not in direct contact with the 
cytoplasm; instead, they stay extracellularly and appear encapsulated. 
3.8 Bacterial encapsulation and biofilm formation inside solid CT26 
tumors 
In addition to transmission electron micrographs, freeze fractures of S. typhimurium-infected 
CT26 tumors were analyzed by scanning electron microscopy.  
As displayed in Fig. 3.31 S. typhimurium 7207 reside in extraordinary structures inside the 
necrosis of solid CT26 tumors. These sheet-like structures that were always found to surround 
Salmonellae inside the tumors resemble biofilms (Romling and Rohde, 1999; Romling et al., 
2000). No cellular structures were visible in the neighborhood of the bacteria.  
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Fig.3.31: S. typhimurium are encapsulated and grow in biofilms inside solid CT26 tumors. (A) Group of 
bacteria that is surrounded by extracellular structures that resemble biofilms. No vital cells are 
detectable. (B) Higher magnification of bacteria inside the biofilm. Bacteria are additionally 
encapsulated. The upper black arrow indicates a capsule that had been damaged during fracture; the 
lower black arrow indicates a bacterium that migrates out of a tube-like capsule. The white bars 
represent 5 µm (A) and 2 µm (B), respectively.  
A
B
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Besides the formation of biofilms by S. typhimurium inside CT26 tumors, the bacteria were 
found to be encapsulated. In Fig. 3.31 B these capsules that surround the Salmonellae are 
highlighted by black arrows. The upper arrow indicates a capsule that was obviously damaged 
during the fracturing procedure of the tumor. The lower arrow marks a single bacterium that 
appears to outgrow a tube-like capsule.  
In summary, Salmonellae that were found to inhabit the necrosis of solid CT26 tumors were 
surrounded by capsules and they additionally form biofilms. The encapsulation and the 
biofilm formation might be a protection mechanism of the bacteria, to avoid contact and 
phagocytosis by host immune cells like neutrophilic granulocytes.  
In fact, when analyzing freeze fractures of S. typhimurium-infected, neutrophil-depleted CT26 
tumors via electron microscopy, biofilm formation was retarded and most of the Salmonellae
were not encapsulated. Fig. 3.32 shows S. typhimurium in neutrophil-depleted solid CT26 
tumors. Contrary to the non-depleted tumors, the bacteria were not associated with the sheet-
like structures of a biofilm as in Fig. 3.31. One single ripped capsule was detectable in Fig. 
3.32 A, as highlighted by the black arrow. Irrespective of the capsule in Fig. 3.32 A, hardly 
any further encapsulated bacteria could be detected. In Fig. 3.32 B it is clearly visible that the 
bacteria were not encapsulated, as the ruffled structure of the bacterial membrane is visible. 
This differs remarkably from the outer structures of the capsules in Fig. 3.31. Despite of this 
phenomenon, the bacteria remain extracellularly. Obviously, additional mechanisms must 
exist that keep the bacteria in this state. 
Taken together, these data indicate that S. typhimurium are induced to form biofilms and 
capsules upon contact to neutrophilic granulocytes. Both mechanisms seem to be a protection 
mechanism of the bacteria, to prevent phagocytosis and/or killing by host neutrophils. In 
addition, encapsulation and biofilm formation might partly explain, why S. typhimurium is not 
found intracellularly. 
In contrast to S. typhimurium SL7207, the laboratory strain E. coli TOP10 did not show any 
biofilm formation or encapsulation inside solid CT26 tumors. As can be seen in Fig. 3.33 rod-
shaped E. coli are located between damaged, necrotic tumor tissue without extraordinary 
structures like biofilms or capsules. The appearance of E. coli TOP10 in Fig. 3.33 B 
resembles the appearance of S. typhimurium in neutrophil-depleted tumors.  
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Fig.3.32: Biofilm formation and encapsulation by S. typhimurium is retarded in neutrophil-depleted CT26 
tumors. (A) Salmonellae inside neutrophil-depleted CT26 tumors. Bacteria are not surrounded by the 
sheet-like structures of the biofilm. The black arrow indicates one single ripped bacterial capsule. (B) 
Higher magnification of the bacteria. Bacteria are not encapsulated. Structures of the bacterial 
membranes are visible. The white bars represent 5 µm (A) and 2 µm (B), respectively.  
A
B
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Fig.3.33: No biofilm formation and encapsulation by E. coli TOP10 inside CT26 tumors. (A) E. coli inside the 
necrosis of CT26 tumors. Bacteria are not surrounded by the sheet-like structures of a biofilm. (B) 
Higher magnification of the bacteria. Bacteria are not encapsulated. The white bars represent 5 µm 
(A) and 2 µm (B), respectively.  
A
B
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Fig.3.34: Biofilm formation and encapsulation by S. flexneri ∆dap in neutrophil-depleted CT26 tumors. (A) 
Shigellae inside neutrophil-depleted CT26 tumors. Bacteria form biofilms and are encapsulated by 
tube-shaped capsules (B) Higher magnification of the bacteria inside tube-shaped capsules. The white 
bars represent 5 µm (A) and 2 µm (B), respectively.  
A
B
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These results correlate well with published data from Romling and Rohde (1999) and 
Romling et al. (2000), who reported multicellular behavior and biofilm formation in several 
S. typhimurium and E. coli species. According to their studies, most E. coli K12 derivatives 
do not show multicellular behavior. As the laboratory strain E. coli TOP10 is a K12 
derivative, its inability to form biofilms would be expected. 
The third bacterial strain that was analyzed via electron microscopy, S. flexneri ∆dap, again 
behaved differently inside solid CT26 tumors. Similar to S. typhimurium SL7207, 
S. flexneri ∆dap did exhibit biofilm formation and encapsulation in non-depleted CT26 tumors 
(data not shown). Interestingly, even after successful depletion of neutrophils, neither biofilm 
formation nor encapsulation of Shigellae seemed to be impaired, as displayed in Fig. 3.34. In 
addition, clear differences between biofilm and capsules of Shigellae and Salmonellae became 
apparent. 
The capsules of S. flexneri ∆dap (Fig. 3.34 A and B) appear thinner than S. typhimurium’s 
(Fig. 3.31 B) and resemble thin tubes. Such tubes appear to be open on both sides (Fig. 3.34 
B). In case of Salmonella, most of the bacteria were individually encapsulated, as only few 
tube-like structures could be observed. In contrast, Shigellae appear not to be encapsulated 
individually (compare Fig. 3.34 B). In addition, the sheet-like structure of Shigella flexneri’s 
biofilm differs from the structure of S. typhimurium’s biofilm.  
Since biofilm formation and encapsulation of S. flexneri ∆dap were not impaired in 
neutrophil-depleted tumors, the mechanisms that are responsible for the formation of biofilms 
and capsules by S. flexneri must differ from the mechanisms that cause biofilm and capsule 
formation by S. typhimurium. Nevertheless, the formation of biofilm and capsules by the two 
bacterial strains was surprising. It might even partly explain the failure of gene transfer. On 
the other hand it opens a wide range of possibilities to future tumor therapies.  
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4 Discussion  
Facultative and obligate anaerobic bacteria as means for tumor therapy have been exploited 
experimentally for several decades. Different kinds of bacteria-mediated tumor-therapies have 
been tested so far and some of them showed very promising results. However, little is known 
about the mechanisms that are involved in bacterial colonization of solid tumors and on 
bacteria-host interactions inside the tumor.  
When dealing with therapeutic applications, such as bacteria-mediated tumor therapy, it is 
essential to know every detail possible in order to optimize the treatment or to prevent 
unexpected side effects.  
The present work started by verifying functional gene transfer of a reporter gene into solid 
CT26 tumors with S. flexneri ∆dap as carrier. Prompted by fluctuating in vivo results, 
investigations turned towards characterization of interactions of S. flexneri ∆dap with the 
mammalian host. These studies were extended to two additional carriers S. typhimurium
SL7207 and E. coli TOP10. 
Electron microscopy unveiled an unexpected encapsulation and the formation of biofilms by 
the two invasive strains S. typhimurium SL7207 and S. flexneri ∆dap inside CT26 tumors. 
Remarkably, the multicellular behavior was not observed for the noninvasive strain E. coli
TOP10. Both, the encapsulation and the biofilm formation of S.  flexneri ∆dap might explain 
the fluctuating results of in vivo gene transfer experiments.  
The second unexpected finding was the enrichment of neutrophils at the place of infection. 
These cells apparently were responsible for the containment of bacteria to the necrotic parts of 
the tumor. Since such infiltrating neutrophils might have adverse effects on bacterial 
dissemination inside the tumors, the depletion of neutrophils was investigated. As intended, 
the depletion enhanced the dissemination of bacteria. In addition, an increase in necrosis and 
spreading of the bacteria into vital tumor tissue could be achieved. 
The characterization of bacteria-host interactions further included the kinetics of bacterial 
settlement inside solid CT26 tumors. S. typhimurium SL7207 were taken as a representative 
tumor-targeting bacterium and were found already short time after administration in the tumor 
associated with blood vessels. Between 6 h and 15 h a tremendous influx of blood was 
observed, which was accompanied by necrosis formation, bacterial growth and the above 
described infiltration of the tumor by neutrophils. After about 24 hours the final scenario for 
tumors colonized by bacteria was established. 
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4.1 Early events in bacterial tumor colonization 
Bacterial escape into the solid tumor 
As early as 30 min to 2 h after systemic infection, the first S. typhimurium SL7207 could be 
detected histologically in blood vessels of CT26 tumors. In rare cases they were found even 
inside the tumor tissue but still in close proximity to blood vessels. These data are in 
agreement with plating experiments of tumors and blood samples from intravenously infected, 
tumor-bearing BALB/c mice (Leschner, S., personal communication). Elimination of 
S. typhimurium from the blood takes place between 2-6 hours after infection and is 
accompanied by a simultaneous increase of bacterial numbers in the tumor. These results are 
in contrast to a publication by Forbes et al. (2003), who reported the elimination of 
S. typhimurium from the blood of MCaIV tumor-bearing SCID-mice after 24 h. The 
discrepancy might be explained by the different mouse strains employed. SCID-mice are 
severe combined immune deficiency mice that cannot produce functional T or B cells and 
therefore do not contain natural antibodies. Such antibodies have been shown to be essential 
for spleen-specific clearance of pathogens from the circulation (MacPherson et al., 2000).  
The exact mechanism of how the bacteria escape into the tumor tissue is not yet clear. 
Basically, two mechanisms are conceivable: the bacteria are transported into the tumor 
passively or they actively escape from the blood into the tumor tissue. 
 A very plausible mechanism is a passive infiltration of bacteria into the tumor. Most tumor 
vessels differ from normal blood vessels, as they are structurally irregular and leaky, with 
irregular diameters and abnormal branching patterns (Less et al., 1991; Less et al., 1997). In 
2000, Hashizume et al. studied the leakiness of blood vessels in MCaIV mouse mammary 
tumors and concluded that some tumor vessels have a defective cellular lining that is 
composed of disorganized, loosely connected, branched or overlapping endothelial cells. The 
openings between those disorganized cells do not only contribute to blood vessel leakiness in 
the tumor, but they also permit the access of macromolecules to the tumor. The size of these 
openings was shown to range between 200 and 2000 nm, depending on the tumor (Hashizume 
et al., 2000). These conclusions were based on experiments using liposomes, which are 
relatively large inert particles that can penetrate tumors through fenestrated endothelium 
(Hashizume et al., 2000). Similarly, Cheong et al. (Cheong et al., 2006) successfully used 
liposome-encapsulated therapeutics in CT26-bearing BALB/c mice. By extrapolation, it can 
be assumed that bacteria as well are able to access tumors via such openings. 
An example of an active transportation is a receptor-mediated mechanism, in which the 
bacteria would have to bind to specific receptors found on endothelial cells that line the blood 
vessels of solid tumors, thereby inducing their own uptake into the solid tumors. Forbes et al. 
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(Forbes et al., 2003) investigated the escape of bacteria from the blood vessels into tumor 
tissue. Salmonellae were observed to only adhere to the walls of blood vessels with very low 
flow rates. It can be imagined that the bacteria rested in dead end blood vessels or in niches of 
irregularly shaped blood vessels with low blood flow rates. Thus, even weak adherence to 
endothelia would facilitate bacterial escape into the tumor via the large openings in the vessel 
walls. 
In a second example of active transportation bacteria could be specifically attracted by 
tumors. In 2006 Kasinskas and Forbes observed that S. typhimurium are specifically 
chemotaxed by tumor cells. They hypothesized the production of specific compounds by 
quiescent cancer cells inside solid tumors. These compounds – although still unknown – could 
explain the targeting of several facultative anaerobic bacteria to solid tumors (Kasinskas and 
Forbes, 2006). 
Both active mechanisms would predict that relatively high numbers of bacteria 
simultaneously bind to endothelial cells or infiltrate the solid tumor. This was actually not 
observed in the present work. In contrast, only single Salmonella could be found inside tumor 
blood vessels 30 min to 6 h after infection and even fewer were found to have escaped into 
the tumor tissue. During the time frame between 6 h and 12 h post infection, rare micro-
colonies could be detected, from which the bacteria started to spread into the tumor tissue. 
These observations cannot be reconciled with the proposed active mechanisms. 
Influx of blood 
Shortly after the escape of single bacteria into the tumor tissue, the invaded bacteria were 
shown to proliferate and start disseminating throughout the tumor. This was accompanied by 
a strong influx of blood into the infected tissue. It is assumed here that the bacteria inside the 
tumor induce the expression and secretion of cytokines or chemokines by the tumor cells or 
by macrophages or neutrophilic granulocytes that were found scattered over the non-infected, 
solid tumors. A prime candidate of secreted factors is tumor necrosis factor α (TNF-α). 
TNF-α has often been shown to be secreted quickly after infection. In addition, TNF-α is 
known to act as a vasoactive agent that modifies the actin cytoskeleton and increases the 
permeability of the endothelial lining of blood vessels (Wojciak-Stothard and Ridley, 2002). 
This may well support in the influx of blood observed 6 h to 15 h post infection, 
macroscopically and microscopically. 
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Attraction and infiltration of neutrophils 
Concomitant to the influx of blood, neutrophils are migrating into the colonized tumor. Very 
likely, such neutrophils are flushed into the tumor, together with the inflowing blood and the 
erythrocytes, as the number of neutrophils inside the tumors slowly increases between 6 h and 
18 h post infection. In addition, specific immigration of neutrophils will be induced by 
bacterial products like N-formylated peptides or the secreted chemokines and cytokines 
mentioned above. Besides TNF-α, secreted neutrophil attracting factors could include 
epithelial-derived neutrophil attractant (ENA; CXCL5), growth-related oncogene α (gro-α; 
CXCL1); monocyte chemoattractant chemokine 1 (MCP-1; CCL2), interferon gamma 
inducible protein 10 (IP-10; CXCL10) and monokine induced by interferon gamma (MIG; 
CXCL9). Such chemokines should be amongst the first chemoattractants to be tested in this 
context in tumor cells and tumor infiltrating phagocytes. 
Once inside the tumor, the neutrophils start to border the infected, partly necrotic tumor tissue 
and are most likely responsible for the local containment of the bacteria. 
Establishment of necrosis and development of a viable tumor rim 
Whenever analyzing tumors colonized by bacteria, the microorganisms are mainly restricted 
to necrosis, while an outer rim of viable tumor cells invariably persists (Minton et al., 2001; 
Dang et al., 2001, Forbes et al., 2003). The large, bacteria-colonized necrosis is most probably 
a result of the bacteria-induced influx of blood. Besides several types of cells, blood contains 
proteins like clotting factors, complement etc.. Inside the tumor, enzymatic cascades are 
activated and the released blood begins to clot. Tissue in contact with the clotted blood 
becomes necrotic.  
A second cause of the emerging necrosis could be the disintegration of blood vessels in the 
hemorrhagic region and the resulting collapse of blood flow. As a result, the constant supply 
of the tumor cells with nutrients and oxygen is stopped. Thus, the tumor cells in the center of 
the tumor are “starved and suffocated to death”.  
The observed viable rim consists of the remaining tumor tissue that was not in contact with 
the inflowing blood and is still supplied with nutrients and oxygen. Interestingly, the same 
phenomenon of a viable tumor rim was reported for solid tumors that were treated with 
vascular-disrupting agents (VDAs) (Tozer et al., 1999; reviewed in Tozer et al., 2005a). 
Tumor center and periphery can display different interstitial blood pressure and vascular 
architecture. Thus, tumor periphery might be less sensitive to vascular shutdown than the 
center. As the interstitial blood pressure rises strongly from tumor periphery to tumor center, 
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an increase in vascular permeability might be catastrophic in the center, while it is tolerated in 
the periphery (reviewed in Tozer et al. 2005a). 
A second factor that might play a role is the complex vascular plexus at the tumor periphery 
compared with a much lower vascular density in the center. In case of extensive vascular 
damage, residual blood flow is likely to persist in the tumor periphery, but less likely in the 
tumor center. According to Tozer et al., this can indeed be observed by microscopic 
techniques (Tozer et al., 2005b). 
The mechanisms that are suggested to play a role for the tumor physiology after treatment 
with VDAs, very likely are the same that lead to necrosis and a viable rim in bacterial tumor 
therapies. Although the increase in vessel permeability is induced differently in both 
therapies, the observations and the outcome are very similar.  
Tozer and his colleagues also found an influx of neutrophilic granulocytes into the solid 
tumor. Although in their case the increase in blood vessel permeability was initially due to 
VDAs, the dying, necrotic cells might have subsequently released neutrophil-attracting factors 
that lead to an immigration of neutrophils. In case of tumor colonizing bacteria neutrophil-
attracting factors from necrotic cells might act in synergy with the chemoattractants induced 
by the microorganisms.  
4.2 Containment of tumor colonizing bacteria by host neutrophils 
The strong influx of neutrophils into the tumor after bacterial settlement has severe 
consequences. By limiting the dissemination of the microorganisms, this will most likely lead 
to restricted efficiency of tumor therapies in terms of (I) equal distribution of cytotoxins or 
other therapeutics that the bacteria transport into the tumor, and (II) direct contact of the 
bacteria with vital tumor cells and tumor cell invasion. The latter would be absolutely 
necessary for gene therapies, e.g. bacteria-mediated gene transfer (Grillot-Courvalin et al., 
2002; Lee et al., 2004) or direct injection of therapeutic proteins or RNA into tumor cells. 
Thus, one of the most urgent issues that have to be addressed is the improvement of bacterial 
dissemination inside solid tumors.  
Inside the tumor, neutrophils probably function as a “border” of leukocytes that intent to 
control the infection. Thereby, they inhibit bacterial dissemination into other parts of the 
body, but also into the vital tumor tissue. This role of neutrophils as the first line of defense 
during bacterial infections can be life-saving in common, unintended infections, but it is most 
likely counteracting when it comes to bacteria-mediated anti-tumor therapy. Indeed, after 
depletion of neutrophils from CT26- and TS/A-tumor bearing BALB/c mice all bacteria tested 
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were able to improve their dissemination throughout the tumor. This was accompanied by 
higher total numbers of bacteria inside the tumor and an increase in necrosis. Most 
importantly, bacteria could now be detected in vital tumor tissue. 
However, the depletion of neutrophils in tumor patients might appear as a “cruel intention”. 
Depletion of such cells seems to deprive the patient of one of his most important natural 
defense mechanisms. Nevertheless, all mice in such experiments survived the depletion 
without aggravation of their health status. Even neutrophil depletion for up to one week did 
not lead to death of the animals (data not shown). 
Obviously, such treatment is not possible for human patients. Consequently, depletion of 
neutrophils in patients should be tumor specific and a complete systemic depletion should be 
avoided. For instance, the infiltration of neutrophils could be prevented by inhibiting the 
influx of such cells. If TNF-α  is the trigger for the induction of increased permeability of the 
tumor blood vessels and neutrophil infiltration, the prevention of its production or its 
neutralization can be a possible direction. However, if influx of blood is important for 
necrosis establishment and enhancement of therapy, neutralization of TNF-α might be 
deleterious for the intended treatment.  
A specific alternative would be to engineer the tumor-targeting microorganisms to secrete 
neutrophil-depleting or -inactivating reagents. For instance, specific antibodies could be 
employed or toxins that bind to cellular receptors, which are only found on neutrophils. 
Nevertheless, to optimize bacterial tumor therapies it is necessary to further investigate the 
exact mechanism how neutrophils interact with bacteria inside the tumor and/or with infected 
or necrotic cells, respectively.  
Generally, the depletion of neutrophils from solid tumors and the prevention of formation of a 
neutrophil border appears to be a promising way to promote bacterial spreading and to ensure 
equal distribution of bacteria-carried, therapeutic agents inside the tumor. This should support 
efficiency and success of all kinds of bacteria-mediated tumor therapies.   
4.3 Biofilm formation and encapsulation inside solid tumors 
An unexpected outcome of the present analysis was the detection of encapsulation and biofilm 
formation by S. typhimurium SL7207 and S. flexneri ∆dap inside solid CT26 tumors. Such a 
phenomenon had not been reported before and might severely influence the efficiency of 
bacteria-mediated tumor therapies. 
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The sheet-like structures that could be observed for S. typhimurium SL7207 strongly resemble 
the multicellular appearance that was described by Romling, et al. (Romling, et al., 1998)) for 
S. typhimurium in vitro. Interestingly, S. flexneri ∆dap also display multicellular behavior 
inside solid CT26 tumors, although both, biofilm and capsules are different from those of
S. typhimurium. S. flexneri was encapsulated in long, tube-like structures, which were 
apparently open on both ends and most likely enclosed several bacteria. In contrast, most of 
the Salmonellae seemed to be individually encapsulated and the majority of capsules detected 
for S. typhimurium were closed on both sites.  
In contrast to both of the above described bacterial strains, the laboratory strain E. coli TOP10 
did not show any capsule or biofilm formation. TOP10 is a K12-derivative and Romling et al. 
(Romling et al., 2005) reported that several K12-derivatives had lost their ability to produce a 
biofilm. Thus, the present data correlate well with such data. 
The observation that biofilm formation and encapsulation is different for S. typhimurium
SL7207 and S. flexneri ∆dap is giving some clues on the induction of such structures. While 
Salmonellae showed an impaired multicellular behavior in neutrophil-depleted CT26 tumors, 
the behavior of Shigellae was not affected by the presence or absence of such cells. This 
suggests that for Salmonellae, multicellular behavior inside solid tumors is a reaction towards 
the host’s immune system. It might represent an evasion mechanism that prevents 
phagocytosis by host neutrophils. In addition, bacterial cells in communities are better 
protected against deleterious agents (Costerton, 1997), which might be in case of tumor 
colonizing Salmonellae antimicrobial peptides that are produced by neutrophils. However, 
this preferred multicellular growth inside solid tumors probably keeps them from infecting 
viable tumor cells and thus might represent an obstacle for DNA transfer or the efficient 
delivery of therapeutic proteins.  
On the other hand, the property to form capsules and biofilms might take place exclusively in 
tumors and not in other tissues. This implies that tumor specific bacterial promoters exist, 
which should allow a highly specific tumor-restricted expression of therapeutic or modulating 
genes like genes encoding toxins or neutrophil-depleting agents.  
The multicellular behavior of S. flexneri ∆dap is apparently not dependent on neutrophils. 
Thus, both biofilm formation and encapsulation by Shigella flexneri might primarily be 
induced by the tumor microenvironment as biofilms generally can improve the metabolic state 
by trapping the nutrients (Costerton et al. 1999). The tube-like structures with open ends on 
both sites might provide the possibility for the bacteria to change their status from sessile to 
migratory by leaving the protective tubes and colonize areas outside necrosis. This would be 
in agreement with the findings that single Shigellae were found in vital tumor tissue. 
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Nevertheless, a general protective role of such structures against the immune system of the 
host should not be excluded. 
The biochemical composition of the observed capsules and biofilms is still unresolved. In 
vitro studies with biofilm-producing S. typhimurium and E .coli (Zogaj et al., 2001) revealed 
that two major components of biofilms produced by S. typhimurium could be thin aggregative 
or curli fimbriae and cellulose. Co-production of both substances lead to the formation of a 
highly hydrophobic network with tightly packed bacterial cells that accumulated in a rigid 
matrix. Electron micrographs of such biofilms strongly resembled the biofilms observed for 
S. typhimurium in CT26 tumors. Thus, cellulose and curli fimbriae are most likely also the 
components of the Salmonella-derived biofilm described here.  
Other unresolved questions are, for instance, the influence of the multicellular behavior on 
bacterial dissemination and on bacteria-host interactions. In general, it is unclear whether this 
behavior is beneficial or detrimental for bacterial tumor therapies. 
All these questions need to be addressed. Thus, genomic and biochemical approaches should 
be employed to characterize the nature of the capsule and the biofilms. This is a prerequisite 
for establishment of appropriate deletion mutants that allow the answering of such questions. 
It will also unequivocally show whether biofilms are the major cause for the low efficiency of 
bacteria-mediated gene transfer into tumor cells in vivo.  
4.4 Bacterial gene transfer into solid tumors 
Transfer of eukaryotic genes into mammalian cells by different Gram-negative and Gram-
positive bacteria has been reported repeatedly (Sizemore et al., 1995; Courvalin et al., 1995; 
Darji et al., 1997). Even a transgene expression in murine melanomas after infection with 
Salmonella choleraesuis has been claimed (Lee et al., 2004; Lee et al., 2005). Despite these 
promising reports, bacterial gene transfer is associated with a number of restrictions such as 
low efficiency and the difficulty to distinguish eukaryotic from prokaryotic gene expression. 
By cloning an intact intron into the eukaryotic reporter gene, the difficulty of distinguishing 
mammalian from bacterial gene expression could be successfully overcome. This system 
allowed the unequivocal proof of effective bacterial gene transfer by S. flexneri ∆dap into 
different tumor cell lines in vitro. Bacterial gene transfer by these bacteria was highly 
reproducible in vitro. In vivo experiments with CT26-bearing BALB/c mice initially indicated 
functional transgene expression inside solid CT26 tumors. However, later experiments were 
met with fluctuating results. Investigations of bacteria-host interactions in the tumor by 
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histology and electron microscopy provided some reasons that might be responsible for such 
results. 
Immune histology suggested that gene transfer is taking place in vivo, as a few cells in each 
tumor section were strongly positive for the reporter protein. Whenever a tumor cell in such 
sections was positive, it was surrounded by S. flexneri. However, the number of luciferase 
expressing tumor cells per tumor was extremely low. Hence, the total amount of luciferase 
was probably too low to be detected by any other method. By extrapolation, when transferring 
genes encoding therapeutic molecules into tumor cells using Shigellae under the present 
conditions in vivo, expression would most likely have only little effect, if any, due to the 
limited number of transfected tumor cells. 
The main reason for low gene transfer efficiency by S. flexneri ∆dap into solid CT26 tumor in
vivo could be the poor dissemination of the bacteria inside the tumor. The majority of bacteria 
were found to accumulate inside large necrotic areas associated with dead cells and only a few 
Shigellae were found neighboring vital cells, into which gene transfer is possible. The 
depletion of neutrophilic granulocytes did not enhance gene transfer efficiency although more 
bacteria were found inside vital tumor tissue. However, the total number of vital tumor cells 
was drastically reduced under these conditions. Therefore, the number of transfected tumor 
cells might still be too low to become detectable. 
A second reason for the fluctuating efficiency of S. flexneri ∆dap-mediated gene transfer in 
vivo could be the encapsulation and biofilm formation by Shigellae. All Shigellae detected 
here are encapsulated and are not in direct contact with vital tumor cells. Thus, gene transfer 
cannot take place. However, the evidence of gene transfer into single tumor cells in the vital 
tumor tissue suggests that the few Shigellae inside vital tumor tissue are not encapsulated or 
enclosed in a biofilm and therefore are able to infect tumor cells and transfer genes. 
In summary, it becomes clear that bacteria-mediated gene transfer might not be the optimal 
bacterial therapy for solid tumors under the present circumstances. While it still might be the 
method of choice for genetic vaccinations or for gene therapies into organs different from 
tumors, it is currently not yet appropriate for transfer of genes into tumor cells in vivo. 
Nevertheless, it should not be completely disregarded as a future way of tumor therapies, 
although priorities for further development of bacterial tumor therapies should lie on 
bacteria-produced proteins as promising alternatives. 
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4.5 Outlook 
Consequently, future directions of research should aim at the construction of genetically 
engineered bacteria that are able to stably produce sufficient amounts of therapeutic 
molecules. Some of such molecules like CD are already active when residing in the bacterial 
cell. However, most therapeutic molecules are likely to be proteins that exert their activity by 
acting directly on the tumor cells. Thus, efficient secretion systems need to be established. 
This may be an ambitious task since bacterial secretion systems exhibit high specificity for 
the molecule secreted and the bacterial strain employed. Therefore, several of the possible 
systems have to be tested to meet the required demands. 
An obvious application of an efficient secretion system would be the delivery of anti-
neutrophilic compounds such as neutrophil-specific toxins or antibodies. Both strategies 
should help to kill or inactivate neutrophils locally without impairing the general health status 
of the patient. This should facilitate bacterial spreading in solid tumors and enhance necrosis 
and death of tumor cells. An enhanced bacterial dissemination in the tumor should also allow 
the bacteria to carry additional therapeutic proteins into the tumor.  
Another option that needs to be tested urgently is the use of bacteria that are deficient in LPS. 
These could be LPS-deficient mutants or Gram-positive bacteria. At present it is unclear, 
which factors cause the release of neutrophil attractants and lead to the infiltration of 
neutrophils. LPS might be such a candidate. Thus, deficiency in LPS might prevent neutrophil 
attraction without limiting the formation of necrosis.  
To ensure a tumor specific expression of such therapeutic molecules, but also of neutrophil-
specific toxins or antibodies, the inquiry of tumor specific promoters is an obvious choice. 
The promoters should be activated exclusively inside solid tumors and thus prevent unwanted 
expression in tissues different from the tumor. The probability of the existence of such 
promoters is rather high. For instance, the formation of bacterial capsules and biofilms inside 
mammalian hosts has up to now only been found in solid tumors and has to be triggered by 
promoters that specifically respond to the conditions in the tumor. Alternatively, promoters, 
which are active only under anaerobic conditions, might be employed. 
At present, the consequences of bacterial biofilm formation in solid tumors are unclear. As 
encapsulation and biofilm formation might influence bacterial dissemination inside tumors 
and, very likely, impair their ability to invade tumor cells in vivo, the investigation of bacterial 
mutants that are unable to form capsules and biofilms could help to improve our knowledge 
about bacteria-tumor interactions. Another option of similar kind is the use of different E. coli
strains, which do or do not have the ability to build biofilms (Zogaj et al., 2001). Additionally, 
non-biofilm-forming E. coli might be engineered to produce invasin of Yersinia enterolytica. 
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The production of invasin renders them invasive and might influence their behavior in solid 
tumors.  
The employment of gene transfer via bacteria into tumor cells should not be disregarded. The 
possibilities listed so far aim at the improvement of bacterial dissemination in the tumor and 
at an improved contact of the bacterial carrier with live tumor cells. Both strategies might 
already enhance DNA transfer. An additional modification that might result in improved 
bacterial gene transfer is the introduction of a gene encoding listeriolysin O of Listeria 
monocytogenes. This should help intracellular bacteria like Salmonella or invasive E. coli to 
escape into the cytosol and allow them to deliver plasmid load.  
Besides different bacterial mutants, additional bacterial species could be investigated. One 
potential candidate is Agrobacterium tumefaciens. This bacterium is known to transfer genes 
into cells of plants and has been shown to transfer DNA into HeLa cells in vitro (Kunik et al., 
2001). Interestingly, this bacterium is able to deliver DNA without invading the host cell. 
Recently, Agrobacterium tumefaciens has been shown to be able to target and proliferate in 
solid tumors in mice (Loessner, unpublished results).  
In summary, further investigations based on the findings of this work, will very likely help to 
improve bacterial tumor therapies and might even render them a powerful alternative or 
additive for conventional tumor therapies. 
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5 Summary 
Systemic administration of facultative anaerobic bacteria into mice that bear a solid tumor 
leads to a preferential accumulation of the microorganism in the tumor. Although facultative 
anaerobic bacteria have already been tested in experimental anti-cancer therapies for several 
decades, only little is known about the mechanisms that are involved in bacterial colonization 
of solid tumors and about bacteria-host interactions inside the tumor.  
The present work deals with several aspects of bacterial tumor colonization and the impacts of 
bacterial settlement (I) on infiltration and composition of cells of the immune system, (II) on 
interactions of bacteria with such cells and (III) on influences of these interactions and of the 
tumor microenvironment on the bacteria and their behavior.  
The originally tested bacteria-mediated gene transfer as a means of bacterial tumor therapy 
was strongly impaired inside solid tumors due to a strong increase of the size of necrosis after 
bacterial infection. Subsequent investigations lead to a better understanding of early bacterial 
settlement inside solid tumors. Short time after systemic administration of bacteria, single 
bacteria find their way into the solid tumor, where they start to form micro-colonies. With 
time such micro-colonies become larger and the bacteria start to spread. Concomitant is a 
strong influx of blood and neutrophilic granulocytes into the tumor. The mechanism that 
causes this influx is yet unknown, but experiments suggest a bacteria-induced release of 
neutrophil chemoattractants by tumor cells or immune cells here. This can result in increased 
blood vessel permeability and in the attraction of neutrophils.  
The region of the tumor that had contact with the inflowing blood eventually becomes 
necrotic and was found to be surrounded by a barrier of host neutrophils. From this time on, 
bacteria are only found inside the necrotic areas, enclosed by a border of neutrophilic 
granulocytes.  
By depleting host neutrophils, dissemination of bacteria inside the tumors and into vital tumor 
tissue could be enhanced. Besides a noticeable higher total number of bacteria inside the 
tumor an increase of the size of necrosis could be observed. Thus, manipulating tumor 
infiltrating neutrophils is one option to improve bacteria-mediated tumor therapy. 
Further experiments unveiled an unexpected encapsulation and the formation of extracellular 
structures by S. typhimurium SL7207 and S. flexneri M90T inside CT26 tumors, but not by E. 
coli TOP10. While encapsulation and biofilm formation observed for S. typhimurium SL7207 
was found to be dependent on the presence of neutrophilic granulocytes, no such correlation 
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could be observed for S. flexneri M90T. This suggests at least two different mechanisms that 
drive tumor-colonizing bacteria into the escape route of a protective biofilm. Mechanisms of 
development, composition and effects of bacterial biofilms inside solid tumors are yet 
unknown. However, their future revelation and the further extension of the findings of this 
work will help to improve bacterial tumor therapies and could give rise to a robust clinically 
relevant use of bacteria in anti-cancer therapies. 
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6 Abbreviations 
5-FC 5-fluorocytosine 
5-FU 5-fluorouracil 
5’-UTR 5’-untranslated region 
BAK BCG-activated cells 
BCG bacille calmette guerin 
bp  base pairs  
CD  cytosine deaminase 
CFU colony forming units 
CIS carcinoma in situ 
CMV cytomegalovirus 
c-onc cellular oncogene 
CT Cholera toxin 
DAEC diffusely adherent E. coli  
DAP diaminopimelic acid 
DC dendritic cells 
DNA deoxyribonucleic acid 
EAEC enteroaggregative E. coli  
EGFR epidermal growth factor receptor 
EHEC enterohemorrhagic E. coli  
EIEC enteroinvasive E. coli  
ENA epithelial-derived neutrophil attractant 
EPEC enteropathogenic E. coli  
ETEC enterotoxigenic E. coli  
FCS fetal calf serum 
gro-α growth-related oncogene α  
Hly hemolysin 
HPV human papilloma virus 
IFN Interferon 
IL interleukin 
IM inner membrane 
IP-10 interferon γ inducible protein 10 
i.p. intraperitoneally 
i.t. intratumorally 
i.v. intravenously 
LAK lymphokine-activated killer cells 
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LD lethal dose 
LLO listeriolysin O 
LPS lipopolyteichoic acid 
LT heat-labile toxin 
mAbs monoclonal antibodies 
MCP-1 monocyte chemoattractant chemokine 1 
MIC monokine induced by interferon γ
MIP-2 macrophage inflammatory protein 1 
MHC major histocompatibility complex 
MNEC meningitis/sepsis-associated E. coli  
MOI multiplicity of infection 
mRNA messenger RNA 
NE neutrophil elastase 
NK natural killer cells 
OM outer membrane 
OVA ovalbumin 
PAMP pathogen associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDGF-R platelet-derived growth factor 
p.i. post infection 
RCC renal cell carcinoma 
RNA ribonucleic acid 
ROS reactive oxygen species 
RT room temperature 
SCID severe combined immune deficiency 
shRNA small hairpin RNA 
SPI Salmonella pathogenicity island 
ST heat-stabile toxin 
SS secretion system 
SV40 simian virus 40 
TA tumor antigen 
TE trypsin-EDTA 
TLR toll-like receptor 
TNF-α tumor necrosis factor α  
TSB tryptic soy broth 
UPEC uropathogenic E. coli  
VEGF vascular endothelial growth factor 
v-onc viral oncogene 
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